56th ERA-EDTA Congress

Final Programme

Budapest, Hungary 2019 June 13th-16th
www.era-edta2019.org

CEPD Continuous Education and Professional Development
June 13th, 2019
Download the Congress App!

Download "ERA-EDTA" from the Google or Apple store.

- Stay updated with the full details of the scientific programme
- Create your personalised agenda
- Access speaker presentations (e-materials), message with faculty, take notes under the slides and tag slides for your own summary
- Receive important notification updates from ERA-EDTA
- Join the ERA-EDTA 2019 Congress Twitter feed
- ... and much more ...

www.era-edta.org
Congress Information

CONTENTS

Welcome Address  
HSN Board  
ERA-EDTA Council  
Scientific Committee, CEPD Committee, Local Organising Committee  
Paper Selection Committee  
Congress Information  
Speakers Information  
EACCME / UEMS Credits  
Accepted Abstracts  
ERA-EDTA Awards and Grants  
ERA-EDTA Information  
HSN Information  
Information for Press/Media Representatives  

SCIENTIFIC PROGRAMME

Thursday, June 13, 2019  
Friday, June 14, 2019  
Saturday, June 15, 2019  
Sunday, June 16, 2019  

Industry Sponsored Symposia  
Exhibitors  

page
4  
6  
7  
8  
9  
15  
18  
21  
23  
24  
26  
28  
29  
31  
49  
83  
113  
123  
151
Dear Colleagues, dear Friends,

The ERA-EDTA Congress returns to Budapest in 2019. The event was held in the Hungarian capital in 1986 and during the last 33 years, a lot of changes have occurred. Our societies and economies are in a permanent state of change, creating new challenges for the nephrology community.

The keyword chosen for this year’s meeting is “Precision Nephrology”. This summarizes what we know, what we think we know and what we need to know to achieve our final goal, that is, to provide the best care for our patients.

The Scientific Committee, chaired by Alberto Ortiz, has worked very hard to provide the latest cutting edge science. He was supported by Danilo Fliser who acted as the Chair of the Paper Selection Committee. Thanks to your enthusiasm, they were able to select among more than 2000 high-quality abstracts. The final form of the programme is the result of many hours of joint work of the Scientific Committee Chair, the Congress Presidents, the Paper Selecting Committee Chair and last but not least Silvia Menoni, the Programme and Faculty Coordinator of the Congress.

On June 13, the first day of the congress, a new, exclusive initiative will be held, the first CEPD day (Continuous Education and Professional Development). This is a unique opportunity for professional development with tailored courses given by top European experts in the field.

The main programme includes three plenary lectures, all given by outstanding scientists and excellent speakers, who will cover aspects of the congress's main scientific topics. The programme will be complemented by various interesting industry symposia.

We also would like to welcome all ERA-EDTA members to the General Assembly of the ERA-EDTA, where the Officers and our President will update you on the work that has been done during the last year.

The programme was organised in conjunction with the Hungarian Society of Nephrology (HSN), which will co-host the event. I would like to take this opportunity to thank the Council of the Society for their professional and technical support. On June 13, there will be a “Special Track” dedicated to the regional and global questions of nephrology, developmental nephrology, roots of diseases in adulthood and history of nephrology, which I hope will attract a wide range of local, regional and international audiences.

There will be a 3,500 sqm exhibition which will involve about one hundred international companies. There will also be a very engaging e-server space where delegates can receive assistance regarding e-materials (European Nephrology Portal - ENP, digital services, WiFi). Here we will also be introducing a new Rare Disease Corner where education on these specific diseases will be provided.
Welcome Address

You are cordially invited to the 2019 Congress in Budapest. We will be exploring the latest innovations, news and developments in Nephrology while being in a friendly atmosphere in the heart of Budapest. This Congress is not only a scientific showcase, but it also gives space for informal meetings and discussions. The congress will not only offer an exceptional scientific programme, but also the chance to see Budapest at its best. The rich history of the city combined with a vivid cultural milieu is waiting for ERA-EDTA visitors. The must-see attractions, the modern gastronomy and the Danube River that divides the city and the old and modern buildings side by side provide a great environment for the 56th ERA-EDTA Congress.

We are looking forward to welcoming you to the ERA-EDTA Congress in Budapest in 2019!

George Reusz
Congress President

Carmine Zoccali
ERA-EDTA President
HUNGARIAN SOCIETY OF NEPHROLOGY
www.nephrologia.hu

MAGYAR NEPHROLOGIAI TÁRSASÁG (MANET)
HUNGARIAN SOCIETY OF NEPHROLOGY

President
György Reusz (2018-2020)

President Elect
László Rosivall (2020-2022)

Secretary General
István Kárpáti

Honorary Presidents
Judit Nagy
Sándor Túri

Vice Presidents
József Balla
Erzsébet Ladányi
János Szegedi
István Wittmann

Secretary and Treasurer
Ádám Remport

Notary
László Wagner

Responsible for Membership Registry
István Barna

www.nephrologia.hu
President
Carmine Zoccali, Italy

Secretary-Treasurer
Ivan Rychlik, Czech Republic

Chairperson of the Administrative Offices /
Renal Science Chair
Danilo Fliser, Germany
(also Chairperson of the Paper Selection Committee)

Editor-in-Chief of “Nephrology Dialysis Transplantation”
Denis Fouque, France

Chairperson of the Registry /
Clinical Nephrology Governance Chair
Ziad Massy, France

Ordinary Council Members
Peter J. Blankestijn, The Netherlands
Annette Bruchfeld, Sweden
Giovambattista Capasso, Italy
Dimitrios Goumenos, Greece
Maria Jose Soler Romeo, Spain
Goce Spasovski, North Macedonia
Kate Stevens, United Kingdom
Christoph Wanner, Germany

Congress Presidents (Budapest, Hungary)
George Reusz, Hungary
Carmine Zoccali, Italy

www.era-edta.org
CONGRESS PRESIDENTS
George Reusz, Hungary
Carmine Zoccali, Italy

CONGRESS SCIENTIFIC COMMITTEE
Chair: Alberto Ortiz, Spain

Hans-Joachim Anders, Germany
Angel Argiles, France
Mustafa Arici, Turkey
József Balla, Hungary
Peter Blankestijn, the Netherlands
Edwina Brown, United Kingdom
Annette Bruchfeld, Sweden
Giovambattista Capasso, Italy
Emilie Cornec-Le Gall, France
Marta Crespo, Spain
Pieter Evenepoel, Belgium
Danilo Fliser, Germany
Helen Liapis, Greece
Jolanta Malyszko, Poland
Ziad Massy, France
George Reusz, Hungary
Ivan Rychlik, Czech Republic
Rukshana Shroff, United Kingdom
Vladimir Tesar, Czech Republic
Wim Van Biesen, Belgium
Carsten Wagner, Switzerland
Carmine Zoccali, Italy

CEPD COMMITTEE
Chair: Loreto Gesualdo, Italy

Danilo Fliser, Germany
Ziad Massy, France
Alberto Ortiz, Spain
Carmine Zoccali, Italy

LOCAL ORGANISING COMMITTEE
Istvan Balla
István Wittmann
László Rosivall
Erzsébet Ladányi
István Kárpáti
ERA-EDTA is grateful to the following physicians for the work done in reviewing the abstracts submitted to this year’s congress.

Chair
Danilo Fliser, Germany

Core group
Alberto Ortiz, Spain
George Reusz, Hungary
Maria Jose Soler Romeo, Spain

Section Chairs

Acid-base and uric acid
Carsten Wagner, Switzerland

Jesus Egido, Spain

Renal development and cystic diseases
Ron Gansevoort, The Netherlands

Genetic diseases and molecular genetics
Olivier Devuyst, Switzerland

Renal pathology. Experimental and clinical
Kerstin Amann, Germany

Hypertension. Experimental
Ulrich O. Wenzel, Germany

Hypertension. Clinical
Michel Burnier, Belgium

Nephrolithiasis and uric acid
Giovanni Gambaro, Italy

Clinical nephrology
Jürgen Floege, Germany

Glomerulonephritis
Claudio Ponticelli, Italy

AKI. Experimental
Andreas Kribben, Germany
AKI. Clinical. Epidemiology and outcome
Norbert H. Lameire, Belgium

AKI. Clinical. Prevention and treatment
Mehmet Sukru Sever, Turkey

CKD. Lab methods, GFR measurement, urine proteomics
Gert Mayer, Austria

CKD. Pathophysiology, progression and risk factors
Ivan Rychlik, Czech Republic

CKD. Clinical epidemiology
Bénédicte Stengel, France

CKD. Anaemia
Michel Jadoul, Belgium

CKD. Bone disease
Pieter Evenepoel, Belgium

CKD. Nutrition, inflammation and oxidative stress
Juan Jesus Carrero, Sweden

CKD. Rehabilitation
Naomi Clyne, Sweden

Diabetes. Basic research
Laetitia Koppe, France

Diabetes. Clinical studies
Peter Rossing, Denmark

Dialysis. Extracorporeal dialysis: techniques and adequacy
Jeroen Kooman, The Netherlands

Dialysis. Peritoneal dialysis
Olof Heimbürger, Sweden

Dialysis. Cardiovascular complications
Carmine Zoccali, Italy

Dialysis. Vascular access
Pietro Ravani, Canada

Dialysis. Anaemia
Tilman B. Drueke, France

Dialysis. Nutrition, inflammation and oxidative stress
Masafumi Fukagawa, Japan

Dialysis. Epidemiology and outcome
Goce Spasovski, North Macedonia
Congress Information

Dialysis. Health services research
Kitty Jager, The Netherlands

Dialysis. Protein energy wasting, inflammation and oxidative stress
Peter Barany, Sweden

Renal transplantation. Experimental, immune-tolerance of allogenic and xenogenic transplants
Bruno Watschinger, Austria

Renal transplantation. Epidemiology and outcome
Karsten Midtvedt, Norway

Renal transplantation. Treatment and immunosuppression
Ondrej Viklicky, Czech Republic

Paediatric nephrology
Christer Holmberg, Finland

History of nephrology
Athanasios Diamandopoulos, Greece

Patient education research and training in nephrology
Mustafa Arici, Turkey

Reviewers

Daniel Abramowicz, Belgium
Marcin Adamczak, Poland
Teresa Adragao, Portugal
Dwomoa Adu, Ghana
Alberto Albertazzi, Italy
Hans-Joachim Anders, Germany
Michele Andreucci, Italy
Theofanis Apostolou, Greece
David Arroyo, Spain
Anders Asberg, Norway
Ayse Balat, Turkey
Bert Bammens, Belgium
Debasish Banerjee, United Kingdom
Carlo Basile, Italy
Yuri Battaglia, Italy
Vincenzo Bellizzi, Italy
Ariela Benigni, Italy
Sunil Bhandari, United Kingdom
Manuel Bigotte Vieira, Portugal
Peter J. Blankestijn, The Netherlands
Detlef Bockenhauer, United Kingdom
Georg Boehmig, Austria
Davide Bolignano, Italy
Mario Bonomini, Italy
Jordi Bover, Spain

Vincent Brandenburg, Germany
Annette Bruchfeld, Sweden
Klemens Budde, Germany
Stephane Burtey, France
Yasar Caliskan, Turkey
Giovanni Cancarini, Italy
Giovambattista Capasso, Italy
Ben Caplin, United Kingdom
Cristina Stela Capusa, Romania
Fernando Carrera, Portugal
Fergus Caskey, United Kingdom
Giuseppe Castellano, Italy
Etienne Cavalier, Belgium
Philippe Chauveau, France
Michal Chmielewski, Poland
Anders Christensson, Sweden
Jerzy Chudek, Poland
Clemens D. Cohen, Germany
Giacomo Colussi, Italy
Rosanna Coppo, Italy
Emilie Cornec-Le Gall, France
Cécile Couchoud, France
Mario Cozzolino, Italy
Josep M. Cruzado, Spain
Adamasco Cupisti, Italy
Mohamed R. Daha, The Netherlands
Andrew Davenport, United Kingdom
Simon Davies, United Kingdom
Angel de Francisco, Spain
Peter de Leeuw, The Netherlands
Johan De Meester, Belgium
Maria Alicja Debska-Slizien, Poland
Guy Decaux, Belgium
Friedo W. Dekker, The Netherlands
Lucia Del Vecchio, Italy
Pierre Delanaye, Belgium
Nada Dimkovic, Serbia
Wilfried Druml, Austria
Magdalena Durlik, Poland
Robert Ekart, Slovenia
Garabed Eknoyan, U.S.A.
Agnete Ekstrand, Sweden
Ragada El-Damanawi, United Kingdom
Kathrin Eller, Austria
Francesco Emma, Italy
Ekrem Erek, Turkey
Bo-Goran Ericzon, Sweden
F. Fevzi Ersoy, Turkey
Martin Edlund, Sweden
Charles Ferro, United Kingdom
Patrik Finne, Finland
Jonathan G. Fox, United Kingdom
Joao M. Frazao, Portugal
Luc Frimat, France
Maurizio Gallieni, Italy
Colin Geddes, United Kingdom
Loreto Gesualdo, Italy
Matthias Girndt, Germany
Griet Glorieux, Belgium
Eric Goffin, Belgium
Dimitrios Goumenos, Greece
Matthew D. Griffin, Ireland
Josep M. Grinyo, Spain
Oliver Gross, Germany
Maria Guedes-Marques, Portugal
Rodrigo Hagemann, Brazil
Nynke Halbesma, United Kingdom
Maria Haller, Austria
Marion Haubitz, Germany
Richard Haynes, United Kingdom
James Heaf, Denmark
Gunnar Heine, Germany
Bruce Hendry, United Kingdom
Luuk Hilbrands, The Netherlands
Karl Hilgers, Germany
Radovan Hojs, Slovenia
Ewout Hoorn, The Netherlands
Mads Hornum, Denmark
Zdenka Hruskova, Czech Republic
Tobias Huber, Germany
Reiko Inagi, Japan
Stefan Jacobson, Sweden
Philippe Jaeger, United Kingdom
Joachim Jankowski, Germany
Alan Jardine, United Kingdom
Faïçal Jarra, Tunisia
David Jayne, United Kingdom
Lina Johansson, United Kingdom
Ann Cathrine Johansson, Sweden
Laurent Juillard, France
Philip Kalra, United Kingdom
Mehmet Kanbay, Turkey
Zeynep Kendi Celebi, Turkey
Petar Kes, Croatia
Markus Ketteler, Germany
Marian Klinger, Poland
Anna Koettgen, Germany
Evangelia Kouidi, Greece
Rafael Kramann, Germany
Anneke Kramer, The Netherlands
Vera Krane, Germany
Daniel Kraus, Germany
Raymond T. Krediet, The Netherlands
Matthias Kretzler, U.S.A.
Martin K. Kuhlmann, Germany
Gurinder Kumar, United Arab Emirates
Ulrich Kunzendorf, Germany
Armin Kurtz, Germany
Mariusz Kusztal, Poland
Laura Labriola, Belgium
David Lappin, Ireland
Maurice Laville, France
Christophe Legendre, France
Jens Leipziger, Denmark
Ewa Lewin, Denmark
Orfeas Liangos, Germany
Monika Lichodziejewska-Niemierko, Poland
Elizabeth Lindley, United Kingdom
Francesco Locatelli, Italy
Johannes Loffing, Switzerland
Carlo Lomonte, Italy
Gérard Londo, France
Merike Luman, Estonia
Iain C. Macdougall, United Kingdom
Bruce MacKinnon, United Kingdom
Iain MacPhee, United Kingdom
Francisco Maduell, Spain
<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Umberto Maggiore</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Francesca Mallamaci</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Jolanta Malyszko</td>
<td>Poland</td>
<td></td>
</tr>
<tr>
<td>Johannes F.E. Mann</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Patrick Mark</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Alejandro Martin-Malo</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Leyre Martin-Rodriguez</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Rosalinde Masereeuw,</td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Ziad Massy</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>Sandro Mazzaferro</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Ellon McGregor</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Bjorn Meijers</td>
<td>Belgium</td>
<td></td>
</tr>
<tr>
<td>Paolo Mene'</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Jan Menne</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Peter Mertens</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Piergiorgio Messa,</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Harald Mischak</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Pablo Molina</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Miklos Z. Molnar</td>
<td>Hungary</td>
<td></td>
</tr>
<tr>
<td>Leo A.H. Monnens</td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Renato Monteiro</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>Eugen Mota</td>
<td>Romania</td>
<td></td>
</tr>
<tr>
<td>Heini Murer</td>
<td>Switzerland</td>
<td></td>
</tr>
<tr>
<td>Evi Nagler</td>
<td>Belgium</td>
<td></td>
</tr>
<tr>
<td>Judit Nagy</td>
<td>Hungary</td>
<td></td>
</tr>
<tr>
<td>Masaomi Nangaku</td>
<td>Japan</td>
<td></td>
</tr>
<tr>
<td>Hans Hellmut Neumayer</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Marlies Noordzij</td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Marina Noris</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Michal Nowicki</td>
<td>Poland</td>
<td></td>
</tr>
<tr>
<td>Menso Nubé</td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Rainer Oberbauer</td>
<td>Austria</td>
<td></td>
</tr>
<tr>
<td>Gurbey Ocac</td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Erkan Ok</td>
<td>Turkey</td>
<td></td>
</tr>
<tr>
<td>Klaus Olgaard</td>
<td>Denmark</td>
<td></td>
</tr>
<tr>
<td>Albert Ong</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Sylvie Opatrná</td>
<td>Czech Republic</td>
<td></td>
</tr>
<tr>
<td>Alberto Ortiz</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Ingrid Os</td>
<td>Norway</td>
<td></td>
</tr>
<tr>
<td>Ulf Panzer</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Andreas Pasch</td>
<td>Switzerland</td>
<td></td>
</tr>
<tr>
<td>Erling B. Pedersen</td>
<td>Denmark</td>
<td></td>
</tr>
<tr>
<td>Alexandre Persu</td>
<td>Belgium</td>
<td></td>
</tr>
<tr>
<td>Licia Peruzzi</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Harm Peters</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Giorgina B. Piccoli</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Maria Pippias</td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Emmanuelle Plaisier</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>Esteban Porrini</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Manuel Praga</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Uwe Querfeld</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Abdul Rashid Tony Qureshi</td>
<td>Sweden</td>
<td></td>
</tr>
<tr>
<td>Helmut Reichel</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Jana Reiterova</td>
<td>Czech Republic</td>
<td></td>
</tr>
<tr>
<td>Halima Resic</td>
<td>Bosnia and Herzegovina</td>
<td></td>
</tr>
<tr>
<td>George Reusz</td>
<td>Hungary</td>
<td></td>
</tr>
<tr>
<td>Ian Roberts</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>J. Mariano Rodriguez-Portillo</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Paola Romagnani</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Alexander Rosenkranz</td>
<td>Austria</td>
<td></td>
</tr>
<tr>
<td>Laszlo Rosivall</td>
<td>Hungary</td>
<td></td>
</tr>
<tr>
<td>Patrick Rossignol</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>Djillali Sahali</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>Alan D. Salama</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Rafael Santamaria</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Antonio Santoro</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Pantelis Sarafidis</td>
<td>Greece</td>
<td></td>
</tr>
<tr>
<td>Elke Schaeffner</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Joost Schansstra</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>Francesco Paolo Schena</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Ralf Schindler</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Georg Schlieper</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Roland E. Schmieder</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Mårten Segelmark</td>
<td>Sweden</td>
<td></td>
</tr>
<tr>
<td>Nurhan Seyahi</td>
<td>Turkey</td>
<td></td>
</tr>
<tr>
<td>Siren Sezer</td>
<td>Turkey</td>
<td></td>
</tr>
<tr>
<td>Neil Sheerin</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Ali M. Shendi</td>
<td>Egypt</td>
<td></td>
</tr>
<tr>
<td>Rukshana Shroff</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Kostas C. Siamopoulos</td>
<td>Greece</td>
<td></td>
</tr>
<tr>
<td>Alice Smith</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Maria José Soler Romeo</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Sandor Sonkodi</td>
<td>Hungary</td>
<td></td>
</tr>
<tr>
<td>Søren Schwarz Sørensen</td>
<td>Denmark</td>
<td></td>
</tr>
<tr>
<td>Jean-Paul Squifflet</td>
<td>Belgium</td>
<td></td>
</tr>
<tr>
<td>Vianda Stel</td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Peter Stenvinkel</td>
<td>Sweden</td>
<td></td>
</tr>
<tr>
<td>Kate Stevens</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Tomasz Stompor</td>
<td>Poland</td>
<td></td>
</tr>
<tr>
<td>Dirk Struijk</td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Frank Strutz</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Guitelkin Suleymanlar</td>
<td>Turkey</td>
<td></td>
</tr>
<tr>
<td>Wladyslaw Sulowicz</td>
<td>Poland</td>
<td></td>
</tr>
<tr>
<td>My Svensson</td>
<td>Norway</td>
<td></td>
</tr>
<tr>
<td>James Tattersall</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Pieter M. ter Wee</td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Vladimir Tesar</td>
<td>Czech Republic</td>
<td></td>
</tr>
<tr>
<td>Friedrich Thaiss</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Burkhard Toenshoff</td>
<td>Germany</td>
<td></td>
</tr>
<tr>
<td>Natalja Tomilina</td>
<td>Russia</td>
<td></td>
</tr>
<tr>
<td>Rezan Topaloglu</td>
<td>Turkey</td>
<td></td>
</tr>
<tr>
<td>Nicholas Topley</td>
<td>United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Jan Tordoir</td>
<td>The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Claudia Torino</td>
<td>Italy</td>
<td></td>
</tr>
<tr>
<td>Roser Torra</td>
<td>Spain</td>
<td></td>
</tr>
<tr>
<td>Francesco Trepiccione</td>
<td>Italy</td>
<td></td>
</tr>
</tbody>
</table>
Held jointly with

Francesco Trevisani, Italy
Giovanni Luigi Tripepi, Italy
Photini-Effie C. Tsilibary, Greece
George Tsirpanlis, Greece
Wim Van Biesen, Belgium
Frank M. van der Sande, The Netherlands
Cees Van Kooten, The Netherlands
Raymond Vanholder, Belgium
Jill Vanmassenhove, Belgium
Roland Veelken, Germany
Marianne Verhaar, The Netherlands
Marc Vervloet, The Netherlands
Giuseppe Vezzoli, Italy
Volker Vielhauer, Germany
Andreas Vychytil, Austria
Christoph Wanner, Germany
Jack Wetzels, The Netherlands
Andrzej J. Wiecek, Poland
Martin Wilkie, United Kingdom
Janusz Witowski, Poland
Ralph Witzgall, Germany
Rainer P. Woitas, Germany
Rudolf Peter Wuthrich, Switzerland
Mahmut Ilker Yılmaz, Turkey
Elena Zakharova, Russia
Wojciech Zaluska, Poland
Gianluigi Zaza, Italy
Carlamaria Zoja, Italy

LATE BREAKING CLINICAL TRIALS ABSTRACTS

Reviewers
Hans-Joachim Anders, Germany
Annette Bruchfeld, Sweden
Danilo Fliser, Germany
Michel Jadoul, Belgium
Alan Jardine, United Kingdom
Alberto Ortiz, Spain
George Reusz, Hungary
Maria José Soler Romeo, Spain
Patrick Rossignol, France
Carmine Zoccali, Italy
Accepted abstracts
Accepted abstracts will be available only online (on the ERA-EDTA portal ENP at www.enp-era-edta.org, click on “E-materials” in the ERA-EDTA Congress 2019 Special Area) or on the Mobile Congress App (search for “ERA-EDTA” on the Google or Apple store).

Admission
Admission to the scientific sessions is strictly reserved to registered CEPD/congress members.
Minors cannot access the session halls even if accompanied by a registered adult. The same also applies to the Exhibition. In order to be fully compliant with both the EFPIA and MedTech Europe Code of Ethical Business Practice, ERA-EDTA does not extend hospitality in any way to persons other than the registered congress participants, i.e. healthcare professionals.

Certificate of attendance
The certificate of attendance is not available as a hard copy onsite. It can ONLY be printed from the restricted area of each CEPD/congress member by going to www.era-edta2019.org/registrations (access is possible only using the congress members credentials). Only the days in which you have actively scanned your badge will be printed in the certificate of attendance.

Coffee breaks
Complimentary coffee will be served in the Exhibition on June 14 and 15, 2019. On June 13 and 16, 2019 refreshments will be served in dedicated areas close to the session rooms.

Congress App
The Mobile Congress App can be downloaded from the Google or Apple store. Search for “ERA-EDTA”. The App contains the full scientific programme and all information about Industry Symposia and Exhibitors.
Standard features enable easy navigation and scheduling. Special features allow you to take notes on slides, vote in live sessions, message the faculty, receive personal content recommendations and notifications, read news and test your knowledge with learning questions of your favourite tracks. New in 2019: view slides during a lecture on your mobile and tag single slides to build your personal summary. To learn more and for a demo visit the e-campus on site.

Congress memberships
Regularly registered congress members are entitled to attend all Scientific and Poster Sessions, Welcome Ceremony and Reception as well as access the Industry Exhibition. Onsite they will also receive a congress kit; the Final Programme, if requested during the registration, will be available at the “badge print and badge distribution” desk.
No registration is available for accompanying guests; however, all registered congress members can take part, with their accompanying guests, in the Welcome Ceremony and Welcome Reception on Thursday, June 13, 2019, provided that they collect a guest badge at the “New Registrations” desks.

All registered CEPD/congress members must wear their name badge when attending any congress event. Only attendants wearing congress members badges are entitled to attend lectures and poster sessions.
The information printed on the badges is exactly the one provided by CEPD/congress members during the registration procedure.
Reprint/Lost-forgotten badges
A “Reprint desk” for lost or forgotten congress members badges will be available in the Registration Area. A replacement badge will cost EUR 20.00 and only payments in cash will be accepted.

CEPD Courses
In order to participate in the CEPD Courses held on Thursday, June 13, 2019, a specific pre-registration is required. Check all information at www.era-edta2019.org/registrations.

Currency
The only currency accepted at the ERA-EDTA Congress will be EUR. A currency exchange service is available for the entire duration of the congress in the Entry Hall III of Hungexpo

EACME / UEMS Credits
The 56th ERA-EDTA Congress has been accredited by EACME® for a maximum of 20 hours of European external CME credits. The CEPD, instead, has been accredited by EACME® for a maximum of 7 hours of European external CME credits.

Facilities at the Hungexpo Budapest
A cloak room is located in the Entry Hall III of the Hungexpo Budapest; this service will be available for the entire duration of the congress. At the cloak room the lost & found service is also provided.

Internet points are available in the Registration Area, Hall F and in the E-Campus, Hall A; a Wi-Fi service is provided in the main public spaces of the congress centre, meeting rooms and exhibition.

There are several food and beverage options located in the congress venue; there are also catering areas in the exhibition.

Grant policy
All ERA-EDTA travel grants had to be applied for in advance and have already been assigned. No additional travel grants, reduced fees or financial support of any kind can be given to registered congress members.

Information desks
In the Registration Area, Hall F an Information Desk will provide you with all the information related to the venue, the services provided and the congress activities.

This desk will have the same opening hours as the Registration Area.

In addition, a Tourist Information Desk is available in the Entry Hall III: here you can receive promotional materials about Budapest, including maps, as well as information about public transportation, sightseeing tours, city walks, day trips outside Budapest, cultural events and restaurant reservations.

Opening hours:
- Wednesday, June 12: 11:00-19:00 hours
- Thursday, June 13: 07:00-18:30 hours
- Friday, June 14: 07:00-18:30 hours
- Saturday, June 15: 07:00-18:30 hours
- Sunday, June 16: 07:30-13:00 hours
Congress Information

Insurance / Liability
Participation in this Congress implies that persons/registered CEPD/congress members agree that the organisers do not assume any liability whatsoever. Upon registration, the congress members accept this proviso. ERA-EDTA cannot be deemed responsible for forgotten, lost or stolen personal belongings and Congress materials.

Language of the Congress
The official language of the Congress is English. No simultaneous translation will be provided.

Lost and Found
See “Facilities at the Hungexpo Budapest”.

Lunch
Snack bars and catering areas will offer snacks and sandwiches for purchase. Most of the Companies that have arranged Industry Sponsored Symposia will offer lunch to registered congress members.

Meetings on the go
Three meeting rooms are available for congress members (only) for face-to-face meetings among colleagues in the exhibition area (booths 1375, 1390, 1395), free of charge. These rooms can be used for maximum one hour meetings. The booking of the rooms can be made directly at the booths.

Post-congress correspondence
If you wish to contact the ERA-EDTA after the Congress, here are the full contact details:
Congress memberships and receipts: registrations@era-edta.org, telephone +39-345-0211784 or +39-366-6814442.
Abstracts and travel grants: abstracts@era-edta.org, telephone +39-346-2425284.
Scientific programme, speakers and chairs: program@era-edta.org, +39-346-2425284.
Congress E-materials: e-materials@era-edta.org,+39-345-9461941.

Printed posters
All presenters who took advantage of the ERA-EDTA offer to have their posters professionally printed and delivered to the congress venue free of charge, should pick up their posters at the Poster Helpdesk on the e-campus – next to the main Poster Area - according to the following time schedule:
Thursday, June 13 16:00 - 19:00 hours
Friday, June 14 07:00 - 19:00 hours
Saturday, June 15 07:00 - 10:00 hours

Programme changes
The organisers cannot assume liability for changes in the programme due to external or unforeseen circumstances.

Registration / Information
The registration and information desks are located in the Registration Area of the Hungexpo Budapest. The desks will be open according to the following time schedule:
Wednesday, June 12 11:00-19:00 hours
Thursday, June 13 07:00-18:30 hours
Friday, June 14 07:00-18.30 hours
Saturday, June 15 07:00-18:30 hours
Sunday, June 16 07:30-13.00 hours
Shuttle Bus
There will be a Congress shuttle bus between Pilango metro station (red line) and the Hungexpo with the following time schedule:

- **Wednesday, June 12**: 10:30-19:30 hours
- **Thursday, June 13**: 07:00-20:00 hours
- **Friday, June 14 and Saturday, June 15**: 07:00-19:00 hours
- **Sunday, June 16**: 07:30-13:00 hours

Social Media
The official hashtag of the 56th ERA-EDTA Congress is #ERAEDTA19. Please use it in all tweets or posts related to the 56th ERA-EDTA Congress. The hashtag is not case sensitive, this means that #ERAEDTA19 is the same as #eraedta19.


SPEAKERS INFORMATION

The Speakers' Preview Room is located on the ground floor of the Hungexpo Budapest and will be open during the following hours, with expert technicians available to assist all speakers:

- **Wednesday, June 12**: 11:00-19:00 hours
- **Thursday, June 13**: 07:00-18:30 hours
- **Friday, June 14**: 07:00-18:30 hours
- **Saturday, June 15**: 07:00-18:30 hours
- **Sunday, June 16**: 07:00-13:00 hours

All presentations need to be prepared as PowerPoint files in 16:9 format and will be loaded on a central server in the Speakers’ Preview Room. All speakers should bring their presentations stored on a CD, DVD or USB memory stick to this room no later than 2 hours before the start of their session (or the afternoon of the day before if the presentation refers to the first morning sessions).

The use of laptop computers will not be possible.

The Disclosure of Interest of all Invited Speakers and Chairs will be made available at the beginning of each session. Moreover, they have been posted on the Budapest Congress website www.era-edta2019.org, under the specific section.
HELP US HELP

Funds will be used for travel grants for young nephrologists to attend the next Congress in Milan!

T-shirt
for your free time

Mug
coffee time

Necktie
for work meetings

Scarf
an elegant touch
E-MATERIALS SERVICES

www.enp-era-edta.org

Instant access to Speaker slides, Abstracts and e-posters. Watch presentations live or webcasts on demand. New in 2019: Organise your post Congress meetings by creating your own slide e-playlist. Find out more at the e-campus.

Log in with your badge number at your existing ENP account or register on ENP.

MOBILE APP

- Full Program Details and Speakers
- Create your own Timeline
- Industry Symposia and Exhibitors
- Access Speaker E-materials
- Take Notes under slides and Tag Slides for your Summary
- Useful Congress information and maps
- Twitter feed of ERA-EDTA 2019

Search for ‘ERA-EDTA’ on the app stores and select ERA-EDTA 2019

E-CAMPUS

- Rare Disease Corner
- E-posters on Touch Screens
- ENP Sign-up and Demo
- Learning Stations
- Meeting Areas, Coffee and Charging
- Technical Support

Visit the e-campus in Hall A

Services supported by:
CME CREDITS

The 56th ERA-EDTA Congress has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 20 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

The Continuous Education and Professional Development (CEPD) Courses have been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 7 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

For more information, visit www.uems.net.

HOW TO RECEIVE EACCME / UEMS CREDITS

ERA-EDTA will track attendance of congress members during the congress in the Hungexpo Budapest each day. Regularly registered congress members must self-scan their badge at the kiosks at the entrance of the lecture rooms (at registered congress members’s own responsibility).

The UEMS certificate reflecting the actual attendance (based on the scanning done) can only be downloaded from the congress members restricted area by going to www.registration.era-edta2019.org/ra/login.php (access is possible only using the congress members credentials), it is NOT sent by post.

ERA-EDTA has provided about 200 educational grants to support the congress attendance of the nephrologists of these countries:

- Czech Republic
- Italy
- Malaysia
- Russia
- Spain

These educational grants have been granted with the unconditional support of following companies:

- B|BRAUN
- cai service
- E|TOR
- FRESENIUS MEDICAL CARE
- KH
- Medtronic
- SPINDIAL
CONGRESS INFORMATION

ACCEPTED ABSTRACTS

Free Communications
The presentation time for all free communication sessions is 10 minutes, followed by 3 minutes of discussion. All speakers are requested to keep to their allotted time. Please ensure that you are in your session hall at least 10 minutes before the session starts, and remain until the end of the session.

All presentations need to be prepared in PowerPoint and need to be in 16:9 format. All speakers should bring their presentations stored on a CD-ROM, DVD or USB memory stick to the Speakers’ Preview Room no later than 2 hours before the start of their session. The use of laptop computers will not be possible.

Posters
Posters will be displayed in the Poster Area of the Hungexpo Budapest. There will be two poster sessions on Friday, June 14 and Saturday, June 15 from 09:30 to 10:45 and from 16:30 to 17:30.

Authors should mount their poster on the day of their session starting at 07:30 and dismantle it after 17:00 hrs the same day. The poster panel measures 90 cm width x 200 cm height (portrait/vertical). The organisers will provide suitable fixing material during this period (07:30-17:00).

The code number of each poster indicates the position of the display board.

Presenting authors are kindly requested to be present throughout the official poster viewing time in order to explain their research and to answer questions from congress members. There will be no guided formal discussion.

ERA-EDTA cannot be deemed responsible for lost or stolen posters.

Posters which are not dismounted by the end of each day will automatically be disposed of.

Printed posters
All presenters who took advantage of the ERA-EDTA offer to have their posters professionally printed and delivered to the congress venue free of charge, should pick up their posters at the Poster Helpdesk on the e-campus – next to the main Poster Area - according to the following time schedule:

Thursday, June 13 16:00 - 19:00 hours
Friday, June 14 07:00 - 19:00 hours
Saturday, June 15 07:00 - 10:00 hours

Abstract numbering system
F = Friday, Sa = Saturday, Su = Sunday
O = free communication, P = poster
e.g. SaP313 = Saturday, poster number 313
ERA-EDTA AWARDS AND GRANTS

Also this year the ERA-EDTA has decided to give up to 90 travel grants for young nephrologists (under 40 years of age) to attend the Budapest Congress. The total sum – EUR 50,000.00 - has thus been allocated to the best rated abstracts in the various categories.

All winners will receive:

a) Free Congress Registration;
b) A grant for EUR 500.00, except for the Presenting Authors of the best abstracts of each category who will receive a grant of EUR 1,000.00.

The Presenting Authors of the two best abstracts of each category will also receive a diploma, independently of age.

The Paper Selection Committee has also selected the 10 best abstracts overall, the authors of which will receive a diploma.

How to collect your grant

In case of free communications, grant winners will have to go to the Faculty & Grants Desk in the Registration Area of the Hungexpo Budapest with the voucher that they will receive from the Chairpersons of their session. Instead, poster presenters will have to go directly to the Faculty & Grants Desk after their presentation.

Congress awards will be given only to the presenting author of the successful abstract, who must show a valid identification picture ID, together with the voucher (if applicable), to the ERA-EDTA staff at the Faculty & Grants Desk after the presentation.

Awards will not be given to co-authors/colleagues/friends/relatives; no exceptions will be made.

No other grants or financial support of any kind, besides the grants mentioned above, will be given to registered congress members.

The free communications which received a travel grant are highlighted in this programme with the symbols below. The complete list of grant winners, including the posters, are available on the congress website at www.era-edta2019.org/travel-grants.

- Ten best abstracts

- Eight best abstracts presented by young authors

- Best abstracts presented by young authors

ASQ Travel Grants

ASQ (Altruistic Support by Questionnaire) is an initiative of the ERA-EDTA meant to help young doctors living in countries with official annual income (GDP - Gross Domestic Product per Capita) below USD 10,000 (source: World Bank) to attend the Congress in Budapest. This grant is meant to cover travel and accommodation expenses; all winners also receive a free congress membership.

Be sure to help and support this initiative, which is based on the number of replies received to the survey sent to all registered congress members after the event: for each 100 replies ERA-EDTA will support one ASQ grant. So don’t forget to fill in the questionnaire!
YOU HAVE HELPED US HELP

Thanks to your generous contribution last year, three travel grants of € 600.00 each were given to:
Dr. Ehab Al-sodany, Dr. Berfu Korucu and Dr. Pravesh Sharma
(Selected among the best young authors of accepted abstracts)

Ehab Al-sodany, Sweden  Berfu Korucu, Turkey  Pravesh Sharma, India

www.era-edta.org
ERA-EDTA MEMBERS (CAT. A AND B) INFORMATION

ERA-EDTA Membership Office
You will find the ERA-EDTA Membership Office in the Registration Area of the Hungexpo Budapest. It is possible to pay membership fees and become a new ERA-EDTA member. The desk will be closed from 8:30 to 11:00 hrs on Saturday, June 15, 2019 due to the General Assembly. You can also apply as a new member and pay your membership fee with your credit card directly online by clicking on www.era-edta.org

How to vote for the new Ordinary Council Members (Full active Members only)
Voting is only available electronically and can be accessed by visiting the ERA-EDTA website at http://web.era-edta.org/council-candidates-2019. Starting this year, the voting station will not be available during the annual congress, thus at the Hungexpo in Budapest, all Full active members, eligible for voting, can retrieve the voting credentials directly from the restricted area of the ERA-EDTA Website- section Vote. Votes can only be cast online. Electronic voting will close on June 15, 2019 09:30 (CEST).

Why should you become an ERA-EDTA member?
As a member you will become part of one of the most influential European Medical Associations! Check out all the benefits:
• NDT (Nephrology Dialysis Transplantation) subscription, including exclusive access to the archives.
• Exclusive live streaming sessions during the ERA-EDTA Annual Congress.
• Unlimited access to ERA-EDTA Congress E-materials, to all ERA-EDTA members who participate at the Congress; 30 E-material sessions to members who do not participate.
• Exclusive access to special content on ENP (i.e. CME courses slides, ERA-EDTA Dialogue).
• Active participation in the decision-making policies of the Association.
• Special discounted congress membership fees at the annual congress.
• Special discounts (35%!) on the costs of Oxford University Press (OUP) books.
• Participation in the Young Nephrologists’ Platform (YNP), if you are under the age of 40 years old.
• Take advantage of special membership fees for low income countries.
• Exclusive free access to EuroPD videos.
• Exclusive free access to Seminars in Dialysis.

To find out more about ERA-EDTA (more advantages, educational initiatives, grants, etc.) visit the homepage www.era-edta.org.

Fast track to become an ERA-EDTA member
Become a member today!

ERA-EDTA offers members exclusive advantages and opportunities

ERA-EDTA members can take advantage of:

- Complimentary subscription to ndt
- Be actively involved in the Society’s Committees and Working Groups
- Congress and course E-Materials and live streaming on EXP
- Special discount of 35% on Oxford University Press books
- Attend the Scientific and Educational Interaction Day (SEID)

Those who become a member at this Congress will receive a small gift.

Go to the Membership desk (in the registration area) to collect your personalised voucher.

www.era-edta.org
HUNGARIAN SOCIETY OF NEPHROLOGY

The Hungarian Society of Nephrology (HSN) is a scientific association of nephrologists which currently has about 350 active members. The final goal of the society is to improve patient care and quality of life. In order to achieve this objective, the society implemented educational programmes for nephrologists and other medical and paramedical professionals.

The HSN provides a background for the Nephrological Section of the Health Professional College by helping decision-makers and legislators with professional data and suggestions. We are supporting research through multiple research and travel grants and also by organising congresses and national and international CME courses on nephrology. The “Nephrology Summer School” is a well-known course which recently celebrated its twentieth anniversary. It is organised by Laszlo Rosivall and supported by the ISN and ERA-EDTA.

Hungary successfully hosted the IFKF congress in 2012.

We have a national journal “Hypertonia es nephrologia” which publishes educational and research articles, further our international official journal “Kidney and blood pressure research” publishes clinical and basic studies related to nephrology, hypertension and cardiovascular research.

The HSN – together with its non-profit partners promotes knowledge about kidney diseases to the public through the “National Kidney Programme”, a large-scale initiative which attracts and unites efforts of organisations from different medical domains, like hypertension, transplantation medicine, diabetes, obesitology etc. We are setting up panel discussions and patient forums; we are also organising courses to educate patients on dialysis (lifestyle, diet, compliance). We are supporting transplantation “road shows” – to encourage living related donation in the families of patients on dialysis. A summer camp for kidney and liver transplanted children and their families is one successful way to help reintegration of these patients into society.

The HSN works closely with international societies such as ISN and ERA-EDTA. The HSN was one of the first to initiate the “World Kidney Day”. Our yearly campaigns are not restricted to this one day only but are regularly promoted through mass media, Facebook, flash mobs etc. In order to articulate the specific endeavours of new generations the HSN - in conjunction with the ERA-EDTA’s Young Nephrologists’ Platform (YNP) – has recently prompted the formation of a young nephrologists working group within the society and sponsored their entry into ERA-EDTA.

Visit the booth to learn more about our programmes and the Society.

More information at: www.nephrologia.hu
INFORMATION FOR PRESS/MEDIA REPRESENTATIVES

Media Guidelines/ Social Media Guidelines
All journalists and media representatives have to sign that they will be compliant with both guidelines as well as with the Embargo Policy when they pick up their press passes.

Embargo Policy
All abstracts presented at the ERA-EDTA are embargoed until the date and time of their presentation. The embargo is lifted at the beginning of the presentation, not at the beginning of the session!

Media Registration
Pre-registered journalists can pick up their press passes at the press office. The press pass provides access to all the sessions and symposia at this congress. For onsite registration, media representatives are similarly requested to come to the press room.
The following identification will be required: press identification/press card and a letter of assignment from the news organization being represented.
Public relations personnel and exhibitors cannot register as Press!

Press Room
ERA-EDTA will be providing a fully-equipped press room (WiFi/printer). Press folders and other materials will be available. The Press Office is located in Hall F, near the Registration Area (please follow the signs), Opening hours:
Thursday, June 13  08:30-18:00
Friday, June 14  07:30-18:00
Saturday, June 15 07:30-18:00
Sunday, June 16  08:00-11:00

Official Hashtag
The official hashtag of the 56th ERA-EDTA Congress is #eraedta19.

ERA-EDTA Press Events
“Pre-Congress” Press Event/Opening Press Conference
Tuesday, June 11, 11:00-12:00
Aesculap Akadémia 1115 Budapest, Halmi út 20-22
This opening press conference will highlight the importance of prevention and early detection of chronic kidney disease. Press packs will be available in Hungarian, too.

Scientific Press Conference
Friday, June 14, 09:00-10:00
ERA Room 1, Hall F-G, mezzanine floor

A selection of the “Late Breaking Clinical Trials” (LBCT) and of papers published in top medical journals at the time of the congress will be presented by their authors and will be discussed.
The embargo of the LBCT is lifted when presentation of the paper commences in the LBCT session of the main program – but not at the press conference itself.

Press Office ERA-EDTA 2019
albersconcept, Dr. Bettina Albers, Jakobstrasse 38, 99423 Weimar, Germany, Tel. +49 3643 7764-23, Fax +49 3643 7764-52, Mobile +49 174 2165629, email: press@era-edta.org.
Visit the new website!

Simple, clear, intuitive and easily navigable from every device

Lots of advantages for our members!

- Very easy access to exclusive content in the restricted area
- Stay updated with ERA-EDTA’s new initiatives
- Find out about the latest novelties of the Committees and Working Groups
- Actively participate in the growth of the Association

www.era-edta.org
Scientific Programme

DAY AT A GLANCE

08:00 - 08:30 **Congress Opening**

08:45 - 12:25 **CEPD**
- Primary & Secondary GN, vasculitis and autoimmune diseases
- CKD
- Hypertension, diabetes, CV diseases in CKD
- Bone Mineral disorders in CKD
- Genetic diseases and rare diseases
- Basic & translational Nephrology

08:45 - 16:00 **CEPD**
- Nephropathology course

13:00 - 16:40 **CEPD**
- Haemodialysis and vascular access
- Renal transplantation
- AKI
- Peritoneal dialysis
- Electrolytes and urolithiasis
- ERA-EDTA Registry

08:45 - 14:45 **Special Track**
- Global and Regional Perspectives

15:15 - 16:45 **Special Session**
- Latest DKD clinical trials: changing the course of the disease

17:00 - 18:15 **Welcome Ceremony**
- Plenary Lecture Rafael Yuste
- Diseases of emergence

16:00 - 20:00 **Exhibition**

18:00 - 19:30 **Welcome Cocktail in the Exhibition**
CONGRESS OPENING

HALL G1

08:00 - 08:30

Welcome words and Presidential address

George Reusz, Local Congress President and President of the Hungarian Society of Nephrology

Presidential address

Carmine Zoccali, ERA-EDTA President
During the 56th ERA-EDTA Congress, only on June 13, 2019, a new exclusive initiative will be held, the first CEPD - Continuous Education and Professional Development.

A unique opportunity for professional development with tailored courses given by top European experts in the field.
HALL G1 08:45 - 12:25

CEPD 1

**Primary and Secondary Glomerulonephritis, vasculitis and auto-immune diseases**

Chairs: **Rosanna Coppo**, Turin, Italy  
**Vladimir Tesar**, Prague, Czech Republic

Focal and segmental glomerulosclerosis (FSGS)  
**Claudio Ponticelli**, Milan, Italy

Membranous Nephropathy  
**Jack Wetzels**, Nijmegen, The Netherlands

IgA Nephropathy  
**Rosanna Coppo**, Turin, Italy

New directions in the treatment of ANCA-associated nephritis  
**Marten Segelmark**, Lund, Sweden

Lupus Nephritis  
**Vladimir Tesar**, Prague, Czech Republic

HALL G2A 08:45 - 12:25

CEPD 2

**CKD**

Chairs: **Raymond Vanholder**, Ghent, Belgium  
**Andrzej Więcek**, Katowice, Poland

Concept and global burden of CKD: current status and beyond  
**Ron Gansevoort**, Groningen, The Netherlands

What is the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+)?  
**Marie Evans**, Stockholm, Sweden

Anaemia management in CKD patients: past, present and the future  
**Andrzej Więcek**, Katowice, Poland

Optimal timing and method for RRT proposed to CKD patients  
**Raymond Vanholder**, Ghent, Belgium
Scientific Programme

HALL G2B

CEPD 3

**Hypertension, Diabetes and CV Disease in CKD**

Chairs: Francesca Mallamaci, Reggio Calabria, Italy  
Esteban Porrini, La Laguna (Tenerife), Spain

Inflammation in CKD: cures at last?  
Danilo Fliser, Homburg/Saar, Germany

Progress in the prevention and cure of diabetic nephropathy  
Lucia Del Vecchio, Lecco, Italy

Prognosis by risk calculators in CKD and in ESRD  
Friedo W. Dekker, Leiden, The Netherlands

LV dysfunction with preserved ejection fraction in CKD: epidemiology, mechanism(s) and therapy  
Patrick Rossignol, Vandœuvre-lès-Nancy, France

HALL F1

CEPD 4

**Bone Mineral disorders in CKD**

Chairs: Markus Ketteler, Stuttgart, Germany  
Marc Vervloet, Amsterdam, The Netherlands

How to prevent fractures in CKD?  
Pieter Evenepoel, Leuven, Belgium

Are we inducing adynamic bone disease, and is that a problem?  
Mathias Haarhaus, Stockholm, Sweden

Is FGF23 outdated?  
Marc Vervloet, Amsterdam, The Netherlands

Don’t forget our old friend Vitamin D  
Justine Bacchetta, Lyon, France
HALL A1
CEPD 5

*Genetic Diseases and Rare Diseases*

Chairs: Olivier Devuyst, Zurich, Switzerland  
Anna Koettgen, Freiburg, Germany

Genetic studies as part of pre-transplant evaluation  
Jan Halbritter, Leipzig, Germany

Genomic studies in adult CKD patients  
Ali G. Gharavi, New York, NY, U.S.A.

Recent GWAS of kidney function markers  
Anna Koettgen, Freiburg, Germany

Polycystic kidney disease: new genes and clinical studies  
Olivier Devuyst, Zurich, Switzerland

Update on tubular and tubulointerstitial diseases  
Detlef Bockenhauer, London, United Kingdom

HALL A2
CEPD 6

*Basic and Transitional Nephrology*

Chairs: Annette Bruchfeld, Stockholm, Sweden  
Paola Romagnani, Florence, Italy

Single cell transcriptomics of solid tissues: choices and challenges  
Sanjay Jain, Saint Louis, MO, U.S.A.

The new age of kidney imaging  
Nicole Endlich, Greifswald, Germany

Gene editing and new models of kidney diseases  
Ariela Benigni, Bergamo, Italy

How we survive acute injury and develop chronic disease: kidney, heart and liver not so different after all  
Paola Romagnani, Florence, Italy

Optogenetic control of inflammation in acute kidney injury  
Mark D. Okusa, Charlottesville, VA, U.S.A.
Scientific Programme

HALL A3

CEPD 7

Nephropathology

Chairs: **Pablo Cannata-Ortiz**, Madrid, Spain  
**Helen Liapis**, Little Rock, AR, U.S.A.

Renal biopsy handling: improving diagnosis in the pre-analytical phase  
**Pablo Cannata-Ortiz**, Madrid, Spain

FSGS on renal biopsy: why an integrated approach to diagnosis is necessary  
**Laura Barisoni**, Durham, NC, U.S.A.

Atypical post-streptococcal GN and complement  
**Isabelle Brocheriou**, Paris, France

Diabetic Nephropathy versus Kidney Diseases in Diabetics  
**Loreto Gesualdo**, Bari, Italy

The histopathologic spectrum of obesity-related glomerulopathy  
**Helen Liapis**, Little Rock, AR, U.S.A.

Update on fibrillary and immunotactoid glomerulopathy  
**Sándor Turkevi-Nagy**, Szeged, Hungary

Renal side effects of novel anti-cancer drugs  
**Joris Roelofs**, Amsterdam, The Netherlands

How to diagnose chronic TCMR in kidney transplants: Banff and the evidence  
**Marion Rabant**, Paris, France
Vascular access

Prevention and treatment of central venous catheter infections
Laura Labriola, Brussels, Belgium

New developments in vascular access: what can we expect for the future?
Joris Rotmans, Leiden, The Netherlands

Guidelines on vascular access creation and management
Evi Nagler, Ghent, Belgium

Haemodialysis

Dialysis care: personalized or universal?
Andrew Davenport, London, United Kingdom

HDF in children: what can we learn from paediatric studies
Rukshana Shroff, London, United Kingdom

How to increase home and self-care haemodialysis?
Sandip Mitra, Manchester, United Kingdom
Scientific Programme

HALL G2A 13:00 - 16:40

CEPD 9

Renal Transplantation

Chairs: Daniel Abramowicz, Antwerp, Belgium
Bruno Watschinger, Vienna, Austria

Can this person receive a kidney: what is the minimal workup that should be done in a healthy kidney transplant candidate?
Luuk Hilbrands, Nijmegen, The Netherlands

How long should a patient with previous cancer wait before being wait-listed?
Bruno Watschinger, Vienna, Austria

How can I evaluate this extended criteria kidney according to ECD, DCD, KDRI?
Umberto Maggiore, Parma, Italy

How should I prevent CMV disease and BK PVN in 2019?
Rachel Hellemans, Antwerp, Belgium

How should I personalise maintenance therapy according to donor/recipient factors?
Klemens Budde, Berlin, Germany

HALL G2B 13:00 - 16:40

CEPD 10

AKI

Chairs: Andreas Kribben, Essen, Germany
Mehmet Sukru Sever, Istanbul, Turkey

Volume management throughout the course of AKI: Risk – Oliguria – RRT – Polyuria
Wim Van Biesen, Ghent, Belgium

AKI in geriatric population and in frailty
Norbert Lameire, Ghent, Belgium

AKI in austere environments
Valerie A. Luyckx, Zurich, Switzerland

Recent clinical trials and update in AKI
Andreas Kribben, Essen, Germany
HALL F1  13:00 - 16:40

CEPD 11

**Peritoneal Dialysis**

Chairs: Andrew Davenport, London, United Kingdom  
Olof Heimbürger, Stockholm, Sweden

PD catheter insertion and complications  
**Victoria R. Briggs**, Sheffield, United Kingdom

How to prescribe APD  
**Carl M. Öberg**, Lund, Sweden

Prevention, diagnostics and treatment of peritonitis  
**Anabela Rodrigues**, Porto, Portugal

Update on PD solutions  
**Monika Lichodziejewska-Niemierko**, Gdańsk, Poland

Changes in peritoneal structure and function with time on PD  
**Johann Morelle**, Brussels, Belgium

HALL A1  13:00 - 16:40

CEPD 12

**Electrolytes and urolithiasis**

Chairs: Ewout Hoorn, Rotterdam, The Netherlands  
Carsten Wagner, Zurich, Switzerland

Disorders of sodium and water  
**Ewout Hoorn**, Rotterdam, The Netherlands

Hypo- and Hyperkalemia  
**Felix Knauf**, Berlin, Germany

Disorders of calcium and magnesium  
**Pascal Houillier**, Paris, France

Acid-Base disturbances and stones (case-based)  
**Nilufar Mohebbi**, Zurich, Switzerland  
**Stephen Walsh**, London, United Kingdom

Stones and electrolytes (case-based)  
**Philippe Jaeger**, London, United Kingdom
Scientific Programme

HALL A2

CEPD 13

ERA-EDTA Registry

Chairs: Kitty Jager, Amsterdam, The Netherlands
Ziad Massy, Paris, France

Different flavours in RCTs and their analyses
Giovanni Luigi Tripepi, Reggio Calabria, Italy

Pros and cons of surrogate outcomes in RCTs
Kitty Jager, Amsterdam, The Netherlands

Mendelian randomization to enable causal inference in observational studies
Friedo W. Dekker, Leiden, The Netherlands

Directed acyclic graphs (DAGs) to address confounding
Natalie Staplin, Oxford, United Kingdom
HALL A4
08:45 - 14:55

SPECIAL TRACK

Global and Regional Perspectives

Introduction

Session 1
08:50 - 10:05

Can we talk about regional common fate in Nephrology?

Chairs: Ziad Massy, Paris, France
Ivan Rychlik, Prague, Czech Republic

The European perspective (epidemiology)
Ziad Massy, Paris, France

The role of supranational – regional societies
Goce Spasovski, North Macedonia

Role of National Registries in Nephrology - Epidemiological and economical point of view
Orsolya Cseprekál, Budapest, Hungary

Special issues of AKI and CKD in low- and middle-income countries
Mehmet Sukru Sever, Istanbul, Turkey

Session 2
10:15 - 11:45

From the molecule to social determinism. Challenges in Nephrology

Chairs: Anupam Agarwal, Birmingham, AL, U.S.A.
Ondrej Viklicky, Prague, Czech Republic

Translational medicine and real life
Anupam Agarwal, Birmingham, AL, U.S.A.

Arteriosclerosis in children on dialysis - prevention vs damage limitation
Rukshana Shroff, London, United Kingdom

Cardiovascular consequences of paediatric CKD
Dieter Haffner, Hannover, Germany

Recent developments in kidney transplantation
Ondrej Viklicky, Prague, Czech Republic

Holistic care for psychosocial complications of chronic kidney disease
Ágnes Haris, Budapest, Hungary
Scientific Programme

Session 3       12:15 - 13:45

The roots of adult diseases go back to childhood

Chairs: Franz Schaefer, Heidelberg, Germany
         Kjell Tullus, London, United Kingdom

The role of prematurity in kidney diseases in children and adults
Attila Szabo, Budapest, Hungary

Adolescent hypertension: transition from the adolescent to the adult
Kjell Tullus, London, United Kingdom

Dialysis: bridging towards transplantation
Lutz Weber, Cologne, Germany

Diabetes - the changing face of a disease
Istvan Wittmann, Pecs, Hungary

Progression of kidney disease in childhood
Franz Schaefer, Heidelberg, Germany

Session 4       13:55 - 14:55

Nephrology: The Hungarian Perspective

Chairs: Judit Nagy, Szaged, Hungary
         George Reusz, Budapest, Hungary

From Koranyi to WKD - Reestablishment of a European Center
László Rosivall, Budapest, Hungary

From RAS to renal tissue repair - visualization of physiology and pathophysiology
Janos Peti-Peterdi, Los Angeles, CA, U.S.A.

Kidney transplantation from Hepatitis C infected donors to uninfected recipients
Miklos Molnar, Memphis, TN, U.S.A.

Mysteries of inheritance
Kálmán Tory, Budapest, Hungary
HALL A4 15:15 - 16:45

Special Session

*Latest DKD clinical trials: changing the course of the disease*

Chair: **Christoph Wanner**, Würzburg, Germany

*Introduction*

Global burden, unmet need
**David Wheeler**, London, United Kingdom

**SONAR**

Study design and enrichment results
**Peter Rossing**, Copenhagen, Denmark

Main results and interpretation
**Hiddo J.L. Heerspink**, Groningen, The Netherlands

Discussion (Questions and Answers)

**CREDENCE**

Study design, methods, renal results/safety
**Vlado Perkovic**, Sydney, Australia

Cardiovascular results
**Meg Jardine**, Sydney, Australia

Discussion (Questions and Answers)

Interpretation and implications of the trials
**Adeera Levin**, Vancouver, Canada
57th ERA-EDTA Congress
MILAN, ITALY
JUNE 6-9, 2020

Exceptionally low pre-registration fee for Milan only available if done during the Budapest Congress
WELCOME CEREMONY

HALL G1 17:00 - 18:00

Welcome words and Presidential address
George Reusz, Local Congress President and President of the Hungarian Society of Nephrology

Welcome address
Balázs Szeneczey, Deputy Mayor of Budapest

Welcome address
Béla Merkely, Rector of Semmelweis University of Budapest

Presidential address
Carmine Zoccali, ERA-EDTA President

Diploma and thanks to Alberto Ortiz, Chair of the Scientific Committee

*Presentation of the ERA-EDTA Award for Outstanding Basic Science Contributions to Nephrology to Olivier Devuyst*

*Presentation of the ERA-EDTA Award for Outstanding Clinical Contributions to Nephrology to Claudio Ronco*

*Presentation of the Stanley Shaldon Award for Young Investigators to Rebecca Herzog*

Plenary Lecture

*Diseases of emergence*
Rafael Yuste, New York, NY, U.S.A.

Welcome Cocktail in the Exhibition

In order to be totally compliant with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code of Conduct, and thus allow pharmaceutical and medical industry to participate in and support our annual Congress, the ERA-EDTA cannot provide any kind of entertainment (music, etc.) during any of its sessions. This is also true with regard to being compliant with the European Union of Medical Specialists (UEMS) accreditation.
We are proud to announce the winners of the 2019 ERA-EDTA Awards

The winners will be awarded by the ERA-EDTA President during the Welcome Ceremony of the 56th ERA-EDTA Congress on June 13, 2019

Outstanding Basic Science Contributions to Nephrology to: Olivier Devuyst

Stanley Shaldon Award for Young Investigators to: Rebecca Herzog

Outstanding Clinical Contributions to Nephrology to: Claudio Ronco

www.era-edta.org
The Congress Organising Committee is very pleased to announce the Run for Kidneys 2019 event which will take place on June 14, 2019 at 4.30 p.m. during the 56th ERA-EDTA Congress at Hungexpo-Budapest.

The Run for Kidneys 2019 proceeds will be donated directly to the Hungarian Nephrology Foundation.

Schedule:
1 p.m.   Opening of the Run Centre
4 p.m.   End of on-site registration
4.15 p.m. Opening ceremony & warm up
4.30 p.m. Start of the 5 km run
5.15 p.m. Announcement of results

(On-site registration closes 30 minutes before the start of the given race)

On-site registration:
Entry Hall III -
Open on June 13, 2019 from 8 a.m. to 6 p.m. and on June 14, 2019 from 8 a.m. to 1 p.m.

The on-site registration can only be settled by cash payment.
The registration fee is 20€. The on-site registration package does not include the unique cotton t-shirt made for the event.

Get fit, challenge yourself and raise awareness for an important issue. For you it’s just a Friday afternoon but for somebody it’s the chance to heal. Stay tuned and support your charity run during the Congress.
49 Final Programme

DAY AT A GLANCE

08:00 - 09:30 **Symposia**
ERS-EDTA Registry 51
Phosphate and FGF23 52
Paediatric Nephrology 53
The many facets of hypoxia in CKD 53

**Free Communications + Mini Lectures**
Molecular insight in renal pathology 54
What should CKD patients eat? 55
Vascular access 56
Bone disease in dialysis 57

09:30 - 10:45 **Poster session**

10:45 - 11:30 **Plenary Lecture Sanjay Jain**
Interface of molecular mechanisms, pathology and genetics of developmental kidney diseases 59

11:45 - 13:15 **Symposia**
Late breaking clinical trials 59
The many faces of monoclonal gammopathy of undetermined significance 60
Improving outcomes in DKD 61
Redefining the ontology of kidney diseases using genomic analysis 62
Brain and nervous system in CKD 63

**Free Communications + Mini Lectures**
Delivery of dialysis: a holistic approach 64
The next generation of transplant therapeutical approaches 65
Managing hypertension 66

13:15 - 14:45 **Industry Symposia** 123

15:00 - 16:30 **Symposia**
ASN Highlights 67
ANCA-associated vasculitis 67
Blood pressure targets 68
Precision medicine for the sensitized transplant recipient 68

**Free Communications + Mini Lectures**
Protein energy wasting and inflammation 69
Novel molecular mechanisms of diabetic nephropathy 70
Clinical CKD 71
Improving outcome in dialysis patients 72

16:30 - 17:00 **Poster session** 73
Scientific Programme

17:00 - 18:30 **Symposia**
- Basic immunology and pathology
- Primary glomerulonephritides
- Salt and disease: a changing scenario
- Sodium: where is it? How does it harm? How could we intervene?
- Start dialysis? Stop dialysis? - Challenging conversations

**Free Communications + Mini Lectures**
- Genetics in kidney disease: unravelling complex interactions
- Clinical nephrology: predicting outcome
- AKI: still difficult to define
- Novel discoveries in CKD pathophysiology
Scientific Programme

HALL G1

Symposium 01

**ERA-EDTA Registry**

Chairs: Kitty Jager, Amsterdam, The Netherlands  
Ziad Massy, Paris, France

The European EDITH kidney nephrologist survey on treatment modality choice  
Rianne de Jong, Amsterdam, The Netherlands

Trends in excess mortality in patients receiving RRT  
Rianne Boenink, Amsterdam, The Netherlands

Post-transplant growth patterns in children  
Jérome Harambat, Bordeaux, France

Dynamic prediction of mortality in advanced CKD using Troponin T – Results from the EQUAL study  
Nicholas Chesnaye, Amsterdam, The Netherlands
Symposium 02

**Phosphate and FGF23**

Chairs: Giovambattista Capasso, Naples, Italy  
Carsten Wagner, Zurich, Switzerland

FGF23 signalling in the kidney  
Reinhold Erben, Vienna, Austria

Regulation of FGF23  
Mariano Rodriguez, Cordoba, Spain

Phosphate toxicity and the kidney  
Carsten Wagner, Zurich, Switzerland

**FREE COMMUNICATIONS**

**FO001**  
LOW PLASMA KLOTHO IS ASSOCIATED WITH CARDIOVASCULAR EVENTS IN HEMODIALYSIS, INDEPENDENTLY OF MAJOR RISK FACTORS, FGF-23, ARTERIAL STIFFNESS AND INTIMA-MEDIA-THICKNESS  
Evangelos Memmos1; Pantelis Sarafidis1; Panagiotis Pateinakis2; Apostolos Tsiantoulas3; Danae Faitatzidou1; Panagiotis Giอากalis1; Vasileios Vasilikos4; Aikaterini Papagianni1; 1Dept nephrology, Hippokration Hosp, Aristotle Univ Thessaloniki, Thessaloniki, Greece; 2Dept nephrology, Papageorgiou Hosp, Thessaloniki, Greece; 3Hemodialysis unit, Bioclinic Thessaloniki, Thessaloniki, Greece; 4Third Dept cardiology, Hippokration Hosp, Aristotle Univ Thessaloniki, Thessaloniki, Greece

**FO002**  
INTRACELLULAR ATP AND INORGANIC PHOSPHATE DEPLETION DURING MAINTENANCE HEMODIALYSIS  
Guillaume Chazot1; Sandrine Lemoine1; Gabriel Kocevar2; Emilie Kalbacher1; Laetitia Gabrielle Normand1; Dominique Sappey-Marinier2; Olivier Rouviere3; Laurent Juillard1; 1Nephrology, Hospices Civils de Lyon - HCL, Lyon, France; 2Univ Claude Bernard Lyon 1, CREATIS (UMR 5220 CNRS & U 1044 INSERM), Villeurbanne, France; 3Dept urinary and vascular imaging, Hôpital Edouard Herriot - HCL, Lyon, France
Scientific Programme

HALL G2B 08:00 - 09:30

Symposium 03

**Paediatric Nephrology**

Chairs: **Rukshana Shroff**, London, United Kingdom
**Kjell Tullus**, London, United Kingdom

Childhood nephrotic syndrome: lessons from the PODONET registry
**Beata S. Lipska-Ziętkiewicz**, Gdańsk, Poland

Evidence based treatment of minimal change nephrotic syndrome: lessons from the PREDNOS trials
**Nicholas Webb**, Manchester, United Kingdom

Novel therapies for childhood minimal change nephrotic syndrome
**Marina Vivarelli**, Rome, Italy

Blood pressure in children
**Kjell Tullus**<sup>ESP</sup>, London, United Kingdom

HALL F1 08:00 - 09:30

Symposium 04

**The many facets of hypoxia in CKD**

Chairs: **Kai-Uwe Eckardt**, Berlin, Germany
**Peter Kotanko**, New York, NY, U.S.A.

Hypoxia and the progression of polycystic kidney disease
**Kai-Uwe Eckardt**, Berlin, Germany

Sleep disordered breathing: a pervasive problem in CKD
**Francesca Mallamaci**, Reggio Calabria, Italy

Intradialytic hypoxia
**Peter Kotanko**, New York, NY, U.S.A.

Chronic interstitial nephritis of unknown etiology is a toxic tubular nephropathy
**Marc de Broe**, Antwerp, Belgium
Free Communication Session 01

Molecular insight in renal pathology

Chairs: Ariela Benigni, Bergamo, Italy
        Maria Vanessa Pérez-Gómez, Madrid, Spain

FREE COMMUNICATIONS

FO003
A NOVEL KIDNEY-TARGETED BIOENGINEERED CARRIER FOR VEGF DELIVERY IN EXPERIMENTAL RENOVASCULAR DISEASE: PROOF OF CONCEPT
Alejandro Chade1; Engel Jason2; Williams Erika2; Bidwell Gene3; 1Physiology and biophysics; medicine; radiology, Univ Mississippi Medical Center, Jackson, U.S.A.; 2Physiology and biophysics, Univ Mississippi Medical Center, Jackson, U.S.A.; 3Neurology; cell and molecular biology, Univ Mississippi Medical Center, Jackson, U.S.A.

FO004
MOLECULAR TARGETING OF RENAL INFLAMMATION USING DRUG DELIVERY TECHNOLOGY IN CHRONIC KIDNEY DISEASE
Alejandro Chade1; Engel Jason2; Williams Erika2; Bidwell Gene3; 1Physiology and biophysics; medicine; radiology, Univ Mississippi Medical Center, Jackson, U.S.A.; 2Physiology and biophysics, Univ Mississippi Medical Center, Jackson, U.S.A.; 3Neurology; cell and molecular biology, Univ Mississippi Medical Center, Jackson, U.S.A.

FO005
THE TOTAL NUMBER OF NEPHRONS AND THE SINGLE NEPHRON eGFR IN DIFFERENT GLomerULAR DISEASES
Davide Viggiano1; Michelangelo Nigro2; Francesco Sessa3; Graziano Vignolini3; Riccardo Campi3; Sergio Semin3; Pier Luigi D'Angeò2; Giuseppe Gigliotti2; Giovambattista Capasso4; 1Nephrology, Univ. Campania "L. Vanvitelli", Naples, Italy; 2Dept nephrology and dialysis, "MM. SS. Addolorata" Hosp, Eboli, Italy; 3Dept urological robotic surgery and renal transplantation, Univ Florence, Careggi Hosp, Florence, Italy; 4Dept translational medical sciences, Univ. Campania "L. Vanvitelli", Naples, Italy

FO006
THE NRF2 ACTIVATOR BARDOXOLONE METHYL INHIBITS CYST FORMATION, REDUCES INFLAMMATION, AND IMPROVES MITOCHONDRIAL FUNCTION IN CELLULAR MODELS OF POLYCYSTIC KIDNEY DISEASE
Greg Miller1; Isaac Trevino1; Lyndsey Mccauley1; Linda Hannigan1; Brandon Probst1; Deborah Ferguson1; Christian Wigley1; 1Reata Pharmaceuticals, Inc., Irving, U.S.A.

FO007
Rab27a DEPENDENT EXOSOME SECRETION FROM TUBULAR EPITHELIAL CELL MEDIATES ALBUMIN HANDLING AND PROMOTES TUBULOINTERSTITIAL INFLAMMATION IN ALBUMINURIC NEPHROPATHY
Feng Ye1; Lv Lin-Li1; Tang Tao-Tao1; Zhong Xin1; Chen Jun1; Liu Bi-Cheng1; 1Nephrology, Southeast Univ, Nanjing, P.R. China

FO008
FATTY ACID RECEPTORS GPR40/GPR84: TWO PROMISING TARGETS IN KIDNEY FIBROSIS
Lyne Gagnon1; Martin Leduc1; Jean-François Thibodeau1; François A. Leblond1; Pierre Laurin1; Brigitte Grouix1; 1Biology, Prometic Biosciences Inc., Laval, Canada
HALL A2

Free Communication Session 02 + Mini Lecture

What should CKD patients eat?

Chairs: Giuliano Brunori, Trento, Italy
        Halima Resic, Sarajevo, Bosnia and Herzegovina

Mini lecture
Muscle protein turnover and low protein diet in patients with CKD
Giacomo Garibotto, Genoa, Italy

FREE COMMUNICATIONS

FO009
PRIORITIES OF NUTRITIONAL ISSUES IN NON-DIALYSIS CKD ACCORDING TO STAKEHOLDERS
Vincenzo Bellizzi1; Juan Jesus Carrero2; Patrizia Calella3; Philippe Chauveau4; Lina Johansson5; Pablo Molina6; Siren Sezer7; Daniel Teta8; Denis Fouque9; On Behalf of ERN Working Group10; 1Nephrology, San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy; 2 Dept medical epidemiology and biostatistics, Karolinska Inst, Stockholm, Sweden; 3 Dept movement sciences and wellbeing, Parthenope Univ, Naples, Italy; 4 Serv nephrologie transplantation dialyse, Centre Hosp Univ Bordeaux et Aurad-Aquitaine, Bordeaux, France; 5 Dept Nutrition and Dietetics, Hammersmith Hosp, London, United Kingdom; 6 Nephrology, Hosp Univ Dr. Peset, Valencia, Spain; 7 Dept nephrology, Baskent Univ, Ankara, Turkey; 8 Serv nephrology, Hôpital du Valais, Sion and Centre Hosp Univ Vaudois (CHUV), Lousanne, Switzerland; 9Centre Hosp Lyon-sud, Dept Nephrology, Univ Lyon, UCBL, Carmen, Lyon, France; 10 European renal nutrition, ERA-EDTA, London, United Kingdom

FO010
KETOANALOGUE SUPPLEMENTATION PRESERVES RENAL FUNCTION BUT DECLINE IN RENAL FUNCTION IS OBSERVED AFTER WITHDRAWING SUPPLEMENTATION - A FOLLOW-UP STUDY OF RANDOMIZED CLINICAL TRIAL
Anita Saxena; Gupta Amit; Trisha Sachan; Dept nephrology, Sanjay Gandhi Postgraduate Inst Medical Sciences, Lucknow, India

FO011
DOES DIETARY POTASSIUM INTAKE ASSOCIATE WITH HYPERKALEMIA IN NON-DIALYSIS DEPENDENT CKD PATIENTS?
Christiane Ramos1; Bruna Ribeiro,1; Andréia Fernandes,2; Lilian Cuppari3; 1Nutrition program, Univ Federal São Paulo, São Paulo, Brazil; 2Nephrology dept, Univ Federal São Paulo, São Paulo, Brazil; 3Nutrition program and nephrology dept, Univ Federal São Paulo, São Paulo, Brazil

FO012
VEGETARIAN SEVERE HYPOPROTEIC DIET SUPPLEMENTED WITH KETO-ANALOGUES FOR PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS: THE INFLUENCE ON LONG TERM PROGNOSIS
Lilianna Garneata1; Carmen Antonia Mocanu2; Andreea Elena Mocanu2; Tudor Petrisor Simionescu2; Ana Maria Firta2; Mugurel Jafal2; Gabriel Mircescu1; 1Internal medicine and nephrology, "Carol Davila" Univ Medicine and Pharmacy, Bucharest, Romania; 2Nephrology, "Dr Carol Davila" Teaching Hosp Nephrology, Bucharest, Romania

FO013
HIF STABILIZER DECREASES MITOCHONDRIAL OXYGEN CONSUMPTION IN SKELETAL C2C12 MYOTUBE
Hiroshi Nishi1; Koji Takemura1; Takaaki Higashihara1; Masaomi Nangaku1; 1Div nephrology and endocrinology, Univ of Tokyo Hosp, Tokyo, Japan
HALL A3
08:00 - 09:30

Free Communication Session 03

Vascular access

Chairs: Robert Ekart, Maribor, Slovenia
José Ibeas, Barcelona, Spain

FREE COMMUNICATIONS

**FO014**
EPIDEMIOLOGY OF ESRD AND VASCULAR ACCESS – LINKS OF ONE CHAIN
Aleksei Zulkarnaev; Natalia Fominikh; Vadim Stepanov; Andrey Vatazin; Surgical Dept transplantology and dialysis, Moscow Regional Research and Clinical Inst, Moscow, Russia

**FO015**
FLUID SHEAR STRESS MEDIATES THE EXPRESSION OF MONOCYTE CHEMOTACTIC PROTEIN-1 BY VASCULAR ENDOTHELIAL CELLS AND ITS SIGNALING PATHWAY
Zhe Wang; Ali Jiang; Fang Wei; Lan Jia; Blood purification, Second Hosp Tianjin medical Univ, Tianjin, P.R. China

**FO016**
HEMODIALYSIS ACCESS PROFILE IN FAILED KIDNEY TRANSPLANT PATIENTS: ANALYSIS OF DATA FROM THE CATALAN RENAL REGISTRY (1998-2016)
Ramon Roca-Tey1; Emma Arcos2; Jordi Comas2; Jaume Tort2; 1Nephrology, Hosp de Mollet, Mollet del Vallès, Barcelona, Spain; 2Registre malalts renals catalunya (rmrc), organització catalana trasplantaments (ocatt), Health Dept Catalonia, Barcelona, Spain

**FO017**
PROSPECTIVE AUDIT TO STUDY SYNER-KINASE USE TO RESTORE PATENCY IN OCCLUDED CENTRAL VENOUS CATHETERS (PASSPORT 1)
Mick Kumwenda1; Sandip Mitra2; Nicholas R Inston3; 1Renal and diabetes, Glan Clwyd Hosp, Rhyl, United Kingdom; 2Renal Medicine, Univ Manchester, Manchester, United Kingdom; 3Renal transplant- and vascular surgery, Queen Elizabeth Hosp Birmingham, Birmingham, United Kingdom

**FO018**
VALIDATION OF BLOOD FLOW/RESISTANCE INDEX RATIO (QX) FOR IDENTIFICATION OF SIGNIFICANT STENOSIS IN ARTERIOVENOUS FISTULAS
Alessandro Colombo1; Giuseppe Coppolino2; Laura Rivioli3; Sebastiano Greco1; Giuseppe Rizzuto1; 1Nephrology and dialysis, Hosp "San Giovanni di Dio", Crotone, Italy; 2Renal unit, Dept Health Sciences, "Magna Graecia" Univ, Catanzaro, Italy; 3Nephrology and dialysis, ASL 5 Torino, Chivasso, Turin, Italy

**FO019**
FERUMOXYTOL MR ANGIOGRAPHY VS DOPPLER US FOR VASCULAR MAPPING BEFORE HEMODIALYSIS ARTERIOVENOUS ACCESS CREATION
Sokratis Stoumpos1; Alfred Tan2; Martin Hennessy2; Ram Kasthuri2; Aleksandra Radjenovic1; David Kingsmore3; Giles H Roditi4; Patrick Mark1; 1Cardiovascular Research Centre, Univ Glasgow, Glasgow, United Kingdom; 2Radiology, Queen Elizabeth Univ Hosp, Glasgow, United Kingdom; 3Renal and transplant unit, Queen Elizabeth Univ Hosp, Glasgow, United Kingdom; 4Inst cardiovasc and medical sciences, Univ Glasgow, Glasgow, United Kingdom
Free Communication Session 04

Bone disease in dialysis

Chairs: Smeeta Sinha, Salford, United Kingdom
Marc Vervloet, Amsterdam, The Netherlands

FREE COMMUNICATIONS

FO020
BONE MINERAL DENSITY AT VARIOUS SITES VERSUS MORTALITY IN END-STAGE RENAL DISEASE (ESRD)
Ken Iseri; Abdul Rashid Qureshi; Lu Dai; Olof Heimburger; Peter Barany; Peter Stenvinkel; Bengt Lindholm; Renal medicine and baxter novum, Dept clinical science, intervention and technology, Karolinska Inst, Stockholm, Sweden

FO021
NATURAL HISTORY, OUTCOMES AND MORTALITY ASSOCIATIONS OF CALCIPHYLAXIS: DATA FROM THE UK CALCIPHYLAXIS REGISTRY
Rajkumar Chinnadurai; Abby Huckle; Janet Hegarty; Philip Kalra; Smeeta Sinha; Renal medicine and vascular research, Salford Royal NHS Foundation Trust and Univ Manchester, Salford, United Kingdom

Special Travel Grant FO022
HELCIOBACTER PYLORI COLONISATION INCREASES PHOSPHATE BINDER PILL BURDEN IN DIALYSIS PATIENTS
Berfu Korucu; Ozant Helvaci; Rezzan Eren Sadioglu; Burak Ozbas; Hasan Yeter; Ulver Derici; 1Nephrology, Gazi Univ Fac Medicine, Ankara, Turkey; 2Nephrology, Ankara Univ Fac Medicine, Ankara, Turkey

FO023
THE PREVALENCE AND INCIDENCE OF VERTEBRAL FRACTURES IN END-STAGE RENAL DISEASE AND THE ROLE OF PARATHYROID HORMONE
Thijs Jansz; Namiko Goto; Adriana Van Balleghoijen; Hanna Willems; Marianne Verhaar; Brigit Van Jaarsveld; 1Dianet Dialyscentra, Utrecht, Netherlands; 2Nephrology, VUmc, Amsterdam, Netherlands; 3Geriatrics, Academic Medical Centre, Amsterdam, Netherlands; 4Nephrology and hypertension, Univ Medical Center Utrecht, Utrecht, Netherlands

FO024
REAL-WORLD SAFETY AND EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE IN PATIENTS UNDERGOING PERITONEAL DIALYSIS: AN INTERIM ANALYSIS OF THE VERIFIE STUDY
Philip Kalra; Denis Fouque; Angel De Francisco; Marc Vervloet; Markus Ketteler; Piergiorgio Messe; Manuela Stauss-Grabbo; Anja Derlet; Sebastian Walpen; Amandine Perrin; Linda Ficociello; Jacques Rottembourg; Jorge Cannata-Andia; Christoph Wanner; Ioannis Boletis; 1Renal medicine, Salford Royal Hosp NHS Trust, Manchester, United Kingdom; 2Nephrology, Univ Claude Bernard, Lyon, France; 3Nephrology, Marques de Valdecilla Univ Hosp, Santander, Spain; 4Dept Nephrology, VU Univ Medical Center, Amsterdam, Netherlands; 5 Nephrology, Coburg Clinic and KF-Dialysis Center, Coburg, Germany; 6Nephrology, Maggiore Hosp, Milan, Italy; 7Clinical research, Fresenius Medical Care, Bad Homburg, Germany; 8Nephrology, Vifor Fresenius Medical Care Renal Pharma, Glattbrugg, Switzerland; 9Renal therapies group, Fresenius Medical Care, Waltham, MA, U.S.A.; 10Nephrology, Groupe Hosp Pitié-Salpêtrière, Paris, France; 11Dept medicine, Univ Oviedo, Oviedo, Spain; 12 Dept Medicine Div Nephrology, Würzburg Univ Hosp, Würzburg, Germany; 13Nephrology, Laiko Univ Hosp, Athens, Greece

FO025
RATIONAL FOR PROPHYLACTIC CALCIUM REPLACEMENT POST PARATHYROIDECTOMY - RATE OF DECLINE OF SERUM CALCIUM IMMEDIATELY POST PARATHYROIDECTOMY
Jaydeesh Khanna Krishnasamy Balasubramanian; Stephanie Fook-Chong; Jiunn Wong; 1Renal medicine, Singapore General Hosp, Singapore, Singapore; 2 Div medicine, Singapore General Hosp, Singapore, Singapore
Scientific Programme

POSTER SESSION
Poster Area
09:30 - 10:45
16:30 - 17:00

Registry.......................................................... REG1 - REG6
Acid-base, nephrolithiasis and uric acid................................. FP001 - FP013
Cell signalling. Cell biology. Hormones................................. FP014 - FP042
Renal development and cystic diseases............................... FP043 - FP056
Renal pathology. Experimental and clinical......................... FP057 - FP105
Clinical nephrology 1................................................... FP106 - FP186
Glomerulonephritis 1..................................................... FP187 - FP246
AKI. Experimental..................................................... FP247 - FP306
AKI. Clinical. Prevention and treatment.............................. FP307 - FP329
CKD. Pathophysiology, progression and risk factors 1.......... FP330 - FP374
CKD. Clinical epidemiology........................................... FP375 - FP440
CKD. Bone disease..................................................... FP441 - FP481
Diabetes. Clinical studies............................................ FP482 - FP522
Extracorporeal dialysis: techniques and adequacy 1.............. FP523 - FP555
Peritoneal dialysis 1.................................................... FP556 - FP605
Dialysis. Cardiovascular complications 1............................ FP606 - FP641
Dialysis. Vascular access 1.......................................... FP642 - FP671
Dialysis. Epidemiology and outcome 1............................... FP672 - FP715
Dialysis. Protein energy wasting, inflammation and oxidative stress ................................. FP716 - FP754
Renal transplantation. Epidemiology and outcome 1.............. FP755 - FP801
Paediatric nephrology.................................................. FP802 - FP835
Late breaking clinical trials.......................................... FP836 - FP847
Scientific Programme

HALL G1

Plenary Lecture 1

Chairs: George Reusz, Budapest, Hungary
        Carmine Zoccali, Reggio Calabria, Italy

*Interface of molecular mechanisms, pathology and genetics of developmental kidney diseases*
Sanjay Jain, Saint Louis, MO, U.S.A.

HALL G1

Symposium 05

**Late Breaking Clinical Trials**

Chairs: Danilo Fliser, Homburg/Saar, Germany
        Maria Jose Soler Romeo, Barcelona, Spain

Effects of linagliptin on kidney outcomes in patients with nephrotic range proteinuria: insights from CARMELINA
Christoph Wanner, Würzburg, Germany

A phase 3b, randomised, double-blind, placebo-controlled study of the efficacy and safety of sodium zirconium cyclosilicate for reducing the incidence of pre-dialysis hyperkalaemia (DIALIZE)
Steven Fishbane, Great Neck, NY, U.S.A.

Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI study
Antonio Bellasi, Bergamo, Italy

Non-skeletal and skeletal effects of high doses versus minimum recommended intake of vitamin D3 in renal transplant recipients in a prospective, multicenter, double-blind, randomized study
Marie Courbebaisse, Paris, France

Efficacy and safety of daprodustat compared with epoetin beta pegol in Japanese non-dialysis patients with anemia of chronic kidney disease: a 52-week, open-label, randomized controlled phase 3 trial
Takayuki Hamano, Osaka, Japan
Symposium 06

The many faces of monoclonal gammopathy of undetermined significance

Chairs: Jolanta Malyszko, Warsaw, Poland
       Jack Wetzels, Nijmegen, The Netherlands

MGRS classification: bringing order to the nomenclature chaos
Tri Nguyen, Utrecht, The Netherlands

MGRS diagnosis: establishing causality is the hardest job
Jolanta Malyszko, Warsaw, Poland

MGRS treatment: should we follow the haematologist or take the lead?
Ben Sprangers, Leuven, Belgium

2019 European Certificate in Nephrology (ECN) Awards

Brief ERA-EDTA-UEMS Ceremony in which the Nephrologists who passed the 2019 ECN exam will receive the diploma from:

Prof Carmine Zoccali
ERA-EDTA President

Prof Jorge Cannata-Andia
UEMS Renal Section Chair

Dr David Lappin
ECN Exam Lead
Scientific Programme

HALL G2B

Symposium 07

Improving outcomes in DKD

Chairs: Radovan Hojs, Maribor, Slovenia
       Sydney Tang, Hong Kong, Hong Kong

Renal inflammation: its pathogenetic role in diabetic kidney disease
Sydney Tang\textsuperscript{HK}, Hong Kong, Hong Kong

SGLT2 inhibitors in the prevention of renal fibrosis
Andrea Fekete, Budapest, Hungary

GLP-1 receptor agonists in DKD: mechanisms and outcomes
Johannes F.E. Mann, Munich, Germany

Update on SGLT2i in CKD
Christoph Wanner, Würzburg, Germany
Symposium 08

Redefining the ontology of kidney diseases using genomic analysis

Chairs: Emilie Cornec-Le Gall, Brest, France
Nine Knoers, Groningen, The Netherlands

Genetic landscape of hereditary amyloidosis
Luisa Lobato, Porto, Portugal

What’s up in hereditary tubulo-interstitial nephritis?
Stanislas Kmoch, Prague, Czech Republic

Adult-onset ESRD of unknown aetiology: when should we think genetics?
Nine Knoers, Groningen, The Netherlands

FREE COMMUNICATIONS

FO026
GLOBAL MICRORNA PROFILING IN HUMAN URINARY EXOSOMES REVEALS NEW DISEASE BIO-MARKERS AND CELLULAR PATHWAYS FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
Tajdida Magayr1; Andrew Streets2; Albert Ong2; 1Sebha Univ, Sabhā, Libya; 2Kidney genetics group, academic nephrology unit, Univ Sheffield, Sheffield, United Kingdom

FO027
DIAGNOSTIC UTILITY OF NEXT GENERATION SEQUENCING TECHNIQUES IN PATIENTS WITH FAMILIAL KIDNEY DISEASE WHO HAVE UNDERGONE PERCUTANEOUS NATIVE KIDNEY BIOPSY
Susan Murray1; Anthony Dorman2; Ciara Mcdonnell1; Neil Fennelly2; Claire Kennedy1; Dervla M. Connaughton3; Katherine Benson4; Caragh Stapleton4; Sarah Cormican1; Louise Ryan1; Anthony J. Bleyer5; Kendrah Kidd5; Brendan Doyle2; Cavalleri Gianpiero4; Friedhelm Hildebrandt6; Peter Conlon1; 1Dept nephrology and transplantation, Beaumont Hosp, Dublin, Ireland; 2Dept pathology, Beaumont Hosp, Dublin, Ireland; 3Dept nephrology, Beaumont Hosp, Dublin, Ireland; 4Dept molecular and cellular therapeutics, Royal College of Surgeons Ireland, Dublin, Ireland; 5Section nephrology, Wake Forest Baptist Health, Winston-Salem, U.S.A.; 6Dept medicine, Boston children’s Hosp, Boston, U.S.A.
HALL A1

Symposium 09

Brain and nervous system in CKD

Chairs: Michel Jadoul, Brussels, Belgium
Kate Stevens, Glasgow, United Kingdom

The gut-brain axis, b2microglobulin and neuroinflammation: a re-interpretation of an old story?
Michel Jadoul, Brussels, Belgium

Anti-inflammatory role of the parasympathetic system in CKD
Annette Bruchfeld, Stockholm, Sweden

Cognitive impairment and kidney disease
Giovambattista Capasso, Naples, Italy

FREE COMMUNICATIONS

★ FO028
COMPREHENSIVE THREE-DIMENSIONAL ANALYSIS (CUBIC-KIDNEY) REVEALS ABNORMAL RE-NAL SYMPATHETIC NERVES AFTER ISCHEMIA-REPERFUSION INJURY
Sho Hasegawa1; Tetsuhiro Tanaka1; Etsuo A Susaki2; Hirotaka Komaba3; Takehiko Wada3; Masafumi Fukagawa3; Hiroki R Ueda2; Masaomi Nangaku1; 1Div Nephrology and Endocrinology, Univ Tokyo, Tokyo, Japan; 2Dept systems pharmacology, Univ Tokyo, Tokyo, Japan; 3Div nephrology, endocrinology and metabolism, Tokai Univ, Isehara, Japan

★ FO029
COGNITIVE IMPAIRMENT WAS ASSOCIATED WITH BRAIN-BLOOD BARRIER PERMEABILITY IN TWO MODELS OF CHRONIC KIDNEY DISEASE IN RATS
Mickaël Bobot1; Guillaume Hache2; Samatha Fernandez2; Laure Balasse2; Pauline Brige2; Sophie Chopinet2; Laurent Thomas2; Nathalie Mckay3; Stéphane Burtey1; Benjamin Guillet2; 1Nephrology and Renal Transplantation, Conception Hosp, Marseille, France; 2Cerimed, Fac Médecine Timone (Aix-Marseille Univ), Marseille, France; 3Research center cardiovascular disease and nutrition (c2vn), inserm 1263 – inra 1260, La Timone (Aix-Marseille Univ), Marseille, France
Free Communication Session 05 + Mini Lecture

Delivery of dialysis: a holistic approach

Chairs: Radomir Naumović, Belgrade, Serbia
        Ioannis L. Stefanidis, Larissa, Greece

Mini lecture
Self-care improves patient outcomes: what is the evidence?
Martin Wilkie, Sheffield, United Kingdom

FREE COMMUNICATIONS

★ FO030
Perspectives and experiences of patients and health-care professionals with geriatric assessment in CKD: A qualitative study
Carlijn Voorend1; Noeleen Berkhout-Byrne2; Yvette Meuleman3; Willem Jan Bos2; Marjolijn Van Burren2; 1Lumc, nephrology dept, Leiden, Netherlands; 2Nephrology, Leiden Univ Medical Center, Leiden, Netherlands; 3Epidemology, Leiden Univ Medical Center, Leiden, Netherlands

FO031
The symptom monitoring with feedback trial (SWIFT): A novel registry-based cluster randomised controlled trial among Australian and New Zealand adults with end-stage kidney disease managed on haemodialysis
Rachael Morton1; Matthew Jose2; Chris Brown3; Paul Bennett4; Suetonia Palmer5; Fergus Caskey6; Laranjo Da Silva Liliana7; Cécile Couchoud8; Shilpa Jesudason9; Stephen Mcdonald4; 1Health Economics, NHMRC Clinical Trials Centre, Univ Sydney, Sydney, Australia; 2Biostatistics, NHMRC Clinical Trials Centre, Univ Sydney, Sydney, Australia; 3Medicine, Univ Tasmania, Hobart TAS, Australia; 4Medicine, Univ Otago Christchurch, Christchurch, New Zealand; 5Nephrology, Royal Adelaide Hosp, Adelaide SA, Australia; 6Biomedical maintenance dept, NephroCare France, Fresnes, France; 7Coordination médicale, NephroCare France, Fresnes, France

★ FO032
The electronic frailty index (EFI) indicates mortality risk in end stage kidney disease (ESKD) patients on dialysis
Relton Sam1; Appalsawmy Usha2; Sohal Kuldeep3; Stoves John4; Birkinshaw John3; Clegg Andy5; West Robert1; Hewison Jenny1; Andrew Mooney6; 1Inst health sciences, Leeds Univ, Leeds, United Kingdom; 2Improvementacademy, Bradford Inst Health Research, Bradford, United Kingdom; 3Connected Yorkshire, Bradford Inst Health Research, Bradford, United Kingdom; 4Renal unit, Bradford Teaching Hospsw Foundation Trust, Bradford, United Kingdom; 5Academic unit elderly care and rehabilitation, Bradford Inst Health Research, Bradford, United Kingdom; 6Renal Unit, Leeds Teaching Hospsw, Leeds, United Kingdom

★ FO033
Burnout syndrome among nephrologists – a burning issue
Ewa Pawlowicz; Michal Nowicki; Dept Nephrology, Hypertension and Kidney Transplantation, Medical Univ Lodz, Lodz, Poland

FO034
Hemodialysis therapy and sustainable growth: The experience of nephrocare france
Bendine Georges1; Autain Fabien1; Bardin Olivier2; Fabre Bruno3; Charles Chazot4; 1Quality and environment dept, NephroCare France, Fresnes, France; 2Technique assistance, Fresenius Medical Care, Fresnes, France; 3Biomedical maintenance dept, NephroCare France, Fresnes, France; 4Coordination médicale, NephroCare France, Fresnes, France
Free Communication Session 06 + Mini Lecture

The next generation of transplant therapeutical approaches

Chairs: Daniel Abramowicz, Antwerp, Belgium
Umberto Maggiore, Parma, Italy

Mini lecture
Molecular targets in renal transplantation: reality or fiction?
Michael Mengel, Edmonton, Canada

FREE COMMUNICATIONS

FO035
EIGHT YEAR FOLLOW-UP OF TOLERANCE INDUCTION IN LIVING DONOR RENAL TRANSPLANTATION
Aruna Vanikar, Inst Kidney Diseases and Research Center, Ahmedabad, India

FO036
THE CATHEPSIN S/PAR2 AXIS CONTRIBUTES TO KIDNEY ALLOGRAFT REJECTION IN MICE
Yutian Lei1; Ehle Benjamin2; Andrassy Joachim2; Hans-Joachim Anders1; 1Renal Div, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU, Munich, Munich, Germany; 2Dept general, visceral, and transplantation surgery, Ludwig Maximilian Univ Munich, Munich, Germany

FO037
HLA ANTIBODY IMMUNIZATION: PREGNANCY AS A NATURAL SOURCE
Carla Burballa1; Sara Outon1; Susana Vazquez1; Laura Linàs-Mallol1; Dolores Redondo1; Maria José Pérez-Sáez1; Carme Garcia2; Marisa Mir1; Carlos Arias-Cabales1; Julio Pascual3; Marta Crespo1; 1Nephrology, Hosp del Mar, Barcelona, Spain; 2Immunology, Lab Referencia Catalunya, Barcelona, Spain

FO038
THE MOLECULAR PROFILE OF SUBCLINICAL ACUTE REJECTION (SAR) IN KIDNEY ALLOGRAFT UNVEIL SPECIFIC MARKERS INVOLVED IN THIS DISEASE
Francesco Paolo Schena1; Sharon Natasha Cox1; Samantha Chiurlia1; Vincenzo Cantaluppi2; Luigi Biancone3; Paolo Rigotti4; Franco Citterio5; Michele Rossini6; 1Schena Foundation, Bari, Italy; 2Univ Eastern Piedmont, Vercelli, Italy; 3Dip scienze mediche, Univ Turin, Torino, Italy; 4Univ Padua, Padova, Italy; 5Policlinico Univ Agostino Gemelli, Roma, Italy; 6Univ Bari Aldo Moro, Bari, Italy

FO039
FERUMOXYTOL MR ANGIOGRAPHY VS CT ANGIOGRAPHY FOR THE ASSESSMENT OF POTENTIAL KIDNEY TRANSPLANT RECIPIENTS
Sokratis Stoumpos1; Pauline Barrientos2; Douglas Black2; Karen Stevenson3; Martin Hennessy2; Alex Vesey3; Ram Kasthuri2; Aleksandra Radjenovic1; David Kingsmore3; Giles H Roditi4; Patrick Mark1; 1Cardiovascular Research Centre, Univ Glasgow, Glasgow, United Kingdom; 2Radiology, Queen Elizabeth Univ Hosp, Glasgow, United Kingdom; 3Renal and transplant unit, Queen Elizabeth Univ Hosp, Glasgow, United Kingdom; 4 Inst cardiovascular and medical sciences, Univ Glasgow, Glasgow, United Kingdom
HALL A4

11:45 - 13:15

Free Communication Session 07 + Mini Lecture

Managing hypertension

Chairs: Markus Ketteler, Stuttgart, Germany
Demetrios Vlahakos, Athens, Greece

Mini lecture
Bariatric surgery: untangling the links between diabetes, hypertension and kidney disease?
Anna Solini, Pisa, Italy

FREE COMMUNICATIONS

Special Travel Grant FO040
ACHIEVED BLOOD PRESSURE AND OUTCOMES IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE STAGE 4-5
Ehab Al-sodany1; Evans Marie2; Heimberger Olof1; Barany Peter2; 1Nephrology, Karolinska Univ Hosp, Stockholm, Sweden; 2Clinical science, intervention and technology, Karolinska Inst, Stockholm, Sweden

FO041
THE EFFECT OF DRY-WEIGHT REDUCTION GUIDED BY LUNG ULTRASOUND ON AMBULATORY BLOOD PRESSURE IN HEMODIALYSIS PATIENTS: A LUST SUB-STUDY
Charalampos Loutradis1; Robert Ekart2; Christodoulos Papadopoulos3; Vasileios Sachpekidis4; Maria Eleni Alexandrou5; Nikolaos Pyrgidis1; Ioanna Minopoulou1; Dorothea Papadopoulou5; Aikaterini Papagianni1; Gerard London6; Carmine Zoccali7; Pantelis Sarafidis1; 1Dept nephrology, Hippokration Hosp, Aristotle Univ Thessaloniki, Thessaloniki, Greece; 2Dept dialysis, Univ Clinical Centre Maribor, Clinic Internal Medicine, Maribor, Slovenia; 3Third Dept cardiology, Hippokration Hosp, Aristotle Univ Thessaloniki, Thessaloniki, Greece; 4Dept cardiology, Papageorgiou Hosp, Thessaloniki, Greece; 5 Dept nephrology, Papageorgiou Hosp, Thessaloniki, Greece; 6Dept nephrology, Hosp and FCRIN INI-CRCTC, Manhes, France; 7Clinical epidemiology of renal diseases and hypertension, CNR-IFC , Reggio Calabria, Italy

FO042
EFFECT OF SGLT-2 INHIBITORS ON AMBULATORY BLOOD PRESSURE: DOSE-RESPONSE META-ANALYSIS AND COMPARATIVE EVALUATION WITH LOW-DOSE HYDROCHLOROTHIAZIDE
Panagiotis Georgianos1; Rajiv Agarwal2; 1Peritoneal dialysis unit, First Dept medicine, AHEPA Hosp, Aristotle Univ Thessaloniki, Thessaloniki, Greece; 2Dept nephrology, Indiana Univ school of medicine, Indianapolis, U.S.A.
Scientific Programme

HALL G1

Symposium 10

**ASN Highlights**

Chairs: Mark Rosenberg, Minneapolis, MN, U.S.A
Christoph Wanner, Würzburg, Germany

AKI
Kathleen D. Liu, San Francisco, CA, U.S.A.

General nephrology & CKD
Tamara Isakova, Chicago, IL, U.S.A.

Hypertension
Debbie L. Cohen, Philadelphia, PA, U.S.A.

HALL G2A

Symposium 11

**ANCA-associated vasculitis**

Chairs: Annette Bruchfeld, Stockholm, Sweden
Ágnes Haris, Budapest, Hungary

Extrarenal involvement in AAV and its impact on the outcome of patients
Vladimir Tesar, Prague, Czech Republic

ANCA-associated vasculitis in the elderly and very elderly
Maria Weiner, Linköping, Sweden

Should the anti-PR3 and anti-MPO patients be treated in a different way?
Jan-Stephan Sanders, Groningen, The Netherlands

Understanding the role of Rituximab in ANCA associated vasculitis
Federico Alberici, Milan, Italy
Scientific Programme

HALL G2B 15:00 - 16:30

Symposium 12

**Blood pressure targets**

Chairs: Johannes F.E. Mann, Munich, Germany
Andrzej Więcek, Katowice, Poland

Optimal BP target for renoprotection in CKD patients is <140/90
Mustafa Arici, Ankara, Turkey

Optimal BP target for renoprotection in CKD patients is <130/80
Pantelis Sarafidis, Thessaloniki, Greece

Managing resistant hypertension
Andrzej Więcek, Katowice, Poland

What are the ambulatory blood pressure targets?
Manuel Gorostidi, Oviedo, Spain

HALL F1 15:00 - 16:30

Symposium 13

**Precision medicine for the sensitized transplant recipient**

Chairs: Umberto Maggiore, Parma, Italy
Bruno Watschinger, Vienna, Austria

Tailoring a transplant route for the sensitized patient on dialysis
Marta Crespo, Barcelona, Spain

Treating the patient while listed
Christophe Legendre, Paris, France

Taking care: balancing immunosuppression avoiding weapons of mass destruction
Julio Pascual, Barcelona, Spain

To transplant or not to transplant: an hamletic dilemma in obese candidates
Davide Bolignano, Reggio Calabria, Italy
Free Communication Session 08

Protein energy wasting and inflammation

Chairs: Ionut Nistor, Iasi, Romania
        Peter Stenvinkel, Stockholm, Sweden

FREE COMMUNICATIONS

FO043  
ENDOTHELIAL DAMAGE IN CHRONIC KIDNEY DISEASE IS MEDIATED THROUGH HISTONE DEACETYLASE UPREGULATION AND CAN BE PREVENTED BY DEFIBROTIDE  
Aleix Cases1; Manel Vera1; Marta Palomo2; Sergi Torramade2; Gines Escolar2; Maribel Diaz-Ricart2; 1Nephrology, Hosp Clinic, Barcelona, Spain; 2 Pathology, Hosp Clinic, Barcelona, Spain

FO044  
GUT MICROBIOTA METABOLITE TRIMETHYLAMINE-N-OXIDE AGGRAVATES PERITONEAL INFLAMMATION VIA ACTIVATING NLRP3-CASPASE 1 PATHWAY  
Lei Zhang; Jing Nie; Xinrong Zhang; Nephrology dept, Nanfang Hosp, Guangzhou, P.R. China

FO045  
ABSENCE OF MEASURABLE CONTACT SYSTEM ACTIVATION OF COAGULATION DURING HAEMODIALYSIS: A RANDOMIZED CROSSOVER STUDY  
Karlien Francois1; Christelle Orlando2; Kristin Jochmans2; Vicky De Meyer1; Christian Tielemans1; Karl Martin Wissing1; 1Nephrology, UZ Brussel, Brussels, Belgium; 2Haematology, UZ Brussel, Brussels, Belgium

FO046  
RELATIONSHIP BETWEEN SURVIVAL AND SERUM PHOSPHATE LEVELS: INTERACTIONS WITH AGE, MALNUTRITION, AND INFLAMMATION  
Xiaoling Ye1; Jeroen Kooman2; Frank M. Van Der Sande2; Jochen Raimann1; Len Usvyat3; Franklin Maddux3; Peter Kotanko4; 1Research, Renal Research Inst, NY, U.S.A.; 2Nephrology, Maastricht Univ Medical Centre, Maastricht, Netherlands; 3Medical office, Fresenius Medical Care North America, Bethlehem, U.S.A.; 4 Research, Renal Research Inst, New York, U.S.A.

FO047  
GUT MICROBIOME IN HEMODIALYSIS PATIENTS TREATED WITH DIFFERENT TYPES OF PHOSPHATE BINDERS  
Ana Merino Ribas1; Ioana Bancu1; Fredzzia Gratero1; Andrea Vergara2; Marc Noguera-Julian3; Roger Paredes3; Jordi Bonal1; 1Nephrology, Hosp Univ Germans Trias i Pujol, Badalona, Spain; 2Microbiology, Hosp Clinic Barcelona, Barcelona, Spain; 3Irsicaixa aids research Inst, Hosp Univ Germans Trias i Pujol, Badalona, Spain

FO048  
REMOVAL OF LARGE-MIDDLE MOLECULES, INHIBITION OF NEUTROPHIL ACTIVATION AND MODULATION OF INFLAMMATION-RELATED ENDOTHELIAL DYSFUNCTION DURING EXPANDED HEMODIALYSIS (HDx)  
Vincenzo Cantaluppi1; Marita Marengo2; Quercia Alessandro3; Mauro Berto3; Gabriele Donati4; Lacquaniti Antonio5; Francesco Cosal6; Giuseppe Gernone7; Ugo Teatini8; Massimiliano Miglior9; Vincenzo Panichi10; 1Dept translational medicine, Univ Eastern Piedmont, Novara, Italy; 2S.C. Nefrologia e Dialisi, ASLCN1, Savigliano, Italy; 3Osp infermi, Nephrology and Dialysis, Biella, Italy; 4Nephrology, dialysis and renal transplantation unit, Sant'Orsola Univ Hosp, Bologna Italy; 5 Papardo Hosp, Nephrology and Dialysis Unit, Messina, Italy; 6Osp civile Taranto, Nephrology and Dialysis Unit, Taranto, Italy; 7Nefrologia e Dialisi Osp “S. Maria degli Angeli” Putignano, ASL BA, Putignano, Italy; 8Asst rhodense, Nephrology and Dialysis unit, Milano, Italy; 9 Versilia Hosp, nephrology and Dialysis, Camaiore (LU), Italy; 10Versilia Hosp, Nephrology and Dialysis Unit, Camaiore, Lucca, Italy, Italy
FREE COMMUNICATIONS

**FO049**
ACTIVATION OF ACETATE/GPR43 PATHWAY MEDIATED BY GUT MICROBIOTA CONTRIBUTES TO INSULIN RESISTANCE OF PODOCYTES IN DIABETIC NEPHROPATHY

_Lu Jian_; Hu Ze Bo; Pei-Pei Chen; Chen-Chen Lu; Jia Xiu Zhang; Xue Qi Li; Ben Yin Yuan; Si Jia Huang; Liu Bicheng ; Kun Ling Ma; Southeast Univ, Inst Nephrology, Nan Jing City, P.R. China

**FO050**
ENDOTHELIAL ADAM17 DELETION ATTENUATES DIABETIC NEPHROPATHY DAMAGE THROUGH PI3K/AKT SIGNALING PATHWAY

_Vanesa Palau_1; Marta Riera1; David Benito1; Julio Pascual1; Maria José Soler2; 1Nephrology dept, Inst Hosp del Mar Investigacions Mèdiques IMIM, Barcelona, Spain; 2 Nephrology dept, Inst Hosp del Mar Investigacions Mèdiques IMIM. pi17/00257, Barcelona, Spain

**FO051**
GLYCOGEN SYNTHASE KINASES 3-α/β INHIBITION ATTENUATES PROGRESSION OF DIABETIC KIDNEY DISEASE BEYOND TREATMENT WITH METFORMIN/RAMIPRIL/EMPAGLIFLOZIN

_Lidia Anguiano Gómez_; Manga Motrapu; Julian Marschner; Hans-Joachim Anders; Renal Div, Medizinische Klinik und Poliklinik IV, Munich, Germany

**FO052**
MYOSTATIN PROMOTES TUBULAR INFLAMMATION IN DIABETIC NEPHROPATHY

_Daniela Verzola1; Annalisa Carta1; Samantha Milanesi1; Michela Saio1; Francesca Viazzi1; Daniela Picciotto1; Chiara Barisione1; Giacomo Garibotto1; 1Div nephrology, dialysis and transplantation, Dept internal medicine, Univ Genoa and IRCCS Osp Policlinico San Martino, Genoa, Italy

**FO053**
ROLE OF KETONE BODY METABOLISM IN SGLT2 INHIBITOR-MEDIATED RENOPROTECTION IN HIGH FAT DIET-FED APOE-KNOCKOUT MICE

_Issei Tomita1; Shinji Kume1; Kosuke Yamahara1; Mako Yasuda-Yamahara1; Naoko Takeda1; Norihisa Osawa1; Masami Chin-Kanasaki1; Tatsuroh Kaneko2; Michael Pieper2; Shin-Ichi Araki1; Hiroshi Megasawa1; 1Medicine, Shiga Univ Medical Science, Otsu, Japan; 2Pharmaceuticals, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany

**FO054**
EFFECTS OF MODULATING AUTOPHAGIC FLUX ON ACTIVATION AND ADHESION MIGRATION OF MACROPHAGES IN DIABETIC NEPHROPATHY

_Yuteng Jiang_; Zhao Yu; Xiaodong Zhu; Yuqiu Liu; Beibei Wu; Canlin Yang; Xiaoliang Zhang; Inst nephrology, zhong da Hosp, Southeast Univ, school medicine, Nanjing, P.R. China
**Clinical CKD**

Chairs: Goce Spasovski, Skopje, North Macedonia  
Andras Tisler, Budapest, Hungary

*Mini lecture*

When should a nephrologist take over – stage 3b or 4 – current perspective  
Goce Spasovski, Skopje, North Macedonia

**FREE COMMUNICATIONS**

**FO055**

EVALUATION OF PREDICTION MODELS FOR PROGRESSION OF CHRONIC KIDNEY DISEASE TO KIDNEY FAILURE: A COMPREHENSIVE EXTERNAL VALIDATION STUDY  
Chava Ramspek1; Marie Evans2; Olof Heimbürger2; Nicholas Chesnaye3; Maciej Szymczak4; Paul Roderick5; Fergus Caskey6; Christoph Wanner7; Friedo Dekker1; Kitty Jager1; Merel Van Diepen1; 1Clinical epidemiology, Leiden Univ Medical Center, Leiden, Netherlands; 2Clinical science, intervention and technology, Karolinska Inst, Solna, Sweden; 3Academic medical center, Dept medical informatics, ERA-EDTA Registry, Amsterdam, Netherlands; 4Nephrology and transplantation medicine, Wroclaw Medical Univ, Wroclaw, Poland; 5Primary care and population sciences, Southampton General Hosp, Southampton, United Kingdom; 6Bristol medical school, Univ Bristol, Bristol, United Kingdom; 7Dept Medicine Div Nephrology, Würzburg Univ Hosp, Würzburg, Germany

**FO056**

HIGH-SENSITIVITY CARDIAC TROPONIN T AND LEFT VENTRICULAR STRUCTURE AND FUNCTION IN CHRONIC KIDNEY DISEASE: RESULTS FROM THE KOREAN COHORT STUDY FOR OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE (KNOW-CKD)  
Eunjeong Kang1; Hyo Jin Kim2; Hyunjin Ryu1; Yunmi Kim2; Kook-Hwan Oh1; Curie Ahn1; 1Dept internal medicine, Seoul National Univ Hosp, Seoul, South Korea; 2Dept internal medicine, Dongguk Univ Gyeongju Hosp, Gyeongju-si, South Korea

**FO057**

IMPROVED SURVIVAL DUE TO BETTER RENAL OUTCOMES IN PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS (AAV) DURING THE YEARS 2000 TO 2015 - A DANISH NATIONWIDE STUDY  
Karl Emil Nelvelg-Kristensen1; Wladimir Szpirt1; Nicholas Carlsson1; Jon Waast Gregersen2; Elizabeth Krarup3; Per Ivarsen4; Christian Torp-Pedersen5; Martin Egfjord1; 1Nephrology, Rigshospitalet, Copenhagen, Denmark; 2Nephrology, Aalborg Univ Hosp, Aalborg, Denmark; 3Nephrology, Herlev Univ Hosp, Herlev, Denmark; 4Nephrology, Aarhus Univ Hosp, Aarhus, Denmark; 5Health science and technology, Aalborg Univ Hosp, Aalborg, Denmark

**FO058**

DETECTION AND MANAGEMENT OF CHRONIC KIDNEY DISEASE AND DIABETES WITH E-TECHNOLOGY BASED INTERVENTION: ANALYSIS OF THE CHRONIC DISEASE EARLY DETECTION AND IMPROVED MANAGEMENT IN PRIMARY CARE PROJECT (CD IMPACT)  
Julia Jones1; Natalie Lumsden1; Koen Simons2; Sanduni Fernando1; Christopher Neil3; Jo-Anne Manski-Nankervis2; Peter Hamblin4; Edward Janus2; Craig Nelson1; 1Nephrology, Western Health, Saint Albans, Australia; 2Medicine, Univ Melbourne, Parkville, Australia; 3Cardiology, Western Health, Saint Albans, Australia; 4Endocrinology, Western Health, Saint Albans, Australia

**★ FO059**

MEASURES OF BLOOD PRESSURE VARIABILITY AND THEIR ASSOCIATION WITH CARDIOVASCULAR AND RENAL OUTCOMES IN PRIMARY CARE CHRONIC KIDNEY DISEASE  
Lucy Chambers1; Susil Pallikadavath1; Rupert Major2; David Shepherd2; James Medcalf3; Gang Xu3; Laura Gray2; Nigel Brunskill3; 1Leicester medical school, Univ Leicester, Leicester, United Kingdom; 2Dept health sciences, Univ Leicester, Leicester, United Kingdom; 3John Walls renal unit, Univ Hosp Leicester, Leicester, United Kingdom
HALL A4       15:00 - 16:30

Free Communication Session 11 + Mini Lecture

Improving outcome in dialysis patients

Chairs: Szilvester Dolgos, Budapest, Hungary

James Heaf, Roskilde, Denmark

Mini lecture
“Doctor: how long may I live in dialysis”?
Jürgen Floege, Aachen, Germany

FREE COMMUNICATIONS

FO060
THE ASSOCIATION BETWEEN FOUR TIMES A WEEK COMPARED TO THREE TIMES A WEEK HAEMODIALYSIS AND SURVIVAL, HOSPISATION AND VASCULAR ACCESS COMPLICATIONS IN EUROPEAN IN-CENTRE PATIENTS

James Fotheringham1; Nicholas Latimer1; Mark Froissart2; Florian Kronenburg3; Peter Stenvinkel4; Jürgen Floege5; Kai-Uwe Eckardt6; David Wheeler7; 1School Health and Related Research, Univ Sheffield, Sheffield, United Kingdom; 2Clinical trial unit, CHUV Centre Hosp Univ vaudois, Lausanne, Switzerland; 3Div genetic epidemiology, Medical Univ Innsbruck, Innsbruck, Austria; 4Dept renal medicine, Karolinska Univ Hosp Huddinge, Stockholm, Sweden; 5Nephrology, RWTH Univ Aachen, Aachen, Germany; 6Medizinische Klinik m. S. Nephrologie und Internistische Intensivmedizin, Charité – Universitätsmedizin Berlin, Berlin, Germany; 7Center nephrology, Univ College London, London, United Kingdom

FO061
DIETARY PATTERNS AND MORTALITY IN ADULTS ON HEMODIALYSIS

Valeria Saglimbene1; Germaine Wong1; Mariella Ruospo2; Suetonia Palmer3; Patrizia Natale2; Vanessa Garcia-Larsen4; Juan Jesus Carrero5; Peter Stenvinkel6; Letizia Gargano7; Marcello Tonelli8; Amparo Bernat7; Delia Timofte7; Marietta Török7; Anna Bednarek-Skubalewska7; Jua Dulawa7; Paul Stroumza7; Charlotte Wollheim7; Jorgen Hegbrant7; Jonathan Craig9; Giovanni Strippoli1; 1School public health, Univ Sydney, Sydney, Australia; 2Diaverum medical-scientific office, Diaverum, Lund, Sweden; 3Medicine, Univ Otago Christchurch, Christchurch, New Zealand; 4International health, Johns Hopkins Bloomberg School Public Health, Baltimore, U.S.A.; 5 Dept medical epidemiology and biostatistics, Karolinska Inst, Solna, Sweden; 6Dept renal medicine, Karolinska Univ Hosp Huddinge, Stockholm, Sweden; 7Diaverum medical-scientific office, Diaverum, Lund, Sweden; 8Cumming school medicine, Univ Calgary, Calgary, Canada; 9College medicine and public health, Flinders Univ, Adelaide, Australia

FO062
COMPARATIVE EFFECTIVENESS OF BISOPROLOL AND CARVEDILOL AMONG PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS

Ping-Hsun Wu1; Yi-Ting Lin2; Mei-Chuan Kuo1; Yi-Wen Chiu1; Shang-Jhy Hwang1; Juan Jesus Carrero3; 1Div Nephrology, Dept Internal Medicine, Kaohsiung Medical Univ Chung-Ho Memorial Hosp, Kaohsiung, Taiwan; 2Dept family medicine, Kaohsiung Medical Univ Chung-Ho Memorial Hosp, Kaohsiung, Taiwan; 3M99, Div Renal Medicine and Baxter Novum, Karolinska Univ Hosp, Stockholm, Sweden

FO063
A PROSPECTIVE STUDY COMPARING OUTCOMES IN DIALYSIS VERSUS CONSERVATIVE CARE IN OLDER PEOPLE WITH END STAGE KIDNEY DISEASE

Maharajan Raman1; Rachel Middleton1; Philip Kalra2; Darren Green1; 1Renal, Salford Royal NHS Foundation Trust, Manchester, United Kingdom; 2Renal medicine, Salford Royal Hosps NHS Trust, Manchester, United Kingdom
FO064
RISK FACTORS FOR UNPLANNED DIALYSIS INITIATION: FINAL RESULTS OF THE NORDIC PERIODIALYSIS STUDY

James Heaf1; Maija Heiro2; Aivars Petersons3; Baiba Vernere4; Johan V Povlsen5; Anette B Sørensen5; Naomi Clyne6; Inge Bumblyte7; Alanta Zilinskiene7; Else Randers8; Niels Løkkegaard9; Mai Rosenberg10; Stig Kjellevold11; Jan D Kampmann12; Björn Rogland13; Inger K Lagreid14; Olof Heimburger15; Bengt Lindholm16; 1Dept medicine, Zealand Univ Hosp, Roskilde, Denmark; 2Dept nephrology, Turku Univ Hosp, Turku, Finland; 3Dept nephrology, P. Stradins University Hosp, Riga, Latvia; 4Dept nephrology, P. Stradins Univ Hosp, Riga, Latvia; 5Dept nephrology, Univ Aarhus, Aarhus, Denmark; 6Dept nephrology, Skåne Univ Hosp Lund, Lund, Sweden; 7Dept nephrology, Lithuanian Univ Health Sciences, Kaunas, Lithuania; 8 Dept medicine, Viborg Regional Hosp, Viborg, Denmark; 9Dept medicine, Holbæk Hosp, Holbæk, Denmark; 10Dept medicine, Univ Hosp Tartu, Tartu, Estonia; 11Dept medicine, Vestfold Hosp, Tønsberg, Norway; 12Dept nephrology, Hosp Southern Jutland, Sønderborg, Denmark; 13Dept medicine, Kristianstad Hosp, Kristianstad, Sweden; 14Dept medicine, St. Olav Univ Hosp, Trondheim, Norway; 15Dept clinical science, Intervention and technology, Karolinska Inst, Stockholm, Sweden; 16Dept clinical science, Intervention and technology, Karolinska Inst, Stockholm, Sweden
POSTER SESSION
Poster Area
09:30 - 10:45
16:30 - 17:00

Registry........................................................................................................ REG1 - REG6
Acid-base, nephrolithiasis and uric acid...................................................... FP001 - FP013
Cell signalling. Cell biology. Hormones....................................................... FP014 - FP042
Renal development and cystic diseases.................................................. FP043 - FP056
Renal pathology. Experimental and clinical......................................... FP057 - FP105
Clinical nephrology 1............................................................................. FP106 - FP186
Glomerulonephritis 1............................................................................. FP187 - FP246
AKI. Experimental.................................................................................. FP247 - FP306
AKI. Clinical. Prevention and treatment................................................. FP307 - FP329
CKD. Pathophysiology, progression and risk factors 1......................... FP330 - FP374
CKD. Clinical epidemiology.................................................................. FP375 - FP440
CKD. Bone disease............................................................................... FP441 - FP481
Diabetes. Clinical studies....................................................................... FP482 - FP522
Extracorporeal dialysis: techniques and adequacy 1............................... FP523 - FP555
Peritoneal dialysis 1............................................................................... FP556 - FP605
Dialysis. Cardiovascular complications 1.............................................. FP606 - FP641
Dialysis. Vascular access 1...................................................................... FP642 - FP671
Dialysis. Epidemiology and outcome 1.................................................... FP672 - FP715
Dialysis. Protein energy wasting, inflammation and oxidative stress........ FP716 - FP754
Renal transplantation. Epidemiology and outcome 1.............................. FP755 - FP801
Paediatric nephrology............................................................................. FP802 - FP835
Late breaking clinical trials..................................................................... FP836 - FP847
Scientific Programme

HALL G1

Symposium 14

Basic immunology and pathology

Chairs: Helen Liapis, Little Rock, AR, U.S.A.
Michael Mengel, Edmonton, Canada

Necroinflammation in kidney transplantation
Andreas Linkermann, Dresden, Germany

Polyoma nephropathy
Jan Ulrich Becker, Cologne, Germany

Banff update
Carmen Lefaucheur, Paris, France

FREE COMMUNICATIONS

FO065
DYNAMICS OF GERMINAL CENTER FORMATION, FOLLICULAR T HELPER CELL NUMBERS AND DONOR-SPECIFIC ANTIBODIES IN A MODEL OF CHRONIC ALLOGRAFT REJECTION
Louisa Steines; Antonia Schuster; Bernhard Banas; Tobias Bergler; Dept nephrology, Univ Hosp Regensburg, Regensburg, Germany

FO066
PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES ARE ASSOCIATED WITH T-CELL MEDIATED REJECTION AMONG KIDNEY TRANSPLANT RECIPIENTS WITH PREFORMED AND DE-NOVO DONOR-REACTIVE T-CELLS
Thomas Schachter1; Natalie Otto2; Petra Reinke3; 1Univ Zurich, Zürich, Switzerland; 2Charité Campus Virchow Clinic, Berlin, Germany; 3Berlin-brandenburg center regenerative therapie bctr, Charité Campus Virchow Clinic, Berlin, Germany
HALL G2A 17:00 - 18:30

Symposium 15

ERA-EDTA/ISN Co-branded Session

**Primary glomerulonephritides**

Chairs: Rosanna Coppo, Turin, Italy  
Jürgen Floege, Aachen, Germany

THSD7A antibody induced disease - pathophysiology and clinical patterns  
**Rolf A.K. Stahl**, Hamburg, Germany

Membranous nephropathy: time for a paradigm shift in diagnosis and treatment  
**Fernando Fervenza**, Rochester, MN, U.S.A.

Serology-based algorithm of the treatment of membranous nephropathy  
**Pierre Ronco**, Paris, France

What is the optimal approach to the treatment of IgA nephropathy in 2019?  
**Jürgen Floege**, Aachen, Germany

HALL G2B 17:00 - 18:30

Symposium 16

**Salt and disease: a changing scenario / Sodium: where is it? How does it harm? How could we intervene?**

Chair: Tilman Drueke, Villejuif, France

Salt and hypertension: a bacterial affair  
**Nicola Wilck**, Berlin, Germany

Tissue sodium storage in end stage kidney disease  
**Christoph Kopp**, Erlangen, Germany

Renal potassium sensing and control of sodium balance  
**Johannes Loffing**, Zurich, Switzerland

Dietary sodium restrictions: yes/no?  
**Attila Szabo**, Budapest, Hungary
Symposium 17

Start dialysis? Stop dialysis? - Challenging conversations

Chairs: Àngel Argilés, Montpellier, France
Andrew Davenport, London, United Kingdom

Dialysis or conservative care?
Wim Van Biesen, Ghent, Belgium

Is this the time to consider dialysis withdrawal?
Monika Lichodziejewska-Niemierko, Gdańsk, Poland

Different conversations for different ethnic groups?
Edwina Brown, London, United Kingdom

Dialysis yes or no?
Same question, different answers depending on the context
Christian Combe, Bordeaux, France
Free Communication Session 12 + Mini Lectures

**Genetics in kidney disease: unravelling complex interactions**

Chairs: Francesca Becherucci, Florence, Italy  
Kálmán Tory, Budapest, Hungary

**Mini lecture**
Interallelic interactions of podocin: genetic, molecular, cellular and clinical aspects  
Kálmán Tory, Budapest, Hungary

---

**FREE COMMUNICATIONS**

**FO067**  
ADTKD-MUC1 IN THE CYPRiot POPULATION: GENOTYPING, DEEP-PHENOTYPING, BIOMARKER DISCOVERY AND THE SEARCH FOR A ROBUST TREATMENT  
Gregory Papagregoriou1; Christoforos Stavrou2; Andrea Christofides1; Constantina Koutsofti1; Martina Zivna3; Eric Kuhn4; Julie Roignot5; Stanislav Knoch3; Anthony J. Bleyer6; Anna Greka7; Constantinos Delta1; 1Molecular medicine research center, Univ Cyprus, Nicosia, Cyprus; 2Nephrology unit, Evangelismos Private Hosp, Pafos, Cyprus; 3Research Unit Rare Diseases, 1st School Medicine, Charles Univ and General Fac Hosp Prague, Prague, Czech Republic; 4Proteomics platform, Broad Inst Harvard and Massachusetts Inst Technology, Cambridge, MA, U.S.A.; 5Kidney disease initiative, Cambridge, MA, U.S.A.; 6Section nephrology, Wake Forest Baptist Health, Winston-Salem, U.S.A.; 7Broad Inst harvard and mit, Broad Inst, Cambridge, U.S.A.

**FO068**  
THE LMX1βR246Q MUTATION INDUCES PODOCYTE INJURY THROUGH DYSREGULATION OF CHOLESTEROL TRANSPORT GENE EXPRESSION  
Gentzon Hall1; G. Michelle Ducasa2; Brandon M. Lane3; Max Lagas3; Maria E. Kovalik1; Olivia G. Gregory1; Guanghong Wu3; Megan Chryst-Stangl3; Liming Wang1; Robert F. Spurney1; Alessia Fornoni2; Rasheed A. Gbadegesin3; 1Medicine, Duke Univ Medical Center, Durham, U.S.A.; 2Medicine, Univ Miami, Miami, U.S.A.; 3Pediatrics, Duke Univ Medical Center, Durham, U.S.A.

**FO069**  
GENETIC ANALYSIS IN DENT DISEASE AND FUNCTIONAL STUDIES OF CLCN5 MUTATIONS IN PATIENTS' KIDNEY BIOPSIES  
Monica Ceol1; Lisa Gianesello2; Giovanna Priante2; Dorella Del Prete2; Franca Anglani2; 1Dept medicine, Clinical Nephrology, Univ Padua, Padua, Italy; 2Dept Medicine, Univ Padua, Padua, Italy

**Mini lecture**
Personalised diagnosis and CKD prediction in genetic tubular disorders  
Francesca Becherucci, Florence, Italy
Scientific Programme

HALL A2

Free Communication Session 13 + Mini Lectures

**Clinical nephrology: predicting outcome**

Chairs: **Wei Chen**, Guangzhou, China
**Vladimir Tesar**, Prague, Czech Republic

*Mini lecture*

The Swedish Health databases; an abundance of possibilities for kidney research

**Juan Jesus Carrero**, Stockholm, Sweden

**FREE COMMUNICATIONS**

- **FO070**
  Long-term cardiorenal outcomes associated with the acute increase of plasma creatinine following renin-angiotensin system blockade in a real-world setting
  **Edouard Fu**1; Marco Trevisan2; Catherine Clase3; Marie Evans4; Bengt Lindholm4; Joris Rotmans5; Merel Van Diepen6; Friedo Dekker6; Juan Jesus Carrero2; 1Dept clinical epidemiology, Leiden Univ Medical Center, Leiden, Netherlands; 2Dept medical epidemiology and biostatistics, Karolinska Inst, Stockholm, Sweden; 3Dept health research methods, evidence, and impact, McMaster Univ, Hamilton, Canada; 4Dept clinical science, intervention and technology, Karolinska Inst, Stockholm, Sweden; 5Dept internal medicine, Leiden Univ Medical Center (LUMC), Leiden, Netherlands; 6Dept clinical epidemiology, Leiden Univ Medical Center, Leiden, Netherlands

- **FO071**
  Combination of urinary matrix metalloproteinases-7 with clinical data and MEST-C score provides early risk prediction for progression of IgA nephropathy
  **Xiaobing Yang**; Hou Fanfan; Div nephrology, Nanfang Hosp, Southern Medical Univ, Guangzhou, P.R. China

- **FO072**
  Oxygen preconditioning prevents contrast-induced nephropathy after cardiac catheterization (OPtion CIN study): multi-center placebo-controlled single-blinded randomized study
  **Yoichi Ajiro**1; Sekiguchi Haruki2; Koretsune Yukihiro3; Suzuki Masahiro4; Shimizu Masatoshi5; Sakagami Satoru6; Yonezawa Kazuya7; Matsubara Hiromi8; Abe Mitsuru9; Takenaka Takashi10; Kawasaki Atsushi11; Ono Yujiro12; Yamada Takaaki13; Taketani Yoshio14; Kato Toru15; Wada Hiromichi9; Mori Fumiaki16; Iwade Kazunori16; Hagiwara Nobuhisa2; Hasegawa Koji1; 1Clinical research, National Hosp Organization Yokohama Medical Center, Yokohama, Japan; 2Cardiology, Tokyo Women’s Medical Univ, Shinjuku, Japan; 3Cardiology, National Hosp Organization Osaka National Hosp, Osaka, Japan; 4Cardiology, National Hosp Organization Saitama National Hosp, Wako, Japan; 5Cardiology, National Hosp Organization Kobe Medical Center, Kobe, Japan; 6Cardiology, National Hosp Organization Kanazawa Medical Center, Kanazawa, Japan; 7Cardiology, National Hosp Organization Hakodate National Hosp, Hakodate, Japan; 8Cardiology, National Hosp Organization Okayama Medical Center, Okayama, Japan; 9Cardiology, National Hosp Organization Kyoto Medical Center, Kyoto, Japan; 10Cardiology, National Hosp Organization Hokkaido Medical Center, Sapporo, Japan; 11Cardiology, National Hosp Organization Tochigi Medical Center, Utsunomiya, Japan; 12Cardiology, National Hosp Organization Nagoya Medical Center, Nagoya, Japan; 13Cardiology, National Hosp Organization Shikoku Medical Center for Children and Adults, Zentsuji, Japan; 15Cardiology, National Hosp Organization Tochigi Medical Center, Utsunomiya, Japan; 16Cardiology, National Hosp Organization Yokohama Medical Center, Yokohama, Japan

*Mini lecture*

Lupus nephritis: the data from China

**Wei Chen**2; Guangzhou, China
FREE COMMUNICATIONS

**FO073**
THE EFFECT OF REPEATED ACUTE KIDNEY INJURY ON SURVIVAL AND PROGRESSION TO END STAGE KIDNEY DISEASE IN CKD
Lynne Sykes1; Osgur Asar2; James Ritchie3; Peter Diggle4; Phillip A Kalra3; 1Emergency assessment unit, Salford Royal NHS Foundation Trust, Manchester, United Kingdom; 2Dept biostatistics and health informatics, Acibadem Univ Hosp Atakent, Istanbul, Turkey; 3Dept renal medicine, Salford Royal NHS Foundation Trust, Manchester, United Kingdom; 4Lancaster medical school, Lancaster Univ, Bailrigg, Lancaster, United Kingdom

**FO074**
REFERENCE CHANGE VALUE IN SERUM CREATININE AND DETECTION OF AKI IN ADULTS
Xu Xin; Fan Fan Hou; Sheng Nie; Dept nephrology, Nanfang Hosp, guangdong, P.R. China

**FO075**
ACUTE KIDNEY DISEASE - A NEW DEFINITION, BUT IS IT USEFUL IN DESCRIBING RENAL OUTCOMES FOLLOWING AKI?
Isma Kazmi1; Rebecca Packington2; Selby Nick3; 1Dept renal medicine, Univ Nottingham, Centre Kidney Research and Innovation, United Kingdom; 2Dept renal medicine, Univ Hosp Derby and Burton, Derby, United Kingdom; 3Centre kidney research and innovation, Univ Nottingham, Derby, United Kingdom

**FO076**
ICD-10 CODING - AN UNRELIABLE INDICATOR FOR ACUTE KIDNEY INJURY RATES AND OUTCOMES IN HOSP IN-PATIENTS
Rachael Logan1; David Baird2; Peter Davey1; Nicosha Desouza1; Bruce Guthrie3; Samira Bell1; 1School medicine, Univ Dundee, Dundee, United Kingdom; 2Renal unit, NHS Tayside, Dundee, United Kingdom; 3 Centre population health sciences, Univ Edinburgh, Edinburgh, United Kingdom

**FO077**
LONG TERM EFFECTS OF ACUTE KIDNEY INJURY ON CHRONIC KIDNEY DISEASE AND PATIENT OUTCOMES: 3-YEAR RESULTS FROM A LARGE PROSPECTIVE PARALLEL GROUP COHORT STUDY
Isma Kazmi1; Rebecca Packington2; Selby Nick3; 1Renal medicine, Univ Nottingham, Centre Kidney Research and Innovation(CKRI), France; 2Dept renal medicine, Univ Hosp Derby and Burton, Derby, United Kingdom; 3Centre kidney research and innovation, Univ Nottingham, Derby, United Kingdom

**FO078**
PROTON PUMP INHIBITORS AND THE RISK OF HOSP-ACQUIRED ACUTE KIDNEY INJURY IN CHILDREN
Sheng Nie1; Xu Xin2; 1National clinical research center kidney diseases, guangzhou, P.R. China; 2Dept nephrology, nanfang Hosp, guangzhou, P.R. China
**Novel discoveries in CKD pathophysiology**

**Free Communication Session 15**

**HALL A4**

**Scientific Programme**

**FRIDAY, JUNE 14 2019**

**17:00 - 18:30**

**Free Communication Session 15**

**Novel discoveries in CKD pathophysiology**

**Chairs:** Charles Ferro, Birmingham, United Kingdom

Griet Glorieux, Ghent, Belgium

---

**FREE COMMUNICATIONS**

**FO079**

**CONCENTRATIONS OF P-CRESYL - AND INDOXYL SULFATE AND THEIR PRECURSORS IN DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE: FROM FECES TO URINE**

Tessa Gryp1; Kim De Paepe2; Frederiek-Maarten Kerckhof2; Wim Van Biesen3; Raymond Vanholder3; Marie Joossens4; Mario Vaneechoutte1; Griet Glorieux3; 1Dept diagnostic sciences, Lab bacteriology research, Ghent Univ, Ghent, Belgium; 2Dept microbial and biochemical technology, center microbial ecology and technology, Ghent Univ, Ghent, Belgium; 3Dept internal medicine and pediatrics, nephrology section, Ghent Univ Hosp, Ghent, Belgium; 4Dept microbiology and immunology, molecular microbiology and microbiome research lab, KU Leuven, Leuven, Belgium

**FO080**

**APABETALONE, AN INHIBITOR OF BET PROTEINS, IMPROVES CARDIOVASCULAR RISK AND REDUCES ALKALINE PHOSPHATASE IN BOTH CVD PATIENTS AND PRIMARY HUMAN CELL CULTURE SYSTEMS**

Dean Gilham1; Laura Tsujikawa1; Sylwia Wasiak1; Christopher Halliday1; Ken Lebioda2; Kamyar Kalantar-Zadeh3; Srinivasan Beddu4; Vincent Brandenburg5; Marcello Tonelli6; Ravi Jahagirdar1; Norman C. W. Wong1; Carmine Zoccali7; Jan O. Johansson8; Michael Sweeney8; Mathias Haarhaus9; Ewelina Kuliakowski1; 1Research and development, Resverlogix Corp, Calgary, Canada; 2Business development, Resverlogix Corp, Calgary, Canada; 3Univ California Irvine Medical Center, Univ California Irvine, School Medicine, Orange, U.S.A.; 4Div nephrology, Univ Utah, School Medicine, Salt Lake City, U.S.A.; 5Dept cardiology and nephrology, Rhein-Maas Klinikum, Würselen, Germany; 6Dept medicine, Univ Calgary, Calgary, Canada; 7Clinical epidemiology of renal diseases and hypertension, CNR-IFC, Reggio Calabria, Italy; 8Research and development, Resverlogix Inc., San Francisco, U.S.A.; 9Dept Nephrology, Karolinska Univ Hosp, Stockholm, Sweden

**FO081**

**METFORMIN ALLEVIATES STROKE SEVERITY IN FEMALE MICE WITH CHRONIC KIDNEY DISEASE THROUGH AMPK ACTIVATION AND SUBSEQUENT DECREASE OF MICROGLIA/MACROPHAGES M1 POLARIZATION**

Maria Grissi1; Cédric Boudot1; Maryam Assem1; Sabrina Poirot-Leclercq1; Gaëlle Lenglet1; Mathilde Lando2; Carine Avondo1; Agnès Boulier1; Jean-Daniel Lalau1; Gabriel Chroukroun1; Ziad Massy3; Said Kame4; Jean-Marc Chillon5; Lucie Henaut1; 1EA7517, Univ Picardie Jules Verne, Amiens, France; 2Fac medicine, Univ Picardie Jules Verne, Amiens, France; 3Div Nephrology, Ambroise Paré Hosp, Paris, France; 4Fac pharmacy, Univ Picardie Jules Verne, Amiens, France; 5Direction clinical research, Amiens Univ Hosp, Amiens, France

**FO082**

**PROGRESSION OF MYOCARDIAL FIBROSIS IN CHRONIC KIDNEY DISEASE**

Manvir Hayer1; Anna Price1; Boyang Liu2; Shanat Baig2; Charles J Ferro3; John Townend2; Rick Steeds2; Nicky Edwards2; 1Nephrology, Univ Hosp Birmingham NHS Foundation Trust, Birmingham, United Kingdom; 2Cardiology, Univ Hosp Birmingham NHS Foundation Trust, Birmingham, United Kingdom; 3Dept nephrology, Univ Hosp Birmingham NHS Foundation Trust, Birmingham, United Kingdom
FO083
CHRONIC FGF23 OVERLOAD FAILS TO INDUCE CARDIAC DYSFUNCTIONS
Maren Leifheit-Nestler1; Miriam A. Wagner1; Juliette Nowak1; Beatrice Richter2; Ineke Böckmann1; Ariana Foinquinos3; Thomas Thum3; Martin Meier4; Oliver J. Müller5; Dieter Haffner1; 1Dept pediatric kidney, liver and metabolic diseases, Hannover Medical School, Hanover, Germany; 2Dept medicine and Div nephrology, Univ Alabama Birmingham, Birmingham, U.S.A.; 3Inst molecular and translational therapeutic strategies, Hannover Medical School, Hanover, Germany; 4Inst Lab animal science, Hannover Medical School, Hanover, Germany; 5Dept internal medicine iii, Univ Hosp Kiel, Kiel, Germany

FO084
APOLIPOPROTEIN C3 INDUCES SYSTEMIC INFLAMMATION AND ORGAN DAMAGE IN CKD BY ALTERNATIVE INFLAMMASOME ACTIVATION VIA A NOVEL PATHWAY
Stephen Zewinger1; Reiser Jochen2; Vera Jankowski3; Eunsil Hahm2; Stefan Schunk1; David Schmit1; Winfried März4; Joachim Jankowski5; Niemeyer Barbara6; Ulrich Laufs7; Danilo Fliser8; Thimoteus Speer1; 1Dept internal medicine, Saarland Univ Hosp, Homburg/Saar, Germany; 2Dept internal medicine, Rush Univ Medical Center, Chicago, U.S.A.; 3Inst molecular cardiovascular research, RWTH Aachen Univ, Aachen, Germany; 4Medical clinic v, Medical Fac Mannheim, Heidelberg Univ (CBTM), Mannheim, Germany; 5Inst Molecular Cardiovascular Research IMCAR, Univ Hosp RWTH Aachen, Aachen, Germany; 6Inst biophysics, Saarland Univ Hosp, Homburg/Saar, Germany; 7Dept cardiology, Universitätsklinikum Leipzig, Leipzig, Germany; 8Dept Internal Medicine IV, Saarland Univ Medical Centre, Homburg/Saar, Germany
DAY AT A GLANCE

08:00 - 09:30 **Symposia**  
Treatment of AKI: next generations therapies and renal replacement therapy in the Intensive Care Unit 85  
Molecular mechanisms of kidney atrophy and fibrosis 85  
Haemodialysis. From incremental approaches to frequent treatments 86  
Regenerative medicine 86  
New insights in molecular mechanism of cardiovascular diseases in CKD 87  
**Free Communications + Mini Lectures**  
Cystic diseases: new genes and modifiers 88  
Rehabilitation and physical exercise in CKD 90

09:30 - 10:45 **Poster session**  
**Industry Symposia** 123  
**ERA-EDTA General Assembly** (for ERA-EDTA members only) 92

10:45 - 11:30 **Plenary Lecture Katalin Susztak**  
Single-cell transcriptomics in kidney disease 93

11:45 - 13:15 **Symposia**  
Optimizing peritoneal dialysis prescription 93  
Complement mediated kidney injury 94  
Controversy: does haemodiafiltration improve patient outcomes and survival? 94  
CKD-MBD patterns and therapeutic approaches: update 2019 95  
The gut-kidney-cardiovascular axis 95  
**Free Communications + Mini Lectures**  
Fighting DKD 96  
Defining outcome in transplantation 97  
Improving cardiovascular complications in CKD 98

13:15 - 14:45 **Industry Symposia** 123

15:00 - 16:30 **Symposia**  
Improving the organ donor pool 99  
Cardiovascular disease in CKD: risk factors and remedies 99  
The hidden risks of haemodialysis 100  
The role of diet in the prevention of CKD progression: food for thought 100  
**Free Communications + Mini Lectures**  
Immunological kidney diseases 101  
CKD-MBD 102  
ESAs and iron: anaemia and beyond 103  
How to prevent AKI 104

16:30 - 17:00 **Poster session** 105
17:00 - 18:30 **Symposia**

- Home haemodialysis: on the move 106
- Overcoming age with frailty evaluation in the kidney transplant recipient 106
- Delivering good quality dialysis - what should we measure? 107
- The paradox of estimated GFR in the era of precision medicine 107

**Free Communications + Mini Lectures**

- Kidney diseases from childhood to adult 108
- Experimental hypertension 110
- Novel approaches to AKI: exosomes and RNA interference 111
- Revisiting PD: a systems biology approach 112
Symposium 18

*Treatment of AKI: next generations therapies and renal replacement therapy in the Intensive Care Unit*

Chairs: Andreas Kribben, Essen, Germany  
Norbert Lameire, Ghent, Belgium

Role and modulation of PGC1alpha in AKI  
*Miguel Fontecha Barriuso*, Madrid, Spain

Modality and dose: where do we stand?  
*Claudio Ronco*, Vicenza, Italy

When to start dialysis: the final answer?  
*Julien Maizel*, Amiens, France

Targeting MAP3Ks to treat AKI  
*Maria Dolores Sanchez-Niño*, Madrid, Spain

Symposium 19

*Molecular mechanisms of kidney atrophy and fibrosis*

Chairs: Hans-Joachim Anders, Munich, Germany  
Tamas Kaucsar, Budapest, Hungary

Diabetes-induced CKD: when kidneys get the munchies  
*Joseph Tam*, Jerusalem, Israel

Does less fibrosis improve renal function? Insights from collagen I-deficiency  
*Matthias Mack*, Regensburg, Germany

Pathology and mechanisms of interstitial granuloma formation  
*Peter Boor*, Aachen, Germany

Connective tissue growth factor and renal fibrosis  
*Marta Ruiz-Ortega*, Madrid, Spain
HALL F1 08:00 - 09:30

Symposium 20

**Haemodialysis. From incremental approaches to frequent treatments**

Chairs: Dimitrios Kirmizis, London, United Kingdom
        Elena Zakharova, Moscow, Russia

The concept of incremental haemodialysis
*Carlo Basile*, Acquaviva delle Fonti, Italy

Clinical experiences with incremental haemodialysis schedules
*Kamyar Kalantar-Zadeh*, Orange, CA, U.S.A.

Clinical impact of Extending Haemodialysis Hours
*Meg Jardine*, Sydney, Australia

Assuring adequate preparation and choice for advanced CKD patients facing kidney failure (CKDopps)
*Christian Combe*, Bordeaux, France

HALL A1 08:00 - 09:30

Symposium 21

**Regenerative medicine**

Chairs: Paola Romagnani, Florence, Italy
        Takashi Yokoo, Tokyo, Japan

Drug targeting of endogenous progenitors for kidney regeneration
*Paola Romagnani*, Florence, Italy

From human embryonic nephron stem cells to mature kidney tissue and regeneration
*Benjamin Dekel*, Ramat Gan, Israel

Kidney regeneration using induced pluripotent stem (IPS) cells
*Takashi Yokoo* ISN, Tokyo, Japan

What can organoids teach us about kidney regeneration?
*Nuria Montserrat*, Barcelona, Spain
Scientific Programme

HALL A2

Symposium 22

New insights in molecular mechanism of cardiovascular diseases in CKD

Chairs: Joachim Jankowski, Aachen, Germany
Heidi Noels, Aachen, Germany

Oxidative stress on myocardial function in CKD
Leticia Prates Roma, Homburg/Saar, Germany

Lipoproteins in CKD-associated vascular diseases
Thimoteus Speer, Homburg/Saar, Germany

Atherosclerosis, cardiac remodelling and CKD
Heidi Noels, Aachen, Germany

Impact of post-translational modification on the genesis and progression of CKD
Joachim Jankowski, Aachen, Germany
FREE COMMUNICATIONS

**SaO001**
THE EFFECT OF L-TYPE AMINO ACID TRANSPORTER 1 IN THE CYST FORMATION OF MODEL MICE FOR POLYCYSTIC KIDNEY DISEASE
Sayo Takeda1; Saori Nishio1; Toru Kimura2; Junya Yamamoto1; Daigo Nakazawa1; Hiroyuki Sakurai2; Tatsuya Atsumi1; 1Dept rheumatology, endocrinology and nephrology, Fac Medicine and Graduate Scho- ol Medicine, Hokkaido Univ, Sapporo, Japan; 2Dept pharmacology and toxicology, Kyorin Univ School Medicine, Mitaka-shi, Japan

**SaO002**
QUANTITATIVE RELATIONSHIP BETWEEN TKV GROWTH RATE AND eGFR RATE OF DECLINE IN ADPKD PATIENTS
Pascal Minini1; Ali Hariri2; Manish Maski3; Vijay Modur2; 1Research and development, Sanofi Aventis, Chilly-Mazarin, France; 2Clinical development, Sanofi Genzyme, Cambridge, MA, U.S.A.; 3Medical Affai- rs, Sanofi Genzyme, Cambridge, MA, U.S.A.

**SaO003**
USE OF THIAZIDE DIURETICS DOES NOT WORSEN DISEASE PROGRESSION IN ADPKD
Bart J. Kramers1; Ron T. Gansevoort1; Rudolf De Boer2; Joost P.h. Drenth3; Johan W. De Fijter4; Jack F.M. Wetzels5; Robert Zietse6; Esther Meijer1; 1Dept nephrology, Univ Medical Center Groningen, Groningen, Netherlands; 2Dept cardiology, Univ Medical Center Groningen, Groningen, Netherlands; 3Dept gastroenterology and hepatology, Radboud Univ Medical Center, Nijmegen, Netherlands; 4Dept nephrology, Leiden, Netherlands; 5Dept Nephrology 464, Radboud Univ Medical Center, Nijmegen, Netherlands; 6Dept internal medicine, Erasmus Medical Center, Rotterdam, Netherlands

**SaO004**
MOSAICISM IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A COMPREHENSIVE CLINICAL AND RADIOLOGICAL DESCRIPTION OF 15 CASES
Vinh Toan Huynh1; Marie-Pierre Audrézet2; Eric Renaudineau3; Cécile Courivaud4; Dan A Hristea5; Régine Perrichot6; Maurice Laville7; Céline Dheu8; Lucie Bessenay9; Hélène Longuet10; Lise-Marie Pouteau11; Claude Péret12; Emilie Corne-Le Gall13; 1Néphrologie, Centre Hosp et Univ Brest, Brest, France; 2 Lab génétique moléculaire histocompatibi- lité, Centre Hosp et Univ Brest, Brest, France; 3Néphrologie et dialyse, Centre Hosp Saint-Malo, Saint Malo, France; 4Néphrologie, Centre Hosp régional Univ Basançon, Besançon, France; 5Néphrologie and dialysis, Centre Hosp Univ Nantes, Nantes, France; 6Néphrologie, hômedialyse, Groupement Hosp brocéliande atlantique, VANNES, France; 7Néphrologie, Lyon Univ Hosp, Lyon, France; 8Néphrologie, Hopitaux civils colmar, Colmar, France; 9 Néphrologie, Centre Hosp Univ Clermont-Ferrand, Clermont- Ferrand, France; 10 Serv néphrologie et immunologie clinique, chru tours - hôpital bretonneau, Tours, France; 11Néphrologie, Hopital Laval, Laval, France; 12Néphrologie, hémodialyse, transplantation, Centre Hosp et Univ Brest, Brest, France; 13Serv néphrologie, Centre Hosp Univ; INSERM U1078, Brest, France
SaO005

CLINICAL PRESENTATION AND PROGNOSIS OF DNAJB11-ASSOCIATED NEPHROPATHY: AN INTERNATIONAL COLLABORATIVE STUDY

Vinh Toan Huynh1; Marie-Pierre Audrézet2; Camille Domenger3; Frank Bridoux3; Guillaume Sere4; Hélène Longuet5; Jean-Michel Halimi5; Study Group Genkyst6; Sarah Senum7; Aurélie Pajot8; Julie Albaret9; Éléonore Ponlot10; Claude Férec2; Albertien M. Van Eerde11; Albert C. Ong12; Peter C Harris7; Yannick Le Meur13; Emilie Corneec-Le Gall14; 1Néphrologie, hémodialyse, transplantation, Centre Hosp et Univ Brest, Brest, France; 2Lab génétique moléculaire et histocompatibilité, Centre Hosp et Univ Brest, Brest, France; 3Dept nephrology, dialysis and renal transplantation, Centre Hosp Univ Poitiers Hopital Jean Bernard, Poitiers, France; 4 Nephrology, Echo Sante, Le Mans, France; 5Serv néphrologie et immunologie clinique, chru tours hôpital bretonneau, Tours, France; 6Nephrologie, CHRU Brest, Brest, France; 7Nephrology and hypertension, Mayo Clinic, Rochester, U.S.A.; 8Dept nephrology, dialysis, Clinique Anjou, Angers, France; 9Dept nephrology and dialysis, Centre Hosp Vichy, Vichy, France; 10 Dept nephrology and dialysis, Hôpital Tenon, Paris, France; 11Afdeling genetica, Universitair Medisch Centrum Utrecht, Utrecht, Netherlands; 12Infection, immunity & cardiovascular disease, Univ Sheffield Medical School, Sheffield, United Kingdom; 13Néphrologie, hémodialyse, transplantation, Centre Hosp et Univ Brest, Brest, France; 14Serv néphrologie, Centre Hosp Univ; INSERM U1078, Brest, France

SaO006

PREVALENCE OF DETECTED INTRACRANIAL ANEURYSMS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) IN 2796 PATIENTS FROM THE GENKYST COHORT

Siriane Lefevre1; Marie-Pierre Audrézet2; Jean-Michel Halimi3; Cecile Vigneau4; Maryvonne Hourmant5; Jacques Dantal5; Eric Renaudineau6; Frank Bridoux7; Jean-François Augusto8; Christophe Charasse9; Pascale Siohan10; Régine Perricht11; Claude Férec2; Yannick Le Meur12; Emilie Corneec-Le Gall13; 1Néphrologie, CHRU Brest, Brest, France; 2Lab génétique moléculaire et histocompatibilité, Centre Hosp et Univ Brest INSERM U1078, Brest, France; 3Serv néphrologie et immunologie clinique, chru tours - hôpital bretonneau, Tours, France; 4Nephrology, Hosp Center Univ Pontchaillou, Rennes, France; 5Dept nephrology, dialysis and renal transplantation, Centre Hosp Univ Nantes, Poitiers, France; 6Néphrologie et dialyse, Centre Hosp Saint-Malo, Saint Malo, France; 7Dept Nephrology, Dialysis and Renal Transplantation, Centre Hosp Univ Poitiers - Hopital Jean Bernard, Poitiers, France; 8Néphrologie, dialyse et transplantation, Centre Hosp et Univ Angers, Angers, France; 9Néphrologie, hémodialyse, Centre Hosp Saint-Brieuc, Saint Brieuc, France; 10Néphrologie, hémodialyse, Centre Hosp Cornouaille, Quimper, France; 11Néphrologie, hémodialyse, Groupement Hosp brocéliande atlantique, Vannes, France; 12Néphrologie, hémodialyse, transplantation, Centre Hosp et Univ Brest, Brest, France; 13Serv néphrologie, Centre Hosp Univ; INSERM U1078, Brest, France
Free Communication Session 17 + Mini Lectures

Rehabilitation and physical exercise in CKD

Chairs: Alice Smith, Leicester, United Kingdom
Amaryllis van Craenenbroeck, Leuven, Belgium

Mini lecture
Can exercise training affect cardiovascular morbidity in patients with CKD?
Amaryllis van Craenenbroeck, Leuven, Belgium

FREE COMMUNICATIONS

SaO007
THE BORG RPE-SCALE TO PRESCRIBE AND MONITOR BALANCE TRAINING IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Philippa Svensson1; Högland Peter2; Hellberg Matthias1; Wisén Anita3; Clyne Naomi1; 1Dept clinical sciences, Lund Univ, Lund, Sweden; 2Dept Lab medicine, Lund Univ, Lund, Sweden; 3Dept health sciences, Lund Univ, Lund, Sweden

SaO008
PHYSICAL ACTIVITY REDUCES 10-YEAR CARDIOVASCULAR DISEASE RISK THROUGH IMPROVEMENT IN BLOOD PRESSURE REGULATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Thomas Wilkinson1; Jared Palmer2; Daniel Nixon1; Alice Smith1; 1Dept health sciences, Univ Leicester, Leicester, United Kingdom; 2Leicester kidney lifestyle team, Univ Hosp Leicester, Leicester, United Kingdom

SaO009
ASSOCIATION BETWEEN INTRADIALYTIC EXERCISE TRAINING IN HEMODIALYSIS PATIENTS AND BURDEN OF THEIR CAREGIVERS
Maycon Moura Reboredo1; Rodrigo Schinniger Assun Garcia2; Leda Marília Fonseca Lucinda2; André Luiz Pimentel3; Emanuele Poliana Lawall Gravina2; Rogério Baumgratz Paula4; José Muniz Pazeli3; Bruno Ville Pinheiro2; 1Federal Univ Juiz de Fora, Juiz de Fora, Brazil; 2Pulmonary and critical care Div, Federal Univ Juiz de Fora, Juiz de Fora, Brazil; 3Medicine, School Medicine Barbacena, Barbacena, Brazil; 4Medicine, Federal Univ Juiz de Fora, Juiz de Fora, Brazil

Mini lecture
Patient related outcomes of physical activity in CKD - what should we measure and why?
Alice Smith, Leicester, United Kingdom
### POSTER SESSION

**Poster Area**

**09:30 - 10:45**

**16:30 - 17:00**

<table>
<thead>
<tr>
<th>Registry</th>
<th>REG1 - REG6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetic diseases and molecular genetics</td>
<td>SP001 - SP036</td>
</tr>
<tr>
<td>Hypertension. Experimental &amp; clinical</td>
<td>SP037 - SP072</td>
</tr>
<tr>
<td>Clinical nephrology 2</td>
<td>SP073 - SP152</td>
</tr>
<tr>
<td>Glomerulonephritis 2</td>
<td>SP153 - SP209</td>
</tr>
<tr>
<td>AKI. Clinical. Epidemiology and outcome</td>
<td>SP210 - SP261</td>
</tr>
<tr>
<td>CKD. Lab methods, GFR measurement, urine proteomics</td>
<td>SP262 - SP296</td>
</tr>
<tr>
<td>CKD. Pathophysiology, progression and risk factors 2</td>
<td>SP297 - SP341</td>
</tr>
<tr>
<td>CKD. HD. Anaemia</td>
<td>SP342 - SP377</td>
</tr>
<tr>
<td>CKD. Nutrition, inflammation and oxidative stress</td>
<td>SP378 - SP416</td>
</tr>
<tr>
<td>CKD. Rehabilitation</td>
<td>SP417 - SP429</td>
</tr>
<tr>
<td>Diabetes. Basic research</td>
<td>SP430 - SP456</td>
</tr>
<tr>
<td>Extracorporeal dialysis: techniques and adequacy 2</td>
<td>SP457 - SP489</td>
</tr>
<tr>
<td>Peritoneal dialysis 2</td>
<td>SP490 - SP538</td>
</tr>
<tr>
<td>Dialysis. Cardiovascular complications 2</td>
<td>SP539 - SP573</td>
</tr>
<tr>
<td>Dialysis. Vascular access 2</td>
<td>SP574 - SP602</td>
</tr>
<tr>
<td>Dialysis. Bone disease</td>
<td>SP603 - SP632</td>
</tr>
<tr>
<td>Dialysis. Epidemiology and outcome 2</td>
<td>SP633 - SP676</td>
</tr>
<tr>
<td>Dialysis. Health services research</td>
<td>SP677 - SP707</td>
</tr>
<tr>
<td>Renal transplantation. Experimental, immune-tolerance of allogenic and xenogenic transplants</td>
<td>SP708 - SP720</td>
</tr>
<tr>
<td>Renal transplantation. Epidemiology and outcome 2</td>
<td>SP721 - SP766</td>
</tr>
<tr>
<td>Renal transplantation. Treatment and immunosuppression</td>
<td>SP767 - SP800</td>
</tr>
<tr>
<td>History of nephrology</td>
<td>SP801 - SP815</td>
</tr>
<tr>
<td>Patient education research and training in nephrology</td>
<td>SP816 - SP833</td>
</tr>
</tbody>
</table>
All ERA-EDTA active members (cat. A and B only) are invited to participate in the ERA-EDTA General Assembly.

Since the meeting room will be monitored, active members must have their 2019 membership card to show at the entrance and their badge scanned.

The membership card can be downloaded from the ERA-EDTA website (restricted area – section “Membership documents and information”).

Full active ERA-EDTA members (cat. A and B) have voice and vote during the meeting. Associate active ERA-EDTA members (cat. A and B) have voice, but cannot vote.
Scientific Programme

HALL G1

Plenary Lecture 2

Chairs: Alberto Ortiz, Madrid, Spain
Ivan Rychlik, Prague, Czech Republic

*Single-cell transcriptomics in kidney disease*
Katalin Susztak, Philadelphia, PA, U.S.A.

---

HALL G1

Symposium 23

*Optimizing peritoneal dialysis prescription*

Chairs: Isaac Teitelbaum, Denver, CO, U.S.A.
Wim Van Biesen, Ghent, Belgium

Why testing peritoneal membrane characteristics?
Johann Morelle, Brussels, Belgium

Optimizing PD initiation and reducing early switches to HD: insights from PDOPPS
Simon Davies, Stoke-on-Trent, United Kingdom

Winner of the Stanley Shaldon Award for Young Investigators

Alanyl-glutamine supplementation in peritoneal dialysis fluids
Rebecca Herzog, Vienna, Austria

Peritoneal dialysis adequacy and outcomes: what really matters?
Isaac Teitelbaum, Denver, CO, U.S.A.
HALL G2A 11:45 - 13:15

**Symposium 24**

**Complement mediated kidney injury**

*Chairs: Ingeborg M. Bajema, Leiden, The Netherlands  
Manuel Macia, Santa Cruz de Tenerife, Spain*

- Histologic classification of lupus nephritis – time for a change?  
  **Ingeborg M. Bajema**, Leiden, The Netherlands

- Pathogenesis of SLE and systemic lupus nephritis – what is new?  
  **Hans-Joachim Anders**, Munich, Germany

- Biologic therapy in lupus nephritis – where are we now?  
  **Gabriella Moroni**, Milan, Italy

- Complement alternative pathway abnormalities in C3 glomerulopathy  
  **Sophie Chauvet**, Paris, France

HALL G2B 11:45 - 13:15

**Symposium 25**

**Controversy: does haemodiafiltration improve patient outcomes and survival?**

*Chairs: József Balla, Debrecen, Hungary  
Carlo Basile, Acquaviva delle Fonti, Italy*

- No  
  **Francesco Locatelli**, Lecco, Italy

- Yes  
  **Peter J. Blankestijn**, Utrecht, The Netherlands

- Increasing convection: what happens to the different uraemic toxins when increasing convection in post-dilutional HDF?  
  **Ángel Argilés**, Montpellier, France

- Does haemodiafiltration improve uraemic neuropathy? Results from the FINESSE RCT?  
  **Amy Kang**, Sydney, Australia
**Scientific Programme**

**HALL F1**  
11:45 - 13:15

**Symposium 26**

**CKD-MBD patterns and therapeutic approaches: update 2019**

Chairs: **Jorge Cannata-Andia**, Oviedo, Spain  
**Mario Cozzolino**, Milan, Italy

Klotho, a new player coming to age  
**Marc Vervloet**, Amsterdam, The Netherlands

New insights in pathogenesis and treatment of vascular calcification  
**Catherine Shanahan**, London, United Kingdom

Osteoporosis in CKD, a diagnostic and therapeutic challenge on the move  
**Pieter Evenepoel**, Leuven, Belgium

Evidence in CKD-MBD guidelines: Is it time to treat? Is it time to wait?  
**Jordi Bover**, Barcelona, Spain

---

**HALL A1**  
11:45 - 13:15

**Symposium 27**

**The gut-kidney-cardiovascular axis**

Chairs: **Francesca Mallamaci**, Reggio Calabria, Italy  
**Raymond Vanholder**, Ghent, Belgium

Gut microbiota and microbial metabolism in CKD across stages of diseases  
**Griet Glorieux**, Ghent, Belgium

Gut dysbiosis and thrombosis  
**Vipul Chitalia**, Boston, MA, U.S.A.

Gut dysbiosis and vascular calcification  
**Ziad Massy**, Paris, France

Role of dietary potassium in natriuresis, blood pressure, and cardio-renal outcomes  
**Ewout Hoorn**, Rotterdam, The Netherlands
**Scientific Programme**

**HALL A2**  
**11:45 - 13:15**

**Free Communication Session 18 + Mini Lectures**

**Fighting DKD**

**Chairs:**  
**Jose Luiz Gorriz**, Valencia, Spain  
**Juan Francisco Navarro-González**, Santa Cruz de Tenerife, Spain

**Mini lecture**  
Diabetic kidney disease in Asia: a growing threat  
**Yuk Lun Cheng**, Hong Kong, Hong Kong

**FREE COMMUNICATIONS**

**SaO010**  
EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS  
**Vlado Perkovic**1; Stephen Bain2; George Bakris3; John Buse4; Thomas Idorn5; Kenneth Mahaffey6; Steven Marso7; Michael Nauck8; Richard Pratley9; Søren Rasmussen5; Peter Rossing10; Karen Tooroe5; Bernard Zinman11; Johannes Mann12; 1The George Inst Global Health, UNSW Sydney, Sydney, Australia; 2Swansea Univ Medical School, Swansea, United Kingdom; 3Univ Chicago Medicine, Chicago, U.S.A.; 4Univ North Carolina School Medicine, Chapel Hill, U.S.A.; 5Novo Nordisk A/S, Søborg, Denmark; 6Medicine, Stanford Center Clinical Research, Stanford School Medicine, Stanford, U.S.A.; 7Research Medical Center, Kansas City, U.S.A.; 8Diabetes Center Bochum-Hattingen, St Josef Hosp (Ruhr-Univ Bochum), Bochum, Germany; 9AdventHealth Translational Research Inst Metabolism and Diabetes, Orlando, U.S.A.; 10Steno Diabetes Center Copenhagen, Gentofte; Univ Copenhagen, Copenhagen, Denmark; 11Lunenfeld-Tanenbaum Research Inst, Mt. Sinai Hosp, Univ Toronto, Toronto, Canada; 12Friedrich Alexander Univ Erlangen, Erlangen, Germany

**SaO011**  
BIOPSY-PROVEN DIABETIC NEPHROPATHY WORSENS RENAL PROGNOSIS IN DIABETIC PATIENT: RESULTS MULTICENTER STUDY BIODIAB-GLOSEN-GEENDIAB  
**Sheila Bermejo**1; Ester Gonzalez2; Nadia Martin3; Rosa Garcia4; Tania Linares5; Esteban Poch6; Noemí Espanza7; Montserrat Díaz-Encarnació8; Agraz Irene9; Maruja Isabel Navarro10; Katia Lopez11; Meritxell Ibernon12; Nuria Garcia13; Diana Lopez13; Adoración Martín-Gómez14; Manuel Praga2; Josep Mª Galceran1; Julio Pascual15; Xavier Fulladosa16; Maria Jose Soler Romeo17; 1Nephrology, Althaia, Xarxa Assistencial Univ Manresa, Manresa, Spain; 2Nephrology, Hosp Univ 12 de Octubre, Madrid, Spain; 3Nephrology, Hosp Univ Girona Doctor Josep Trueta, Girona, Spain; 4Nephrology, Hosp Palamos, Palamós, Spain; 5Nephrology, Gregorio Marañón Hosp, Madrid, Spain; 6Nephrology and renal transplantation, Hosp Clinic Barcelona, Barcelona, Spain; 7Nephrology, Hosp Insular Gran Canaria, Las Palmas de Gran Canaria, Spain; 8Nephrology, Puigvert Hosp, Barcelona, Spain; 9Nephrology, Vall d’Hebron Univ Hosp, Barcelona, Spain; 10Nephrology, Hosp Univ Germans Trias i Pujol, Badalona, Spain; 11Nephrology, Fundación Hosp Alcorcón, Alcorcón, Spain; 12Nephrology, Hosp Sant Joan Despí Moisés Broggi, Sant Joan Despí, Spain; 13Nephrology, Clinica Univ Navarra, Pamplona, Spain; 14Nephrology, Hosp de Poniente, Almeria, Spain; 15Nephrology Dept, Hosp del Mar, Barcelona, Spain; 16Nephrology, Hosp Univ Bellvitge, L’Hospitalet de Llobregat, Spain; 17Nephrology, Hosp del Mar Hosp Univ Vall d’Hebron pi17/00257 redinren, Barcelona, Spain

**SaO012**  
GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS AND THE RISK OF CARDIO-RENAL OUTCOMES IN DIABETIC PATIENTS SURVIVING A MYOCARDIAL INFARCTION  
**Marco Trevisan**1; Karolina Szummer2; Tomas Jernberg3; Juan Jesus Carrero1; 1Dept medical epidemiology and biostatistics, Karolinska Inst, Stockholm, Sweden; 2Dept medicine, Karolinska Inst, Stockholm, Sweden; 3Dept clinical sciences, Karolinska Inst, Stockholm, Sweden

**Mini lecture**  
Clinical Practice Guideline on management of patients with diabetes and advanced chronic kidney disease  
**Maria Jose Soler Romeo**, Barcelona, Spain
FREE COMMUNICATIONS

SaO013
ARCHETYPE ANALYSIS IDENTIFIES DISTINCT PROFILES IN RENAL TRANSPLANT RECIPIENTS WITH TRANSPLANT GLOMERULOPATHY ASSOCIATED WITH ALLOGRAFT SURVIVAL
Yassin Bouatou1; Aubert Olivier1; Sarah Higgins2; Denis Viglietti1; Marion Rabant3; Michael Mengel4; Jean-Paul Duong Van Huyen1; Carmen Lefaucheur5; Alexandre Loupy1; 1Paris translational research center organ transplantation, INSERM, Paris, France; 2Nephrology, Univ Sherbrooke, Sherbrooke, Canada; 3Pathology, Hôpital Necker, Paris, France; 4 Dept Lab Medicine and Pathology, Univ Alberta, Edmonton, Canada; 5Dept Nephrology and Kidney Transplantation, Saint-Louis Hosp, Paris, France

SaO014
ALLOGRAFT GENE EXPRESSION ASSESSMENT PREDICTS GRAFT LOSS IN KIDNEY RECIPIENTS WITH CHRONIC ANTIBODY-MEDIATED REJECTION
Denis Viglietti1; Benjamin Adam2; Jean-Paul Duong Van Huyen1; Olivier Aubert1; Denis Glotz1; Christophe Legendre1; Alexandre Loupy1; Carmen Lefaucheur1; Michael Mengel1; 1Paris translational research center organ transplantation, INSERM, Paris, France; 2Dept Lab medicine and pathology, Univ Alberta, Edmonton, Canada

SaO015
DEFINING RESPONSE TO TREATMENT IN KIDNEY RECIPIENTS WITH ACUTE T CELL-MEDIATED REJECTION
Yassin Bouatou1; Denis Viglietti1; Daniele Pievani1; Jean-Paul Duong Van Huyen1; Olivier Aubert1; Denis Glotz1; Christophe Legendre1; Alexandre Loupy1; Carmen Lefaucheur1; 1Paris translational research center organ transplantation, INSERM, Paris, France

SaO016
18F-FDG PET/CT IMAGING AT 3 MONTHS POST TRANSPLANTATION EXCLUDES SUBCLINICAL REJECTION IN KIDNEY TRANSPLANT RECIPIENTS
Oriane Hanssen1; Laurent Weekers1; Pierre Lovinfosse2; Alexandre Jadoul2; Alexandre Huynen3; Catherine Bonvoisin1; Antoine Bouquegneau1; Roland Hustinx2; Francois Jouret1; 1Nephrology, CHU Liège, Liège, Belgium; 2 Nuclear medicine, CHU Liège, Liège, Belgium; 3 Structural engineering, Univ Liège, Liège, Belgium

SaO017
EPITOPE MATCHING PREDICTS IMMUNIZATION AFTER ALLOGRAFT FAILURE CAUSING LONGER WAITING TIME FOR RE-TRANSPLANTATION
Fabian Halleck1; Marina Merkel1; Paul Bach2; Matthias Niemann3; Nils Lachmann4; Lukas Lehner1; Klemens Budde1; Staeck Oliver5; 1Dept nephrology and medical intensive care, Charité Universitätsmedizin Berlin, Berlin, Germany; 2Inst biometry and clinical epidemiology, Charité, Universitätsmedizin Berlin, Berlin, Germany; 3R&d, Pirche AG, Berlin, Germany; 4Inst transfusion medicine, h&i Lab, Charité Universitätsmedizin Berlin, Berlin, Germany; 5Dept nephrology and intensive care, Charité Universitätsmedizin Berlin, Berlin, Germany
**Improving cardiovascular complications in CKD**

**Chairs:** Marian Goicoechea, Madrid, Spain  
Petar Kes, Zagreb, Croatia

**Mini lecture**  
PCSK9 in kidney disease  
Thimoteus Speer, Homburg/Saar, Germany

---

**FREE COMMUNICATIONS**

**SaO018**  
THE RELATIONSHIP BETWEEN SERUM URIC ACID AND ALL-CAUSE MORTALITY: SYSTEMATIC REVIEW AND META-ANALYSIS OF 3,034,994 PARTICIPANTS  
Leonard Browne1; Oisín O’cealligh1; Eoghan Quinn1; Claudio Borghi2; Austin G. Stack3; 1Graduate entry medical school, Univ Limerick, Limerick, Ireland; 2 Dip scienze mediche e chirurgiche, Univ Bologna, Bologna, Italy; 3 Dept nephrology, Univ Hosp Limerick & Health Research Inst, Univ Limerick, Limerick, Ireland  
SaO019  
LUNG ULTRASOUND GUIDED DRY-WEIGHT PROBING REDUCES CARDIAC CHAMBERS DIMENSIONS AND LEFT VENTRICULAR FILLING PRESSURES IN HEMODIALYSIS PATIENTS WITH HYPERTENSION  
Charalampos Loutradis1; Pantelis Sarafidis1; Christodoulos Papadopoulos2; Vasilios Sachpekidis3; Robert Ekart4; Barbara Krunic5; Efstrathios Pagourelis2; Maria Toupourleka2; Antonios Karpetas6; Athanasios Bikos7; Ioannis Tsouchnikas1; Nikolaos Pyrgidis1; Ioanna Minopoulou1; Maria Eleni Alexandrou8; Efstrathios Mitsopoulou8; Claudia Torino9; Akaterini Papagianni1; Carmine Zoccali9; 1Dept Nephrology, Hippokration Hosp, Aristotle Univ Thessaloniki, Thessaloniki, Greece; 2Third Dept cardiology, Hippokration Hosp, Aristotle Univ Thessaloniki, Thessaloniki, Greece; 3Dept cardiology, Papageorgiou Hosp, Thessaloniki, Greece; 4Dept dialysis, Univ Clinical Centre Maribor, Clinic Internal Medicine, Maribor, Slovenia; 5Dept cardiology, Univ Clinical Centre Maribor, Clinic Internal Medicine, Maribor, Slovenia; 6Therapeutiki, Hemodialysis Unit, Thessaloniki, Greece; 7Protypo, Hemodialysis Unit, Thessaloniki, Greece; 8Dept nephrology, Papageorgiou Hosp, Thessaloniki, Greece; 9Clinical epidemiology of renal diseases and hypertension, CNR-IFC, Reggio Calabria, Italy

**SaO020**  
MACROPHAGE MIGRASOMES PROVIDE NUCLEATING FOCI FOR CALCIFIC MINERAL FORMATION  
Xiaodong Zhu; Yuqiu Liu; Yu Zhao; Yuteng Jiang; Beibei Wu; Xiaoliang Zhang; Inst nephrology, zhong da Hosp, Southeast Univ, school medicine, nanjing, P.R. China

**SaO021**  
PLATELETS IN THE UREMIC MILIEU - EXPLORING THE LINK BETWEEN PROTEIN CARBAMYLATION AND PLATELET DYSFUNCTION IN ESRD  
Veronika Binder1; Brith Bergum1; Stephane Jaisson2; Philippe Gillery2; Joar Sivertsen3; Tor Hervig1; Ronak Tilvawala4; Venkatesh Nemmar4; Paul Thompson4; Jan Potempa5; Hans-Peter Marti6; Piotr Mydel1; 1Dept clinical science, Univ Bergen, Bergen, Norway; 2Lab biochemistry and molecular biology, Univ Reims Champagne-Ardenne, Reims, France; 3Dept immunology and transfusion medicine, Haukeland Univ Hosp, Bergen, Norway; 4Dept biochemistry and pharmacology, Univ Massachusetts, Worcester, MA, U.S.A.; 5Fac biochemistry biophysics and biotechnology, Jagiellonian Univ, Krakow, Poland; 6Dept clinical medicine, Univ Bergen, Bergen, Norway

**SaO022**  
ADDUCTOME OF HDL FROM NON-DIABETIC HEMODIALYSIS PATIENTS  
Nans Florens1; Calzada Catherine2; Delolme Frederic3; Page Adeline3; Guebre-Egziabher Fisum1; Laurent Juillard2; Soulage Christophe O2; 1Néphrologie, Hosp Édouard Herriot, Lyon, France; 2Univ Lyon, carmen, inserm u1060, insa lyon, Univ Claude Bernard Lyon 1, inra u139, Claude Bernard Univ Lyon 1, Villeurbanne, France; 3Protein science facility, sfr biosciences cnrs ums3444, inserm us8, ucbl, ens lyon, Inst Biochimie et Chimie des Protéines (IBCP), Lyon, France

www.era-edta2019.org
Scientific Programme

HALL G1

Symposium 28

**Improving the organ donor pool**

Chairs: Carmen Lefaucheur, Paris, France
Miklos Molnar, Memphis, TN, U.S.A.

Controlled Cardiac Donor Death program in Spain: one vision for the future
Beatriz Dominguez Gil, Madrid, Spain

Kidney protection in living donors
Charles Ferro, Birmingham, United Kingdom

Compatibility barriers/Increasing the pool of marginal donors
Rainer Oberbauer, Vienna, Austria

Identifying organizational barriers to organ donation in hospitals
Axel Rahmel, Frankfurt, Germany

HALL G2A

Symposium 29

**Cardiovascular disease in CKD: risk factors and remedies**

Chairs: Gérard London, Fleury-Mérogis, France
Luxia Zhang, Beijing, China

Why is the risk of stroke so high in CKD and in dialysis patients?
Sydney Tang, Hong Kong, Hong Kong

Clinical trials and research priorities in dialysis patients
Csaba P. Kovesdy, Memphis, TN, U.S.A.

Modifiable risk factors for cardiovascular disease in CKD: a hierarchical approach
Rajiv Agarwal, Indianapolis, IN, U.S.A.

China Kidney Network (CK-NET):
Opportunities for Kidney Disease in the Era of Big Data
Luxia Zhang, Beijing, China
Symposium 30

**The hidden risks of haemodialysis**

Chairs: Maria Haller, Linz, Austria
Jaroslav Rosenberger, Kosice, Slovakia

- Silent ischemia during haemodialysis
  Christopher W. McIntyre, London, Canada

- Haemodynamic instability and ischemic brain injury
  Adrian Covic, Iași, Romania

- Tolerability of extracorporeal treatments in 2019
  Jeroen Kooman, Maastricht, The Netherlands

Clinical Practice Guideline on Vascular Access
Maria Haller, Linz, Austria

Symposium 31

**The role of diet in the prevention of CKD progression: food for thought**

Chairs: Juan Jesus Carrero, Stockholm, Sweden
Goce Spasovski, North Macedonia

- Dietary protein restriction: PRO
  Denis Fouque, Lyon, France

- Dietary protein restriction: AGAINST
  Marc Vervloet, Amsterdam, The Netherlands

- Dietary acid reduction and CKD progression: Adjunctive benefits when done with fruits and vegetables
  Donald Wesson, Dallas, TX, U.S.A.

- Vitamin K supplementation to improve vascular stiffness in patients with chronic kidney disease category 3b or 4: the K4Kidneys randomised controlled trial
  Patrick Mark, Glasgow, United Kingdom
Scientific Programme

HALL A1
15:00 - 16:30

Free Communication Session 21 + Mini Lecture

Immunological kidney diseases

Chair: Pierre Ronco, Paris, France

Mini lecture
New therapies in the Henoch-Schönlein syndrome
Roberta Fenoglio, Turin, Italy

FREE COMMUNICATIONS

SaO0023
ANTI-PLA2R1 ANTIBODIES INDUCE IN VITRO CYTOTOXICITY MEDIATED BY COMPLEMENT ACTIVATION
Latëb Maël1; Christine Payre2; Brglez Vesna3; Vincent L M Esnault3; Gérard Lambeau4; Barbara Seitz-Polski3; 1Serv nephrologie, Hosp Pasteur, Nancy, France; 2Umr7275, cnrs, uca, lpmc, Valbonne, France; 3Serv nephrologie, Hosp Pasteur, Nice, France; 4Umr 7275 cnrs/uca, lpmc, Valbonne, France

SaO0024
CHILDHOOD-ONSET ANCA-ASSOCIATED RENAL VASCULITIS: LONG-TERM OUTCOME OF A MULTICENTER COHORT OF 54 BIOPSY-PROVEN CASES
Marta Calatroni1; Filippo Consonni2; Susanna Fiasella3; Dritan Curi3; Meileh Sarah Abu3; Laura Fortunato4; Leonardo Tomelii2; Marco Allinovi4; Paola Romagnani5; Gian Marco Ghiggeri6; Augusto Vaglio7; Paediatric Aav Consortium Italian3; 1Nephrology unit, San Matteo Hosp, Pavia, Italy; 2Pediatrics, Univ Firenze, Firenze, Italy; 3Nephrology, Univ Firenze, Firenze, Italy; 4Nephrology, Careggi Univ Hosp, Firenze, Italy; 5DENOTHE, Univ Firenze, Firenze, Italy; 6Dept nephrology, G. Gaslini Children Hosp, Genoa, Italy; 7Univ Firenze, Firenze, Italy

SaO0025
PROGNOSIS OF GLOMERULONEPHRITIS WITH NON RANDALL MONOCLONAL IMMUNOGLOBULIN G DEPOSITS: A RETROSPECTIVE MULTICENTRE STUDY
Opheïlie Fourdinier1; Marc Ulrich2; Alexandre Karras3; Jerome Olagne4; David Buob5; Cecile Vigneau6; Jean-Baptiste Gibier7; Gabriel Chroukroun1; Dimitri Titeca-Beauport1; 1Div nephrology, Amiens Univ Hosp, Amiens, France; 2Div nephrology, C.H., Valenciennes, France; 3Div nephrology, Hosp European Georges-Pompidou AP-HP, Paris, France; 4Div nephrology, Hosp Civil - Hosp Academics Strasbourg, Strasbourg, France; 5Div pathology, Tenon Hosp AP-HP, Paris, France; 6Div nephrology, Hosp Center Univ Pontchaillou, Rennes, France; 7Div pathology, C.H. Régional Univ Lille, Lille, France

SaO0026
RENAI DAMAGE IN ANCA-ASSOCIATED VASCULITIS IN INCIDENT AND RELAPSING PATIENTS - PATTERNS AND PROGRESSION USING REAL WORLD DATA
Peter Rutherford; Dieter Götte; David Worthington; Medical, Vifor Pharma, Zürich, Switzerland

SaO0027
FROM NEW EPITOPE IDENTIFICATION TO PERSONALIZED MEDICINE IN PLA2R1-RELATED MEMBRANOUS NEPHROPATHY
Joana Justino1; Vesna Brglez1; Guillaume Dolla1; Alexandra Rousseau2; Christelle Zaghri1; Christine Payre1; Barbara Seitz-Polski4; Vincent L M Esnault4; Christophe Mariat5; Karine Dahan6; Hanna Debiec7; Pierre Ronco7; Gérard Lambeau1; 1Umr 7275 cnrs/uca, lpmc, Valbonne, France; 2Urc-est, Hosp Saint-Antoine, Paris, France; 3Umr7275, cnrs, uca, lpmc, Valbonne, France; 4Serv nephrologie, Hosp Pasteur, Nice, France; 5Serv nephrologie, Hosp Nord, Saint-Étienne, France; 6Nephrology, Tenon Hosp AP-HP, Paris, France; 7Inserm umr_s 1155 batiment recherche, Hopital Tenon, Paris, France
Free Communication Session 22 + Mini Lecture

**CKD-MBD**

Chairs: Sandro Mazzaferro, Rome, Italy  
Pablo Antonio Ureña Torres, Saint Ouen, France

*Mini lecture*
Calciphylaxis
Vincent Brandenburg, Aachen, Germany

**FREE COMMUNICATIONS**

**SaO028**

**BONE FRACTURES IN PATIENTS ON RENAL REPLACEMENT THERAPY: DOES DIABETES INCREASE THE RISK?**
Sabina Chaudhary Hauge1; Bo Abrahamsen2; Gunnar Gislason3; Jonas Bjerring Olesen3; Kristine Hommel2; Ditte Hansen1; 1Dept nephrology, Herlev Hosp, Herlev, Denmark; 2Dept medicine, Holbæk Hosp, Holbæk, Denmark; 3Dept cardiology, Gentofte Hosp, Gentofte, Denmark

**SaO029**

**THE BURDEN OF FRACTURES IN EARLY CHRONIC KIDNEY DISEASE: ANALYSIS OF CARTAGENE**
Louis-Charles Desbiens1; Rémi Goupil2; François Madore2; Fabrice Mac-Way1; 1Fac et département médecine, CHU Quebec Univ Laval, Quebec, Canada; 2Fac et département médecine, Hopital Sacré-Coeur, Montréal, Canada

**SaO030**

**HYPOCALCEMIA AND BONE MINERAL CHANGES FOLLOWING DENOSUMAB TREATMENT IN END-STAGE RENAL DISEASE PATIENTS WITH LOW BONE MINERAL DENSITY: A 2-YEAR OBSERVATIONAL STUDY**
Rikako Hiramatsu; Hoshino Junichi; Ubara Yoshifumi; Kidney centre, Toranomon Hosp, Tokyo, Japan

**SaO031**

**BONE BIOPSY GUIDES CLINICAL DECISION-MAKING OF PARATHYROIDECTOMY AFTER KIDNEY TRANSPLANTATION**
Satu Keronen1; Leena Martola1; Heikki Kröger2; Eero Honkanen1; 1Abdominal center/ nephrology, Helsinki Univ Hosp, Helsinki, Finland; 2Dept orthopedics, traumatology and hand surgery, Kuopio Univ Hosp, Kuopio, Finland

**SaO032**

**NON-OXIDIZED PTH (n-oxPTH) - BUT NOT OXIDIZED PTH (oxPTH) -STIMULATES FIBROBLAST GROWTH FACTOR 23 (FGF23) AND INCREASES ONLY MODERATELY IN CKD PATIENTS AND KIDNEY TRANSPLANT RECIPIENTS**
Shufei Zeng1; Dieter Hafnner2; Uwe Querfeld3; Chang Chu1; Torsten Slowinski3; Thomas Bernd Dschietzig3; Bernhard Karl Krämer1; Florian Lang3; Franz Schäfer4; Martina Feger5; Michael Föller5; Berthold Hocher1; 1Fifth Dept medicine (nephrology/endocrinology/rheumatology), Heidelberg Univ, Heidelberg, Germany; 2Dept pediatric kidney, liver and metabolic diseases, pediatric research center, Hannover Medical School, Hannover, Germany; 3Dept cardiology, charité-universitätsmedizin berlin, Berlin, Germany; 4Center Paediatrics and Adolescent Medicine, Univ Heidelberg, Heidelberg, Germany; 5Pediatric nephrology, Charité-Universitätsmedizin Berlin, Berlin, Germany
Scientific Programme

HALL A3
15:00 - 16:30

Free Communication Session 23 + Mini Lecture

ESAs and iron: anaemia and beyond

Chairs: Kai-Uwe Eckardt, Berlin, Germany
Dimitrios Kirmizis, London, United Kingdom

Mini lecture
Vascular calcification and Iron metabolism – are they connected?
József Balla, Debrecen, Hungary

FREE COMMUNICATIONS

SaO033
IV IRON DOSING AND INFECTION RISK IN THE PIVOTAL TRIAL: A PRE-SPECIFIED SECONDARY ANALYSIS
Iain C. Macdougall1; Claire White1; Chante Reid1; Stefan D. Anker2; Sunil Bhandari3; Kenneth Farrington4; Philip A. Kalra5; John McMurray6; Heather Murray7; Charles Tomson8; David C. Wheeler9; Christopher G. Winearls10; Ian Ford1; 1Dept renal medicine, King's College Hosp, London, United Kingdom; 2Dept cardiology, Charité Universitätsmedizin Berlin, Berlin, Germany; 3Nephrology, Hull Univ Teaching Hosp NHS Trust, Hull, United Kingdom; 4Renal unit, Lister Hosp, Stevenage, United Kingdom; 5Dept renal medicine, Salford Royal NHS Foundation Trust, Manchester, United Kingdom; 6British heart foundation cardiovascular centre, Univ Glasgow, Glasgow, United Kingdom; 7Robertson centre biostatistics, Univ Glasgow, Glasgow, United Kingdom; 8Urology and renal Servs, Newcastle Freeman Hosp, High Heaton, United Kingdom; 9Center nephrology, Univ College Hosp, London, London, United Kingdom; 10 Oxford kidney unit, Oxford Univ Hosp NHS Foundation Trust, Oxford, United Kingdom

SaO034
HYPOXIA ENHANCES UREMIA-INDUCED ERYPTOSIS AND OXIDATIVE STRESS
Gabriela F Dias1; Sara Soares Tozoni1; Gabriela Bohnen1; Caroline Carvalho1; Stephany Van Der Goot1; Roberto Pecoits-Filho1; Peter Kotanko2; Andrea N Moreno-Amaral3; 1Ppgcs, Pontifícia Univ Católica Paraná, Curitiba, State Paraná, Brazil; 2Icahn school medicine mount sinai, Renal Research Inst, New York, NY, U.S.A.; 3Pontifícia Univ Católica Paraná, Curitiba, Brazil

SaO035
SINGLE 1000 MG INFUSION OF IRON ISOMALTOSIDE 1000 DEMONSTRATES A MORE RAPID HEMOGLOBIN RESPONSE AND REDUCED RISK OF CARDIOVASCULAR ADVERSE EVENTS COMPARED TO MULTIPLE DOSE IRON SUCROSE IN PATIENTS WITH IRON DEFICIENCY ANEMIA AND NON-DIALYSIS-DEPENDENT CKD
Sunil Bhandari1; Lars Lykke Thomsen2; 1Nephrology, Hull Univ Teaching Hosps NHS Trust, Hull, United Kingdom; 2Clinical and non-clinical dept, Pharmacosmos, Holbaek, Denmark

SaO036
EFFICACY AND SAFETY OF DAPRODUSTAT COMPARED WITH DARBEPOETIN ALFA IN JAPANESE HEMODIALYSIS PATIENTS WITH ANEMIA: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL
Tadao Akizawa1; Masaomi Nangaku2; Taeko Yonekawa3; Nobuhiko Okuda3; Shinya Kawamatsu4; Tomohiro Onoue5; Yukihiro Endo3; Katsutoshi Harai6; Hirofumi Ozeki7; Alexander R. Cobitz8; 1Div nephrology, Showa Univ Med., Tokyo, Japan; 2Div nephrology and endocrinology, Univ Tokyo School Medicine, Tokyo, Japan; 3Medicines development, GlaxoSmithKline, Tokyo, Japan; 4Clinical operations, GlaxoSmithKline, Tokyo, Japan; 5Biomedical data sciences, GlaxoSmithKline, Tokyo, Japan; 6Clinical pharmacology, GlaxoSmithKline, Tokyo, Japan; 7Medical affairs, GlaxoSmithKline, Tokyo, Japan; 8Medicine delivery, GlaxoSmithKline, Collegeville, U.S.A.

SaO037
THE PRO-FIBROTIC EFFECT OF HIGH DOSE MK-8617 (HIF-PHI) ON CKD MICE IS MEDIATED BY NOVAL KLF5 GENE REGULATING PATHWAY
Zuolin Li; Lv Linli; Wang Bin; Tang Tao-Tao; Cao Jing-Yuan; Liu Bicheng; Inst nephrology, Southeast Univ, Nanjing, P.R. China
Free Communication Session 24 + Mini Lectures

How to prevent AKI

Chairs: Catalina Martin-Cleary, Madrid, Spain
Claudio Ronco, Vicenza, Italy

Mini lecture
Prevention of AKI in oncology
Laura Cosmai, Milan, Italy

FREE COMMUNICATIONS

**SaO038**
PREOPERATIVE URINARY DICKKOPF-3 (DKK3) PREDICTS POSTOPERATIVE ACUTE KIDNEY INJURY AND TRANSITION INTO CKD IN PATIENTS UNDERGOING CARDIAC SURGERY
Stefan Schunk1; Alexander Zarbock2; Melanie Meersch2; Mira Küllmar2; John A Kellum3; David Schmit1; Martina Wagner1; Triem Sarah1; Stefan Wagenpfeil4; Hermann-Josef Gröne5; Hans-Joachim Schäfers6; **Danilo Fliser7**, Stephen Zewinger1; Thimoteus Speer1; 1Dept internal medicine, Saarland Univ Hosp, Homburg/Saar, Germany; 2Dept anesthesiology, intensive care medicine and pain medicine, Univ Hosp Münster, Münster, Germany; 3Center critical care nephrology, Dept critical care medicine, Univ Pittsburgh, Pittsburgh, U.S.A.; 4Inst medical biometry, epidemiology & medical informatics, Saarland Univ Hosp, Homburg/Saar, Germany; 5Dept cellular and molecular pathology, German Cancer Research Center, Heidelberg, Germany; 6Dept thoracic and cardiovascular surgery, Saarland Univ Hosp, Homburg/Saar, Germany; 7Dept Internal Medicine IV, Saarland Univ Medical Centre, Homburg/Saar, Germany

**SaO039**
RECOMBINANT HUMAN C1 ESTERASE INHIBITOR (CONESTAT ALFA) IN THE PREVENTION OF CONTRAST-INDUCED NEPHROPATHY IN HIGH-RISK PATIENTS (PROTECT): A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND SINGLE-CENTER TRIAL
Anneza Panagiotou1; Stephan Moser1; Tobias Breidhardt1; Ingmar Heijnen2; Gregor Fahmi3; Christoph Kaiser3; Leo Bonati4; Marten Trendelenburg1; Raban Jeger3; **Michael Osthoff1**, 1Div internal medicine, Universitätsspital Basel, Basel, Switzerland; 2Div medical immunology, Universitätsspital Basel, Basel, Switzerland; 3Dept cardiology, Universitätsspital Basel, Basel, Switzerland; 4Div neurology and stroke center, Universitätsspital Basel, Basel, Switzerland

**SaO040**
IMPACT OF ELECTRONIC ALERTS FOR ACUTE KIDNEY INJURY ON PATIENT OUTCOMES: AN OBSERVATIONAL COHORT STUDY
**David Baird1**, Nicosha Desouza2; Rachael Logan3; Bruce Guthrie4; Samira Bell1; 1Renal unit, NHS Tayside, Dundee, United Kingdom; 2Population health and genomics, School Medicine Univ Dundee, Dundee, United Kingdom; 3School medicine, Univ Dundee, Dundee, United Kingdom; 4Centre population health sciences, Univ Edinburgh, Edinburgh, United Kingdom

Mini lecture
AKI in hospital: risk factors and strategies for prevention
**Samira Bell**, Dundee, United Kingdom
Scientific Programme

POSTER SESSION
Poster Area
09:30 - 10:45
16:30 - 17:00

Registry.................................................................................................................. REG1 - REG6
Genetic diseases and molecular genetics.......................................................... SP001 - SP036
Hypertension. Experimental & clinical............................................................. SP037 - SP072
Clinical nephrology 2....................................................................................... SP073 - SP152
Glomerulonephritis 2....................................................................................... SP153 - SP209
AKI. Clinical. Epidemiology and outcome....................................................... SP210 - SP261
CKD. Lab methods, GFR measurement, urine proteomics........................... SP262 - SP296
CKD. Pathophysiology, progression and risk factors 2................................. SP297 - SP341
CKD, HD. Anaemia......................................................................................... SP342 - SP377
CKD. Nutrition, inflammation and oxidative stress........................................ SP378 - SP416
CKD. Rehabilitation....................................................................................... SP417 - SP429
Diabetes. Basic research.................................................................................. SP430 - SP456
Extracorporeal dialysis: techniques and adequacy 2..................................... SP457 - SP489
Peritoneal dialysis 2........................................................................................ SP490 - SP538
Dialysis. Cardiovascular complications 2...................................................... SP539 - SP573
Dialysis. Vascular access 2............................................................................. SP574 - SP602
Dialysis. Bone disease.................................................................................... SP603 - SP632
Dialysis. Epidemiology and outcome 2.......................................................... SP633 - SP676
Dialysis. Health services research................................................................. SP677 - SP707
Renal transplantation. Experimental, immune-tolerance of allogenic
and xenogenic transplants.............................................................................. SP708 - SP720
Renal transplantation. Epidemiology and outcome 2.................................... SP721 - SP766
Renal transplantation. Treatment and immunosuppression.......................... SP767 - SP800
History of nephrology..................................................................................... SP801 - SP815
Patient education research and training in nephrology................................. SP816 - SP833
HALL G1

Symposium 32

*Home haemodialysis: on the move*

Chairs: Olof Heimbürger, Stockholm, Sweden
Francesco Locatelli, Lecco, Italy

Reducing the costs of end stage renal disease while delivering quality health care: are home therapies the answer?
Wim Van Biesen, Ghent, Belgium

Striving to achieve an integrated home dialysis system
Maria Fernanda Sion Robledo, Pamplona, Spain

Vascular access in HHD: the Achilles tendon?
Sandip Mitra, Manchester, United Kingdom

Home haemodialysis - a prescription for long-term survival
Naomi Clyne, Lund, Sweden

HALL G2A

Symposium 33

*Overcoming age with frailty evaluation in the kidney transplant recipient*

Chairs: Dimitrios Goumenos, Patras, Greece
Rainer Oberbauer, Vienna, Austria

Are frailty and sarcopenia definitions precise enough to establish a clinical diagnosis in the patient with chronic disease?
Juan Jesus Carrero, Stockholm, Sweden

Why and how to evaluate frailty before kidney transplantation
Daniel Abramowicz, Antwerp, Belgium

Outcomes of frail patients after kidney transplantation
Maria José Pérez-Sáez, Barcelona, Spain

Ethics aspects in frail recipients and the organ donor pool
Francesco Paolo Schena, Bari, Italy
Symposium 34

Delivering good quality dialysis - what should we measure?

Chairs: Edwina Brown, London, United Kingdom
Maria Haller, Linz, Austria

Small solute clearance: what are the pitfalls?
Enric Vilar, Stevenage, United Kingdom

Patient-reported outcomes: are these fit for purpose?
Ken Farrington, Stevenage, United Kingdom

Towards a multidimensional measure of dialysis adequacy?
Pieter Evenepoel, Leuven, Belgium

How to measure residual renal function
Andrew Davenport, London, United Kingdom

Symposium 35

The paradox of estimated GFR in the era of precision medicine

Chairs: Pierre Delanaye, Liège, Belgium
Esteban Porrini, La Laguna (Tenerife), Spain

Overview of the error of creatinine and cystatin-c-based formulas in clinical practice
Esteban Porrini, La Laguna (Tenerife), Spain

Measured GFR in clinical practice, the Swedish experience
Anders Christensson, Malmö, Sweden

Which method to measure GFR and in which clinical conditions?
Pierre Delanaye, Liège, Belgium

MRI approaches to assess kidney injury and function
Faikah Güler, Hannover, Germany
Scientific Programme

HALL A1  17:00 - 18:30

Free Communication Session 25 + Mini Lecture

Kidney diseases from childhood to adult

Chairs: Ron Gansevoort, Groningen, The Netherlands  Rukshana Shroff, London, United Kingdom

Mini lecture
Role of complement in the pathogenesis and progression of IgA nephropathy  Rosanna Coppo, Turin, Italy

FREE COMMUNICATIONS

SaO041  SOLUBLE CD89-IgA1 COMPLEXES AND GALACTOSE DEFICIENT-IgA1 ARE BIOMARKERS ASSOCIATED WITH HISTOLOGIC INFLAMMATION IN CHILDREN IgA NEPHROPATHY  Alexandra Cambier1; Gleeson James2; Abbad Lillia2; Deschenes Georges3; Julien Hogan1; Berthelot Laureline2; Ben Mkaddem Sanaa2; Rabant Marion4; Peuchmaur Michel5; Guillon Boyer Olivia6; Ulinski Tim7; Robert Thomas8; Mesnard Laurent9; Renato C Monteiro2; 1Néphrologie et hémodialyse pédiatrique, Hôpital Robert-Debré, Paris, France; 2lnserm u1149 & cnrs erl8252, centre recherche inflammation, Univ Paris Diderot, Fac Médecine, Site Xavier Bichat, Paris, France; 3Néphrologie pédiatrique, hopital robert debré, paris, France; 4Serv anatomopathologie, Hopital Necker, paris, France; 5Serv anatomopathologie, Hôpital Robert-Debré, Paris, France; 6 Serv néphrologie pédiatrique, Hopital Necker, paris, France; 7Néphrologie pédiatrique, hopital Armand Trousseau, paris, France; 8Centre néphrologie et transplantation rénale, APHM, Marseille, France, France; 9Serv néphrologie et transplantation untr, hopital Tenon, paris, France

SaO042  CLINICAL AND HISTOLOGICAL DIFFERENCES BETWEEN ADULTS AND CHILDREN IN NEW ONSET IgA NEPHROPATHY  Alexandra Cambier1; Rabant Marion2; Peuchmaur Michel3; Couderc Anne1; Deschenes Georges4; Guillon Boyer Olivia5; Julien Hogan1; Robert Thomas6; 1Néphrologie et hémodialyse pédiatrique, Hôpital Robert-Debré, Paris, France; 2Serv anatomopathologie, Hopital Necker, paris, France; 3Serv anatomopathologie, Hôpital Robert-Debré, Paris, France; 4Néphrologie pédiatrique, hopital robert debré, paris, France; 5Serv néphrologie pédiatrique,Hopital Necker, paris, France; 6Centre néphrologie et transplantation rénale, APHM, Marseille, France, France

SaO043  CHITOTRIOSIDASE: A NOVEL ALTERNATIVE BIOMARKER FOR THE THERAPEUTIC MONITORING OF NEPHROPATHIC CYSTINOSIS?  Koenraad Veys1; Mohamed A Elmonem2; Maria Van Dyck1; Mirian Janssen3; Elisabeth Cornelissen4; Katharina Hohenfeller5; Giusi Princi6; Francesco Emma7; Lambertus P. Van Den Heuvel8; Elena Levchenko1; 1Dept paediatrics, Univ Hosp Leuven (UZ Leuven), Leuven, Belgium; 2Dept clinical pathology, Cairo Univ, Cairo, Egypt; 3 Dept internal medicine, Radboud umc, Nijmegen, Netherlands; 4 Dept paediatrics, Radboud umc, Nijmegen, Netherlands; 5Dept pediatrics, SudOstBayern Klinikum Traunstein, Traunstein, Germany; 6Div rheumatology and immuno-rheumatology research laboratories, Bambino Gesù Children’s Hosp, Rome, Italy; 7Div nephrology, Dept pediatric subspecialties, Bambino Gesù Children’s Hosp, IRCCS, Rome, Italy; 8Lab pediatric nephrology, Dept development & regeneration, KU Leuven campus Gasthuisberg Onderwijs & Navorsing 3, Leuven, Belgium
SaO044
HYPOGAMMAGLOBULINEMIA DURING THE RTX TREATMENT IN STEROID DEPENDANT NEPHROTIC SYNDROME
Cyrielle Parmentier1; Jean-Daniel Delbet1; Stéphane Decramer2; Guillon Boyer Olivia3; Deschenes Georges4; Ulinski Tim1; 1Néphrologie pédiatrique, hopital Armand Trousseau, paris, France; 2Renal fibrosis lab, Inserm U1048/I2MC, Toulouse, France; 3Serv néphrologie pédiatrique, Hopital Necker, paris, France; 4Néphologie pédiatrique, hopital robert debré, paris, France

SaO045
RELATIONSHIP BETWEEN DIALYSIS DOSE (spKt/V) AND SURVIVAL IN PATIENTS ON MAINTENANCE HEMODIALYSIS FROM CHILDHOOD
Verena Gotta1; Andrew Atkinson1; Olivera Marsenic2; Marc Pfiste1; 1Pediatric pharmacology and pharmacoenergetics, Univ Basel Children's Hosp, Basel, Switzerland; 2Pediatric nephrology, Yale Univ School Medicine, New Haven, CT, U.S.A.
HALL A2  17:00 - 18:30

Free Communication Session 26 + Mini Lecture

Experimental hypertension

Chairs: Johannes Loffing, Zurich, Switzerland
       Gérard London, Fleury-Mérogis, France

Mini lecture
The overdriven glomerulus as a CV risk factor
Francesca Mallamaci, Reggio Calabria, Italy

FREE COMMUNICATIONS

SaO047  EFFECTS OF RENAL DENERVATION ON RENAL FUNCTION, PLASMA RENIN ACTIVITY AND BLOOD PRESSURE IN RATS FED A LOW POTASSIUM DIET
Gábor Szénási1; Attila Patócs2; Bencsáth Pál2; Szalay Csaba1; Szentmihályi Klára3; Hamar Péter1; László Rosival4; 1Inst pathophysiology, Semmelweis Univ, Budapest, Hungary; 2Second Dept medicine, Semmelweis Univ, Budapest, Hungary; 3Inst materials and environmental chemistry, Hungarian Academy of Sciences, Budapest, Hungary; 4Inst Pathophysiology, International Nephrology Research & Training Centre, Semmelweis Univ, Budapest, Hungary

SaO048  THE EFFECT OF DRY-WEIGHT REDUCTION GUIDED BY LUNG ULTRASOUND ON AMBULATORY AORTIC BLOOD PRESSURE AND ARTERIAL STIFFNESS PARAMETERS IN HEMODIALYSIS PATIENTS: A LUST SUB-STUDY
Charalampos Loutradis1; Pantelis Sarafidis1; Robert Ekart2; Barbara Krunic3; Antonios Karpetas4; Athanasios Bikos5; Ioannis Tsouchnikas1; Marietta Theodorakopoulou1; Maria Kalaitzoglou1; Maria Eleni Alexandrou6; Panagiotis Pateinakis6; Dorothea Papadopoulou6; Claudia Torino7; Carmine Zoccali7; Gerard London8; Aikaterini Papagianni1; 1Dept Nephrology, Hippokration Hosp, Aristotle Univ Thessaloniki, Thessaloniki, Greece; 2Dept dialysis, Univ Clinical Centre Maribor, Clinic Internal Medicine, Maribor, Slovenia; 3Dept cardiology, Univ Clinical Centre Maribor, Clinic Internal Medicine, Maribor, Slovenia; 4Therapeutiki, Hemodialysis Unit, Thessaloniki, Greece; 5Protypo, Hemodialysis Unit, Thessaloniki, Greece; 6Dept nephrology, Papageorgiou Hosp, Thessaloniki, Greece; 7Clinical epidemiology of renal diseases and hypertension, CNR-IFC , Reggio Calabria, Italy; 8 Dept nephrology, Hosp and FCRIN INI-CRCTC, Manhes, France

SaO049  VASCULAR CALCIFICATION IS ASSOCIATED WITH WNT-SIGNALING PATHWAY AND BLOOD PRESSURE VARIABILITY IN CHRONIC KIDNEY DISEASE RATS
Ruoxi Liao; Liya Wang; Jiameng; Yuqin Xiong; Yupei Li; Mei Han; Heng Jiang; Mahajan Anil; Baihai Su; Dept nephrology, West China Hosp, Sichuan Univ, Chengdu, P.R. China

SaO050  PATIROMER PREVENTS THE RISE IN BLOOD PRESSURE INDUCED BY 5/6th NEPHRECTOMY
Lingyun Li1; Lawrence Lee1; Ansgar Conrad1; Alain Romero1; David A. Bushinsky2; 1Medical and scientific affairs, Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, U.S.A.; 2Div nephrology, Dept medicine, Univ Rochester School Medicine, Rochester, U.S.A.
Free Communication Session 27

**Novel approaches to AKI: exosomes and RNA interference**

Chairs: Peter Hamar, Budapest, Hungary
Andreas Linkermann, Dresden, Germany

FREE COMMUNICATIONS

**SaO051**
A BOTTOM-UP APPROACH TO REDUCE ANIMAL NUMBERS IN COMPOUND SCREENING
Julian Marschner; Renal Div, Medizinische Klinik und Poliklinik IV, München, Germany

**SaO052**
NOVEL PATHOPHYSIOLOGIC ROLE OF MIR-146A FOR SPLENIC MACROPHAGE INTERFERENCE IN SEPSIS-RELATED KIDNEY INJURY
Yoshio Funahashi1; Noritoshi Kato2; Takui Ishimoto2; Tomoki Kosugi2; Shoichi Maruyama2; 1Dept nephrology, Komaki City Hosp, Komaki, Japan; 2Dept nephrology, Nagoya Univ Graduate School Medicine, Nagoya, Japan

**SaO053**
EXOSOMES DERIVED FROM HYPOXIA HK-2(HUMAN RENAL PROXIMAL TUBULAR EPITHELIAL CELL LINE) CELLS PROMOTES TUBULAR EPITHELIAL CELL PROLIFERATION VIA MICRONA TARGETING AT CCND1
Ying Tang; Wenjuan Yu; Junzhe Chen; Honghui Zeng; Sha Fu; Shengnan Ge; Anping Xu; Dept nephrology, sun yat-sen memorial Hosp, guangzhou, P.R. China

**SaO054**
EXOSOMES DERIVED FROM 3D CULTURED MESENCHYMAL STEM CELLS AMELIORATE AKI BY PROMOTING TECs REPAIR
Jing-Yuan Cao; Tang Tao-Tao; Zuolin Li; Jun Chen; Di Yin; Lin-Li Lv; Bi-Cheng Liu; Inst nephrology, Southeast Univ, Nanjing, P.R. China

**SaO055**
CREATININE INDEPENDENT SYSTEMIC BIOMARKER FOR SEVERITY OF ACUTE KIDNEY INJURY AFTER MAJOR SURGERY AND TRANSPLANTATION
Kirill Kreimann1; Robert Greite1; Igor Tudorache2; Lena Schiffer1; Ralf Lichtinghagen3; Song Rong1; Mi-Sun Jang1; Jan Hinrich Bräsen4; Julian Doricic1; Akin Sarisin5; Florian Vondran5; Vijith Vijayan6; Wilfried Gwinner1; Christine Fegbeutel2; Axel Haverich2; Andreas Leffler7; Hermann Haller1; Stephan Immenschuh6; Faikah Gueler1; 1Nephrology, 2Thoracic surgery, 3Clinical chemistry, 4Pathology, 5Visceral surgery, 6Transfusion medicine, 7Anesthesiology, Hannover Medical School, Hannover, Germany

**Special Travel Grant SaO056**
CHITOSAN-HDAC5 SIRNA NANOPARTICLE TREATMENT REDUCE MACROPHAGE ACTIVATION INDUCED BY OXALATE CRYSTALS AND ATTENUATES INFLAMMATION AND ACUTE KIDNEY INJURY
Sharma Pravesh; Kalyani Karnam; Kavitha Sedmaki; Akshay Salegaonkar; Vamsi Krishna Venuganti; Onkar Prakash Kulkarni; Dept pharmacy, Bits-Pilani Hyderabad Campus, Hyderabad, Telangana, India
Scientific Programme

HALL A4

17:00 - 18:30

Free Communication Session 28 + Mini Lecture

Revisiting PD: a systems biology approach

Chairs: Christoph Aufricht, Austria, Vienna
          Rafael Selgas, Madrid, Spain

Mini lecture
The global fluid study
Mark Lambie, Stoke-on-Trent, United Kingdom

FREE COMMUNICATIONS

SaO057
CROSS-OMICS ANALYSIS OF TRANSCRIPTOME, PROTEOME AND METABOLOME DYNAMICS DURING PERITONEAL DIALYSIS
Rebecca Herzog1; Florian Wiesenhofer1; Vychytil Andreas2; Christoph Aufricht3; Klaus Kratochwill1; 1Cd Lab molecular stress research in pd, Div paediatric nephrology, Medical Univ Vienna, Vienna, Austria; 2Medicine iii, Medical Univ Vienna, Wien, Austria; 3Paediatric nephrology, Medical Univ Vienna, Wien, Austria

SaO058
A THREAD TYPE HIGH-DENSITY COLLAGEN MATERIAL PREVENTS PROGRESSION OF PERITONEAL FIBROSIS
Kei Nagase1; Shigehisa Aoki2; Mitsuru Noguchi1; Shuji Toda3; 1Urology, Saga Univ, Saga, Japan; 2Saga Univ, Saga, Japan; 3 Pathology, Saga Univ, Saga, Japan

SaO059
LONG TERM GLYCEMIC VARIABILITY AND THE RISK OF MORTALITY IN DIABETIC PATIENTS ON PERITONEAL DIALYSIS
Hanri Afghahi1; Salmir Nasic2; Helena Rydell3; Henrik Hadimeri1; Khaled Alhomsi1; Johan Svensson2; 1Dept nephrology, Skaraborg Central Hosp, Skövde, Sweden; 2Dept research and development, Skaraborg Central Hosp, Skövde, Sweden; 3Dept nephrology, Karolinska Univ Hosp, Stockholm, Sweden

SaO060
SYSTEMS BIOLOGY ANALYSIS OF LITHIUM-MEDIATED CYTOPROTECTION IN IN VITRO AND IN VIVO PERITONEAL DIALYSIS
Rebecca Herzog1; Guadalupe Gonzalez-Mateo2; Maria Bartosova3; Claus Peter Schmit3; Manuel Lopez-Cabrera2; Christoph Aufricht4; Klaus Kratochwill1; 1Cd Lab molecular stress research in pd, Div paediatric nephrology, Medical Univ Vienna, Vienna, Austria; 2Molecular biology centre severo ochoa, immunology and cellular biology, Univ autonoma Madrid, Madrid, Spain; 3 Center paediatric and adolescent medicine, Univ Heidelberg, Heidelberg, Germany; 4 Paediatric nephrology, Medical Univ Vienna, Wien, Austria

SaO061
UNPLANNED START ON PD DOES NOT AFFECT PD CATHETER - OR PATIENT SURVIVAL: A MULTICENTER, PROSPECTIVE DANISH OBSERVATIONAL COHORT STUDY
Johan Vestergaard Povlsen1; Kjeld Erik Otte2; Pia Veldt Larsen3; Jesper Noergaard Bech4; Gabor Graehn5; Joergen Erik Jensen6; Per Iversen7; 1Nephrology, ER Aarhus Univ Hosp, Aarhus, Denmark; 2Medicine, Kolding Sygehus, Kolding, Denmark; 3Public health, Univ Southern Denmark, Odense, Denmark; 4Univ clinic nephrology and hypertension, Holstebro Hosp, Holstebro, Denmark; 5Internal medicine, Soenderborg Hosp, Soenderborg, Denmark; 6Nephrology, Odense Univ Hosp, Odense, Denmark; 7Nephrology, Aarhus Univ Hosp, Aarhus, Denmark

www.era-edta2019.org
DAY AT A GLANCE

08:30 - 10:00 **Symposia**
- AKI: current problems in clinical practice
- Frail elderly: management best at home
- Novel therapies in hereditary kidney diseases
- Digging the aetiology of hypertension

**Free Communications + Mini Lectures**
- Fluids and electrolytes
- From cell physiology to new therapeutical targets
- Haemodialysis improving solute removal
- Finetuning immunosuppression in kidney transplantation

10:15 - 11:00 **Plenary Lecture Csaba P. Kovesdy**
The pre-dialysis to renal replacement therapy transition

11:00 - 12:30 **Special Session**
Nephrology Pearls
HALL G1  
08:30 - 10:00

Symposium 36

AKI: current problems in clinical practice

Chairs: Michael Heung, Ann Arbor, MI, U.S.A.  
        Mehmet Sukru Sever, Istanbul, Turkey

Introducing organizational-level programs of intervention for AKI
John Stoves, Bradford, United Kingdom

Heart failure and AKI
Stephan von Haehling, Goettingen, Germany

Genetic susceptibility and AKI
Michael Heung, Ann Arbor, MI, U.S.A.

References to urinary tract disease in the Works of Thomas of Wroclaw (1297-1378), the Continuator of Arnaldo de Villanova’s Medical Thought
Janusz OstrowskiIIAHN, Warsaw, Poland

HALL G2A  
08:30 - 10:00

Symposium 37

Frail elderly: management best at home

Chairs: Raymond Vanholder, Ghent, Belgium  
        Angela Yee Moon Wang, Hong Kong, Hong Kong

Integrating geriatric assessment into routine dialysis care
Edwina Brown, London, United Kingdom

Addressing potentially inappropriate medications in older adults with kidney disease
Rasheeda Hall, Durham, NC, U.S.A.  
        YNP/ASN Exchange  
        Speaker suggested by

Clinical Practice Guideline on management of older patients with advanced chronic kidney disease
Adrian Covic, Iasi, Romania

Outcomes on assisted PD Patient and Caregiver Priorities for Outcomes in Peritoneal Dialysis
Angela Yee Moon Wang, Hong Kong, Hong Kong
HALL G2B

Symposium 38

**Novel therapies in hereditary kidney diseases**

Chairs: **Olivier Devuyst**, Zurich, Switzerland  
**Roser Torra**, Barcelona, Spain

- New therapeutic targets in Alport syndrome  
  **Roser Torra**, Barcelona, Spain

- Targeted therapies in ADPKD: what will be in the pipeline in 2020?  
  **Ron T. Gansevoort**, Groningen, The Netherlands

- Therapeutic management of cystinuria: today and tomorrow  
  **John Sayer**, Newcastle upon Tyne, United Kingdom

- Efficacy and safety of the long-acting complement C5 inhibitor ravulizumab in adult patients with atypical haemolytic uraemic syndrome (aHUS)  
  **Hermann Haller**, Hannover, Germany

HALL F1

Symposium 39

**Digging the aetiology of hypertension**

Chairs: **Mustafa Arici**, Ankara, Turkey  
**Pantelis Sarafidis**, Thessaloniki, Greece

- Thrombotic microangiopathy and malignant hypertension  
  **Jean-Michel Halimi**<sup>ESH</sup>, Tours, France

- Insights from adverse effects of drugs  
  **Petra Tesarova**, Prague, Czech Republic

- Out-of-office BP monitoring and BP variability in chronic kidney disease: current concepts and future directions  
  **Pantelis Sarafidis**<sup>ESH</sup>, Thessaloniki, Greece

- Novel techniques for blood pressure lowering  
  **Roland Schmieder**, Erlangen, Germany
**Free Communication Session 29 + Mini Lecture**

**Fluids and electrolytes**

Chairs: **Felix Knauf**, Berlin, Germany  
**László Rosivall**, Budapest, Hungary

**Mini lecture**

Renal and intestinal oxalate transport, inflammation and CKD  
**Felix Knauf**, Berlin, Germany

---

**FREE COMMUNICATIONS**

SuO001  
**ACID-BASE DYNAMICS DURING HEMODIALYSIS: QUANTITATIVE INSIGHTS FROM A NOVEL PHYSIOLOGY-BASED MATHEMATICAL MODEL**  
Alhaji Cherif1; Vaibhav Maheshwar1; Doris H. Fuertinger2; Alfred Gagel2; David A. Bushinsky3; Peter Kotanko1; 1Research Div, Renal Research Inst, New York, U.S.A.; 2Global research and development, Fresenius Medical Care Deutschland, Bad Homburg, Germany; 3School medicine and dentistry, Univ Rochester, Rochester, U.S.A.

SuO002  
**LOW POTASSIUM LEVELS AND MORTALITY IN HEMODIALYSIS PATIENTS**  
Josep Mora-Macià1; Olaya Lamas2; Abraham Rincón2; Francesc Moreso3; Rosa Ramos2; 1Nephrocare león, Fresenius Medical Care, Granollers, Spain; 2Medical dept, Fresenius Medical Care Spain, Madrid, Spain; 3Nephrocare, Fresenius Medical Care, Terrassa, Spain

SuO003  
**THICK ASCENDING LIMB CLAUDINS ARE ALTERED TO PRODUCE HYPERCALCIURIA IN METABOLIC ACIDOSIS**  
Gheun-Ho Kim1; Sua Kim2; Chor Ho Jo2; 1Hanyang Univ Hosp, Seoul, South Korea; 2Inst biomedical science, Hanyang Univ, Seoul, South Korea

SuO004  
**SERUM URIC ACID AND MORTALITY RISK AMONG HEMODIALYSIS PATIENTS: AN ASSOCIATION MODIFIED BY BODY COMPOSITION?**  
Adam Zawada1; Juan Jesus Carrero2; Denis Fouque3; Katharina Ihle1; Stefano Stuard4; Adelheid Gauly1; Anke Winter1; Rosa Ramos5; Bernard Canaud6; 1Medical office emea, clinical & epidemiological research, Fresenius Medical Care, Bad Homburg, Germany; 2Dept medical epidemiology and biostatistics, Karolinska Inst, Solna, Sweden; 3Dept nephrology, Univ lyon, ucll, carmen, Centre Hosp Lyon-Sud, Lyon, France; 4Operations & digital strategies, clinical & therapeutical governance, Fresenius Medical Care, Bad Homburg, Germany; 5Dept médico, Fresenius Medical Care España, S.A., Tres Cantos, Spain; 6Medical office emea, Fresenius Medical Care, Bad Homburg, Germany

SuO005  
**PREDICTING PRESCRIBED DIALYSIS BICARBONATE TO CORRECT ACIDEMIA: APPLICATION OF A NOVEL PHYSIOLOGY-BASED MATHEMATICAL MODEL**  
Alhaji Cherif1; Vaibhav Maheshwar1; Doris H. Fuertinger2; Alfred Gagel2; Stephan Thijsse1; David A. Bushinsky3; Peter Kotanko1; 1Research Div, Renal Research Inst, New York, U.S.A.; 2Global research and development, Fresenius Medical Care Deutschland, Bad Homburg, Germany; 3School medicine and dentistry, Univ Rochester, Rochester, U.S.A.
Scientific Programme

HALL A2

08:30 - 10:00

Free Communication Session 30 + Mini Lecture

*From cell physiology to new therapeutical targets*

Chairs: Yoshitaka Isaka, Suita, Japan
Tamas Kaucsar, Budapest, Hungary

Mini lecture
Autophagy in kidney diseases
Yoshitaka IsakaJSN, Suita, Japan

FREE COMMUNICATIONS

SuO006
DELETION OF SMAD3 WORSONS LUPUS NEPHRITIS BY PROMOTING B CELL ACTIVATION VIA E4BP4-MINCLE-SYK MECHANISM
Jinhong Li1; Yang Hui2; Tang Mk Patrick3; Zhu Wenjian1; Huang Xiaoru4; Zheng Zhihua1; Lan Huiyao4; 1Dept nephrology, Seventh affiliated Hosp Sun-yat Sen Univ, Shenzhen, P.R. China; 2Dept nephrology, Sun-yat Sen memorial Hosp, Guangzhou, P.R. China; 3Dept anatomical and cellular pathology, The Ch, Hong Kong, P.R. China; 4Dept medicine & therapeutics, Prince of Wales Hosp, Chinese Univ Hong Kong, Hong Kong, P.R. China

SuO008
RENAL PROGENITOR CELLS PROTECT TUBULAR EPITHELIAL CELLS FROM CISPLATIN-INDUCED DAMAGE BY OVER-EXPRESSING THE CYP1B1 GENE
Fabio Sallustio1; Claudia Curci2; Simona Simone2; Angela Picerno3; Giuseppe De Palma4; Rossana Franzin2; Giuseppe Castellano2; Anna Gallone1; Giovanni Battista Pertosa2; Loreto Gesualdo2; 1Dept basic medical sciences, neurosciences and sense organs, Univ Bari Aldo Moro, Bari, Italy; 2Dept emergency and organ transplantation nephrology unit, Univ Bari Aldo Moro, Bari, Italy; 3Dept emergency and organ transplantation, Univ Bari Aldo Moro, Bari, Italy; 4Experimental oncology and biobank management unit, Giovanni Paolo II / I.R.C.C.S. Cancer Inst, Bari, Italy

SuO009
DIFFERENTIATION OF INDUCED PLURIPOTENT STEM CELLS INTO RENAL ORGANOIDS
Figen Cakiroglu1; Antonia Thomitzek2; Philipp Ralffs2; Jürgen Rohwedel2; 1Univ Hosp Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; 2Inst virology and cell biology, Univ Lübeck, Lübeck, Germany

SuO010
THE EXPRESSION OF FERROPTOSIS IN RENAL FIBROSIS
Xiang Zhong1; Xue Yang2; Huan Wang1; Yi Li1; Guisen Li1; Li Wang1; 1Dept nephrology, Sichuan Academy Medical Science and Sichuan Provincial People’s Hosp, Chengdu, P.R. China; 2Sichuan Academy Medical Science and Sichuan Provincial People’s Hosp, Chengdu, P.R. China
HALL A3 08:30 - 10:00

Free Communication Session 31 + Mini Lecture

**Haemodialysis improving solute removal**

Chairs: **Erzsébet Ladányi**, Miskolc, Hungary  
**Marius Miglinas**, Vilnius, Lithuania

**Mini lecture**

New approaches to enhance removal, particularly of protein bound solutes  
**Joachim Jankowski**, Aachen, Germany

**FREE COMMUNICATIONS**

SuO011

RANDOMIZED CONTROLLED TRIAL OF MEDIUM CUT-OFF OR HIGH-FLUX DIALYZER ON QUALITY-OF-LIFE OUTCOMES IN MAINTENANCE HEMODIALYSIS PATIENTS  
Jeong-Hoon Lim1; Yeongwoo Park2; Kye Hwa Jeong1; Hee-Yeon Jung1; Ji-Young Choi1; Sun-Hee Park1; Chan-Duck Kim1; Yong-Lim Kim1; **Jang-Hee Cho**1; 1Internal medicine, Kyungpook Univ, medical school, Dongin 2(i)-ga, Jung-gu, Daegu, South Korea; 2Statistics, Kyungpook national Univ, Daegu, South Korea

SuO012

INTRADIALYTIC ON-LINE MULTICOMPONENT REDUCTION RATIO MONITORING IN SPENT DIALYSATE BY A NOVEL MINIATURIZED OPTICAL SENSOR  
**Kristjan Pilt**1; Jürgen Arund1; Annika Adoberg2; Liisi Leis2; Ivo Fridolin1; Merike Luman2; 1Dept health technologies, Tallinn Univ Technology (TalTech), Tallinn, Estonia; 2Nephrology centre, North Estonia Medical Centre, Tallinn, Estonia

SuO013

LONG-TERM EVALUATION OF ACETATE-FREE CITRATE CONCENTRATE: 2.5-YEAR EXPERIENCE OF REAL-LIFE  
**Giuseppe Gernone**1; Francesco Detomaso1; Adele Mitrotti2; Francesca Partipilo2; Vito Pepe1; Stefania Pietanza2; Roberto La Rosa2; 1Nefrologia e dialisi, Osp Santa Maria Degli Angeli, Putignano, Italy; 2Nefrologia e dialisi, San Giacomo Hosp, Monopoli, Italy

SuO014

NURSE ASSISTED HOME HEMODIALYSIS BY USING NxStage Cycler, A NEW MODALITY FOR TREATING, HOME BOUND, MULTI COMORBID AND DEBILITATED HEMODIALYSIS PATIENTS: ONE YEAR EXPERIENCE  
**Bassam Bernieh**; Ahmed Ahmed; Mohamed Yassin Galal; Bienmelyn Hernandez; Hussam Abdulrazek; Teena Ramos; Eva Alipala; William Prinsloo; Redwan Yousef Al; Home Hemodialysis, HHD for Home Health Care, Al Ain, United Arab Emirates

SuO015

REDUCING INTRADIALYTIC COMPLICATIONS WITH AUTOMATED TARGET BLOOD VOLUME CONTROL  
**Susanne Kron**1; Daniel Schneditz2; Til Leimbach3; Joachim Kron3; 1Dept Nephrology and Internal Intensive Care Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany; 2Otto Loewi Research Center, Medical Univ Graz, Graz, Austria; 3Kfh-Nierenzentrum Berlin-Köpenick, KfH Kuratorium für Dialyse und Nierentransplantation e.V., Berlin, Germany
Free Communication Session 32 + Mini Lecture

**Finetuning immunosuppression in kidney transplantation**

Chairs: **Giuseppe Grandaliano**, Foggia, Italy
        **Adam Remport**, Budapest, Hungary

*Mini lecture*

TRANSFORM, the largest trial ever done in transplantation: lessons after 3 years

**Julio Pascual**, Barcelona, Spain

**FREE COMMUNICATIONS**

**SuO016**

PREDICTORS OF GRAFT FUNCTION IMPROVEMENT AFTER CONVERSION FROM CALCINEURIN INHIBITORS TO BELATACEPT IN KIDNEY RECIPIENTS WITH CALCINEURIN INHIBITOR NEPHROTOXICITY

Daniele Pievani; **Denis Vigiatti**; Kevin Louis; Denis Glotz; Christophe Legendre; Alexandre Loupy; Carmen Lefaucheur; Paris translational research center organ transplantation, INSERM, Paris, France

**SuO017**

INTERLEUKIN-2 RECEPTOR ANTIBODY INDUCTION THERAPY IN STANDARD-RISK RENAL TRANSPLANT IN TACROLIMUS ERA: UK REGISTRY DATA

**Hatem Ali**1; Sharma Ajay2; Ihab Shaheen3; Jon Jin Kim3; Mohsen Elkossi3; Ravi Pararajasingam3; Halawa Ahmed4; 1Royal Stoke Univ Hosp, stoke-on-trent, United Kingdom; 2Royal liverpool Univ Hosp, Liverpool, United Kingdom; 3Inst medical sciences, Fac medicine, liverpool, United Kingdom; 4Urology, Programme Director MSc Renal Transplantation Science Univ Liverpool, Sheffield, United Kingdom

**SuO018**

ROLE OF ANTI THYMOCYTE GLOBULIN INDUCTION THERAPY IN INCREASING THE RISK OF MONOMORPHIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER POST KIDNEY TRANSPLANT

Ahmed Daoud1; **Hatem Ali**2; Sharma Ajay 3; Halawa Ahmed4; 1Renal, Cairo Univ,cairo, Egypt; 2Royal Stoke Univ Hosp, stoke-on-trent, United Kingdom; 3 Royal liverpool Univ Hosp, Liverpool, United Kingdom; 4Urology, Programme Director MSc Renal Transplantation Science Univ Liverpool, Sheffield, United Kingdom

**SuO019**

SAFETY AND OUTCOMES OF DIFFERENT INDUCTION THERAPIES AMONG RENAL TRANSPLANT PATIENTS WITH MODERATE AND SEVERE FRAILTY

**Hatem Ali**1; Ahmed Daoud2; Ingi Elsayed3; 1Royal Stoke Univ Hosp, stoke-on-trent, United Kingdom; 2Renal, Cairo Univ, cairo, Egypt; 3Nhs, Univ Hosp North Midlands, Stoke-on-Trent, UK, United Kingdom

**SuO020**

A NOVEL REGIMEN FOR BELATACEPT IMPROVES OUTCOME IN KIDNEY TRANSPLANTATION

**Flavio Vincenti**1; Joey Leung1; Qizhi Tang1; John Roberts1; Zoltan Laszik2; Jun Shoij3; 1Surgery, 2Pathology, 3 Nephrology, Univ California San Francisco Parnassus Campus, San Francisco, U.S.A.
HALL G1  10:15 - 11:00

Plenary Lecture 3

Chairs: József Balla, Debrecen, Hungary
       Kate Stevens, Glasgow, United Kingdom

The pre-dialysis to renal replacement therapy transition
Csaba P. Kovesdy, Memphis, TN, U.S.A.

HALL G1  11:00 - 12:30

Special Closing Session

Nephrology Pearls

Chairs: Orsolya Cseprekál, Budapest, Hungary
       Alberto Ortiz, Madrid, Spain

Epidemiology and Clinical Nephrology
Marie Evans, Stockholm, Sweden

ESKD and Dialysis
Jonathan Fox, Glasgow, United Kingdom

Kidney Transplantation
Bruno Watschinger, Vienna, Austria

Glomerulonephritis
Rosanna Coppo, Turin, Italy
Schedule your scientific and educational updates on your agenda

Save the dates!

SEID: October 26, 2019

57th ERA-EDTA CONGRESS: June 6-9, 2020
58th ERA-EDTA CONGRESS: June 5-8, 2021
59th ERA-EDTA CONGRESS: May 19-22, 2022
VISIT
our booth at # 820

Don’t miss the opportunity to meet some of our key leaders at the booth: check out their schedule in the ERA-EDTA Daily Newspaper!
# INDUSTRY SPONSORED SYMPOSIA

## Friday, June 14, 2019

<table>
<thead>
<tr>
<th>Hall</th>
<th>09:30-10:45</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>PACE-CME - Boehringer Ingelheim/Lilly</td>
<td>124</td>
</tr>
<tr>
<td>A1</td>
<td>Baxter Healthcare</td>
<td>125</td>
</tr>
<tr>
<td>A2</td>
<td>Fresenius Medical Care</td>
<td>126</td>
</tr>
<tr>
<td>A3</td>
<td>NxStage Medical</td>
<td>127</td>
</tr>
<tr>
<td>A4</td>
<td>AstraZeneca</td>
<td>128</td>
</tr>
<tr>
<td></td>
<td><strong>Hall</strong> 13:15-14:45</td>
<td></td>
</tr>
<tr>
<td>G2A</td>
<td>Fresenius Medical Care</td>
<td>129</td>
</tr>
<tr>
<td>G2B</td>
<td>Baxter Healthcare</td>
<td>130</td>
</tr>
<tr>
<td>F1</td>
<td>Charité-Vifor Fresenius Medical Care Renal Pharma</td>
<td>131</td>
</tr>
<tr>
<td>A1</td>
<td>Novo Nordisk</td>
<td>132</td>
</tr>
<tr>
<td>A2</td>
<td>Amgen Europe</td>
<td>133</td>
</tr>
<tr>
<td>A3</td>
<td>Mundipharma</td>
<td>134</td>
</tr>
<tr>
<td>A4</td>
<td>Sanofi Genzyme</td>
<td>135</td>
</tr>
</tbody>
</table>

## Saturday, June 15, 2019

<table>
<thead>
<tr>
<th>Hall</th>
<th>09:30-10:45</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>G2B</td>
<td>PACE-CME - Vifor Fresenius Medical Care Renal Pharma</td>
<td>136</td>
</tr>
<tr>
<td>F1</td>
<td>PACE-CME - Novo Nordisk</td>
<td>137</td>
</tr>
<tr>
<td>A1</td>
<td>AstraZeneca</td>
<td>138</td>
</tr>
<tr>
<td>A2</td>
<td>Takeda</td>
<td>139</td>
</tr>
<tr>
<td>A3</td>
<td>Astellas</td>
<td>140</td>
</tr>
<tr>
<td>A4</td>
<td>Asahi Kasei Medical Europe</td>
<td>141</td>
</tr>
<tr>
<td></td>
<td><strong>Hall</strong> 13:15-14:45</td>
<td></td>
</tr>
<tr>
<td>G2A</td>
<td>Vifor Fresenius Medical Care Renal Pharma</td>
<td>142</td>
</tr>
<tr>
<td>G2B</td>
<td>Alexion Pharmaceuticals</td>
<td>143</td>
</tr>
<tr>
<td>F1</td>
<td>B. Braun Avitum</td>
<td>144</td>
</tr>
<tr>
<td>A1</td>
<td>PACE-CME - Resverlogix</td>
<td>145</td>
</tr>
<tr>
<td>A2</td>
<td>Fresenius Kabi</td>
<td>146</td>
</tr>
<tr>
<td>A3</td>
<td>Bayer AG</td>
<td>147</td>
</tr>
<tr>
<td>A4</td>
<td>Amicus Therapeutics</td>
<td>148</td>
</tr>
<tr>
<td></td>
<td>PRESENTATION Zydus Trans-Immune (A Division of Cadila Healthcare)</td>
<td>149</td>
</tr>
</tbody>
</table>
SGLT2 Inhibition in CKD: Discussing the key questions and evidence

Chair: John Deanfield, London, United Kingdom

Introduction
John Deanfield, London, United Kingdom

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?
Rajiv Agarwal, Indianapolis, IN, U.S.A.

The knowns and unknowns of SGLT2 inhibition in CKD
Paola Fioretto, Padua, Italy

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?
Will Herrington, Oxford, United Kingdom

Discussion
All faculty

PACE-CME, funded by an unrestricted educational grant from BOEHRINGER INGELHEIM/LILLY

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit.
Each participant should claim only those hours of credit that have been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognised each other’s accreditation systems as substantially equivalent.
Industry Sponsored Symposia

Friday, June 14, 2019
Hall A1

09:30-10:45

Remote Patient Management (RPM) in PD: Benefits Realized and Beyond

Chair: Beata Naumnik, Bialystok, Poland

Opportunities to improve care in PD
Martin Wilkie, Sheffield, United Kingdom

Using RPM in APD: What do we know and what do we need to know?
Jeffrey Perl, Toronto, Canada

What healthcare-related outcome improvements can we expect from RPM?
Claudio Ronco, Vicenza, Italy

Organised by BAXTER HEALTHCARE
Industry Sponsored Symposia

Friday, June 14, 2019 09:30-10:45
Hall A2

Fluid management options for your home patients

Chair: Wim Van Biesen, Ghent, Belgium

Ultrafiltration or Fluid Balance? Learnings from the IPOD-PD study
Wim Van Biesen, Ghent, Belgium

Enhancing fluid management with Home HD
James Heaf, Copenhagen, Denmark

Can sodium management improve fluid balance in PD?
Monika Lichodziejewska-Niemierko, Gdansk, Poland

Organised by FRESENIUS MEDICAL CARE
**Survival After End Stage Renal Failure: Preventing Cardiac Death in ESRD Patients**

Chair: Mari Vilpakka, Lathi, Finland

Challenge of Fluid Management in Hemodialysis
**Maria Fernanda Slon**, Pamplona, Spain

Cardiovascular Disease Challenges with Volume Overload, Heart Failure and Hypertension
**Piotr Ponikowski**, Wroclaw, Poland

More frequent therapy: The key to volume and symptom control?
**Nicholas Sangala**, Portsmouth, United Kingdom

A patient experience on fluid management and blood pressure control
**Johan Sandstrom**, Helsingborg, Sweden

Organised by **NXSTAGE MEDICAL**
Industry Sponsored Symposia

Friday, June 14, 2019 09:30-10:45
Hall A4

The Potassium Challenge in Kidney Disease: Assessing Recent Data and Advances in the Management of Hyperkalaemia

Chair: Juan-Jesus Carrero, Stockholm, Sweden

Chair’s introduction
Juan-Jesus Carrero, Stockholm, Sweden

What is the clinical impact of hyperkalaemia in CKD?
Juan-Jesus Carrero, Stockholm, Sweden

Treating hyperkalaemia: What is the way forward?
Manish Sood, Ottawa, Canada
Bruce Spinowitz, New York, NY, U.S.A.

How will novel K⁺ binders improve clinical care in different patient populations?
All faculty

Supported by an unrestricted educational grant from ASTRazeneca

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit.
Each participant should claim only those hours of credit that have been spent in the educational activity.

Organised by: University Hospital of Umeå, Sweden
Course Director: Professor Ulf Näslund
Industry Sponsored Symposia

Friday, June 14, 2019
Hall G2A

13:15-14:45

Present and future of sodium and water handling to improve outcomes in ESKD patients

Chairs: Jeroen Kooman, Maastricht, The Netherlands
Peter Kotanko, New York, NY, U.S.A.

New insights in sodium and water physiology in kidney disease
Jens Titze, Singapore, Singapore

Today’s way of managing sodium
Nicholas Selby, Derby, United Kingdom

Future perspectives to individualise dialysis sodium management
Bernard Canaud, Montpellier/France, Bad Homburg/Germany

Organised by FRESENIUS MEDICAL CARE
Industry Sponsored Symposia

Friday, June 14, 2019
Hall G2B

13:15-14:45

Expanded Hemodialysis: When Innovation Meets the Need

Chair: Laurent Juillard, Lyon, France

Large Uremic Toxins: The Heart and Fire of it all
Peter Stenvinkel, Stockholm, Sweden

The Case for HDx: Emerging Evidence
Mario Cozzolino, Milan, Italy

Expanded Hemodialysis: What can we expect from the HDx therapy?
Laurent Juillard, Lyon, France

Organised by BAXTER HEALTHCARE
Industry Sponsored Symposia

Friday, June 14, 2019
Hall F1
13:15-14:45

Anaemia and iron deficiency in patients with CKD – Time for a pivotal change in management strategies?

Chairs: Christopher G. Winearls, Oxford, United Kingdom
George Reusz, Budapest, Hungary

Treatment of anaemia and iron deficiency in patients with CKD – consensus and controversies
Kai-Uwe Eckardt, Berlin, Germany

Iron therapy in patients with CKD – what do we know about optimal dosing strategies?
Christopher G. Winearls, Oxford, United Kingdom

Anaemia and iron deficiency management in CKD – a cardiovascular perspective
Stefan D. Anker, Berlin, Germany

Interactive discussion
Christopher G. Winearls, Oxford, United Kingdom
George Reusz, Budapest, Hungary
Kai-Uwe Eckardt, Berlin, Germany
Stefan D. Anker, Berlin, Germany

Organised by CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN

Supported by an unrestricted educational grant from VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
Industry Sponsored Symposia

Friday, June 14, 2019
Hall A1
13:15-14:45

**Improving renal outcomes in type 2 diabetes: A potential novel role for GLP-1 receptor agonists**

Chair: **Vlado Perkovic**, Sydney, Australia

Diabetic kidney disease: Learnings so far
**Peter Rossing**, Copenhagen, Denmark

Delaying progression of renal impairment in people with type 2 diabetes and chronic kidney disease: Focus on GLP-1 receptor agonists
**Johannes Mann**, Munich, Germany

GLP-1 and the kidney: Potential mechanisms at play
**Marcel Muskiet**, Amsterdam, The Netherlands

Q&A and closing remarks
All faculty

Organised by **NOVO NORDISK**
Industry Sponsored Symposia

Friday, June 14, 2019
Hall A2

Metabolic complications of CKD: From heart to bone (and back)

Chair: Charles Ferro, Birmingham, United Kingdom

Welcome and introduction
Charles Ferro, Birmingham, United Kingdom

Dyslipidaemia in CKD: where do we stand?
Charles Ferro, Birmingham, United Kingdom

Recent advances in the management of secondary hyperparathyroidism
Jürgen Floege, Aachen, Germany

Management of the risk of osteoporosis in patients with CKD
Marie-Hélène Lafage-Proust, Saint-Étienne, France

Panel discussion and meeting close
Charles Ferro, Birmingham, United Kingdom

Organised by AMGEN EUROPE
**Reshaping the future in diabetic kidney disease: From mechanism to outcomes**

*Chair: Maarten Taal, Nottingham, United Kingdom*

**Welcome & objectives**
*Marten Taal, Nottingham, United Kingdom*

The pathophysiology of diabetic kidney disease: translating mechanisms into outcomes - the renal aspects of SGLT2 inhibitors
*Per-Henrik Groop, Helsinki, Finland*

Reshaping the future with SGLT2 inhibitor renal outcome trials
*David Wheeler, London, United Kingdom*

**Interactive panel discussion**
*All faculty*

Organised by **MUNDIPHARMA**
Industry Sponsored Symposia

Friday, June 14, 2019
Hall A4

**The clue to understanding the complexity of Fabry disease**

Chair: *Alberto Ortiz*, Madrid, Spain

Genotype-phenotype in Fabry disease: why it is clinically relevant
*Dominique P. Germain*, Paris, France

New insights from the application of FAbry STabilization indEX (FASTEX) in large population of Fabry cases
*Renzo Mignani*, Riccione, Italy

Fabry disease revisited: management and treatment recommendations for adult patients. What is in it for the nephrologists?
*Alberto Ortiz*, Madrid, Spain

Organised by *SANOFI GENZYM*E
RAASi and Hyperkalaemia in Cardiorenal Disease: Opportunities for optimizing outcomes

Chairs: John Cunningham, London, United Kingdom
Matthew Weir, Baltimore, MD, U.S.A

Introduction
John Cunningham, London, United Kingdom

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks
Patrick Rossignol, Nancy, France

Addressing the risk of hyperkalaemia: Is there a sweet spot for potassium binding?
Peter van der Meer, Groningen, The Netherlands

Managing hyperkalaemia in cardiorenal patients: Novel therapeutic insights to optimize outcomes
Matthew Weir, Baltimore, MD, U.S.A.

Discussion
John Cunningham, London, United Kingdom

PACE-CME, funded by an unrestricted educational grant from VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit.
Each participant should claim only those hours of credit that have been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
**Industry Sponsored Symposia**

Saturday, June 15, 2019      09:30-10:45
Hall F1

**Impacting progression and outcomes of DKD: Translating novel insights with GLP-1 RA to practice**

Chair: Melanie Davies, Leicester, United Kingdom

Introduction
Melanie Davies, Leicester, United Kingdom

Importance of protection and prevention in cardiorenal disease
John Deanfield, London, United Kingdom

The science behind vascular and renal benefits of GLP-1 receptor agonists
Filip Krag Knop, Copenhagen, Denmark

Clinical outcomes of GLP-1 RA in kidney disease: Current evidence and ongoing trials
Frederik Persson, Copenhagen, Denmark

Discussion
All faculty

PACE-CME, funded by an unrestricted educational grant from **NOVO NORDISK**

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit. Each participant should claim only those hours of credit that have been spent in the educational activity. **The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.**
Industry Sponsored Symposia

Saturday, June 15, 2019    09:30-10:45
Hall A1

SGLT2 inhibition and the kidney: Mechanistic revelations and clinical implications

Chair: Adeera Levin, Vancouver, Canada

Welcome and introduction
Adeera Levin, Vancouver, Canada

SGLT2 inhibition: New insights into the mechanisms for kidney protection
Hiddo J.L. Heerspink, Groningen, The Netherlands

SGLT2 inhibition: Implications for clinical practice
Roberto Pecoits-Filho, Ann Arbor, MI, U.S.A

Panel discussion and Q&A
All faculty

Supported by an unrestricted educational grant from AstraZeneca

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit. Each participant should claim only those hours of credit that have been spent in the educational activity.

Organised by: University Hospital of Umeå, Sweden
Course Director: Professor Ulf Näslund
Industry Sponsored Symposia

Saturday, June 15, 2019
Hall A2

09:30-10:45

Fabry disease: Biomarkers, goals and management

Chair: Trond Jenssen, Oslo, Norway

Welcome and introduction
Trond Jenssen, Oslo, Norway

Biomarkers in Fabry disease: diagnosis and monitoring
Patricio Aguiar, Lisbon, Portugal

Critical review of therapeutic goals in Fabry disease
Christoph Wanner, Würzburg, Germany

How to achieve these goals?
Bojan Vujkovac, Slovenj Gradec, Slovenia

Organised by TAKEDA
Industry Sponsored Symposia

Saturday, June 15, 2019
Hall A3

09:30-10:45

Anaemia of CKD: Exploring the Causes, Treatments and Challenges

Chair: David Wheeler, London, United Kingdom

Welcome and introduction
David Wheeler, London, United Kingdom

The underlying pathophysiology and the changes that occur in erythropoiesis that lead to anaemia of CKD
Lucia Del Vecchio, Lecco, Italy

How anaemia of CKD is currently treated and the greatest challenges
Sunil Bhandari, Hull, United Kingdom

Questions and answers
David Wheeler, London, United Kingdom
Lucia Del Vecchio, Lecco, Italy
Sunil Bhandari, Hull, United Kingdom

Organised by ASTELLAS
Industry Sponsored Symposia

Saturday, June 15, 2019
Hall A4

Apheresis in autoimmune diseases

Chair: Reinhard Klingel, Cologne, Germany

The potential of therapeutic apheresis to control autoimmunity
Antonio Santoro, Bologna, Italy

Therapeutic Apheresis meeting antibody-related challenges in kidney transplantation
Denis Glotz, Paris, France

Indications for therapeutic apheresis in nephrotic syndromes
Mario Schiffer, Erlangen, Germany

Organised by ASAHI KASEI MEDICAL EUROPE
Industry Sponsored Symposia

Saturday, June 15, 2019      13:15-14:45
Hall G2A

Navigating CKD-MBD in 2019: Expert perspectives

Chair: Jordi Bover, Barcelona, Spain

Current concepts and controversies in the management of SHPT
Markus Ketteler, Stuttgart, Germany

Treatment options to address hyperphosphataemia
Marc Vervloet, Amsterdam, The Netherlands

Organised by VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
Industry Sponsored Symposia

Saturday, June 15, 2019
Hall G2B

13:15-14:45

*Diagnosis and management of aHUS: A multifaceted disease*

Chair: Manuel Praga, Madrid, Spain

Welcome and introduction
Manuel Praga, Madrid, Spain

Approach to the patient with thrombotic microangiopathy (TMA)
Bernd Schröppel, Ulm, Germany

Special care for special patients - aHUS and kidney transplantation
Moglie Le Quintrec, Montpellier, France

Special care for special patients - pregnancy associated aHUS
Manuel Praga, Madrid, Spain

Organised by ALEXION PHARMACEUTICALS
Frailty in today’s hemodialysis routine

Chair: Martin Kuhlmann, Berlin, Germany

Frailty in hemodialysis, assessment and consequences
Martin Kuhlmann, Berlin, Germany

Complex CKD and dialysis patients: How to integrate their needs
Marcello Tonelli, Calgary, Canada

KUF max: Convective volume optimization for frail patients
Angel Argiles, Montpellier, France

Organised by B.BRAUN AVITUM
Industry Sponsored Symposia

Saturday, June 15, 2019
Hall A1
13:15-14:45

Vascular calcification in kidney disease: Epigenetics as a novel approach?

Chairs: Peter Stenvinkel, Stockholm, Sweden
        Jürgen Floege, Aachen, Germany

Introduction
Peter Stenvinkel, Stockholm, Sweden

Epigenetic mechanisms targeting ALP: A pathway for prevention?
Marta Ruiz-Ortega, Madrid, Spain

The role of ALP as predictor of cardiovascular events and vascular calcification in CKD
Mathias Haarhaus, Stockholm, Sweden

Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition
Vincent Brandenburg, Aachen, Germany

Discussion & summary
Jürgen Floege, Aachen, Germany

PACE-CME, funded by an unrestricted educational grant from RESVERLOGIX

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit. Each participant should claim only those hours of credit that have been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
Industry Sponsored Symposia

Saturday, June 15, 2019  13:15-14:45
Hall A2

**Nutritional Management of CKD**

Chair: Denis Fouque, Lyon, France

Nutritional Management of CKD

Kamyar Kalantar-Zadeh, Los Angeles, CA, U.S.A.

Clinical Evidence of Ketoanalogue-Supplemented Protein Restriction in Predialysis Patients

Liliana Garneata, Bucharest, Romania

Organised by FRESENIUS KABI
Industry Sponsored Symposia

Saturday, June 15, 2019
Hall A3

13:15-14:45

Emerging Pathways in Diabetic Kidney Disease Progression: A Focus on the MR Receptor

Chairs: George Bakris, Chicago, IL, U.S.A
        Hermann Haller, Hannover, Germany
        Frédéric Jaisser, Paris, France

Unmet Needs in the Current Management of DKD
George Bakris, Chicago, IL, U.S.A.

Understanding the Role of the MR in DKD
Hermann Haller, Hannover, Germany

MR in Renal Disease
Frédéric Jaisser, Paris, France

Organised by BAYER AG
Managing Fabry Disease - Evolving Insights in Renal Involvement

Chair: Gere Sunder-Plassmann, Vienna, Austria

Welcome and Introduction
Gere Sunder-Plassmann, Vienna, Austria

A Deeper Look into the Mechanisms of Fabry Nephropathy
Einar Svarstad, Bergen, Norway

Management of Fabry Disease – Podocytes and Beyond
Michael Mauer, Minneapolis, MN, U.S.A.

Migalastat in the Fabry Clinic - Real-life Experience from the UK
Derralynn Hughes, London, United Kingdom

Summary and Close
Gere Sunder-Plassmann, Vienna, Austria

Organised by AMICUS THERAPEUTICS
Industry Sponsored Symposia

Saturday, June 15, 2019
Presentation Theatre

Induction and state of the art regimens in kidney transplant

Chairs: Anil Kumar Bhalla, New Delhi, India
       Amit Gupta, Lucknow, India
       Raj Kumar Sharma, Lucknow, India
       Bhupendra Gandhi, Mumbai, India

Moderator: Shankaran Sundar, Bangalore, India

Is induction therapy required in non-HLA sensitized patients?
Sishir Gang, Nadiad, India

Induction therapy in highly sensitized patients
Nassim Kamar, Toulouse, France

Induction therapy in ABO incompatible transplants
Ashwani Gupta, New Delhi, India

Induction therapy in steroid free regimens
Sanjeev Gulati, New Delhi, India

Supported by an unrestricted educational grant from
ZYDUS TRANS-IMMUNE (A DIVISION OF CADILA HEALTHCARE)
Exhibitors

THURSDAY, JUNE 13th, 2019

16:00-20:00 Exhibition Open
18.00-19:30 Welcome Reception in the Exhibition

FRIDAY, JUNE 14th, 2019

09:30-17:30 Exhibition Open
09:30-10:45 Break and Exhibition Visit
11:30-11.45 Break and Exhibition Visit
16:30-17:00 Break and Exhibition Visit

SATURDAY, JUNE 15th, 2019

09:30-17:30 Exhibition Open
09:30-10:45 Break and Exhibition Visit
11:30-11.45 Break and Exhibition Visit
16:30-17:00 Break and Exhibition Visit

SUNDAY, JUNE 16th, 2019

The Exhibition is closed
Exhibitors List A-Z

Exhibiting Company .......... Booth(s) No.

3M Deutschland GmbH ........................................... 65
5.9 Srl Care Weighting System .................................. 1.260
A Uno Tec Srl .......................................................... 1.355
AcimeFrame ........................................................... 1.325
Actual Medical Devices ........................................... 1.240
Aferetica Srl ............................................................ 1.360
Alexion ................................................................. 645
Almed Group .......................................................... 385
Alnylam Pharmaceuticals ........................................ 113
Amgen Europe Gmbh .............................................. 695
Amicus Therapeutics ............................................... 275
Asahi Kasei Medical ................................................ 895
Astellas Pharma Europe Ltd ..................................... 1.335
AstraZeneca ............................................................ 885
Aurinia Pharmaceuticals Inc .................................... 070
B. Braun Avitum AG ............................................... 460
Bain Medical ............................................................. 925
Baxter ................................................................. 360
Bayer AG ................................................................. 840
Bionic Medizintechnik GmbH ................................ 1.135
Bioteque Corporation ............................................. 1.400
Bodystat Ltd ............................................................ 1.143
Boehringer Ingelheim and Eli Lilly Diabetes Alliance .... 123
Borla Industrie ......................................................... 1.255
Clearum GmbH ........................................................ 980
Clinical Nephrology .................................................. 795
Culligan Italiana S.p.A .............................................. 345
Curemed Nordic AB Sweden ..................................... 265
CytoSorbents Europe GmbH ....................................... 1.360a

Exhibiting Company .......... Booth(s) No.

D.Med Healthcare .................................................. 155
DaVita ................................................................. 005
Dialife SA .............................................................. 380
Dr. Schär AG/SPA .................................................. 1.320
DWA GmbH & Co. KG ............................................ 310
Education & Future Events ........................................ 815
Effemme Spa ........................................................... 965
Emodial ................................................................. 635
ERA-EDTA Activities ............................................... 820
ERA-EDTA Milan 2020 Congress ................................ 820
EuroPD ................................................................. 1.010
European Society for Paediatric Nephrology .............. 1.245
Fameco GME .......................................................... 1.154
Farmasol Medical Devices Company INC .............. 1.133
Fist Assist Devices, LLC ........................................... 1.225
Fresenius Kabi Deutschland GmbH ................................ 1.460
Fresenius Medical Care ............................................ 420
Gardhen Bilance Srl .................................................. 740
Geistlich Pharma AG ............................................... 1.140
Greiner GmbH ......................................................... 310
GSK - Glaxo Smith Kline ........................................ 1.235
Guangdong Biolight Meditech Co., Ltd ...................... 580
Hansa Biopharma ..................................................... 1.220
Healthwell Medical Tech. Co., Ltd ........................ 030
HERCO Wassertechnik GmbH .................................. 1.145
Immundiagnostik AG ............................................... 001
Immuno-Biological Laboratories (IBL-Japan) ............ 114
Imuna Pharm a.s ................................................... 1.420
InBody Co., Ltd ....................................................... 075
Infomed SA ............................................................. 1.060
<table>
<thead>
<tr>
<th>Exhibiting Company</th>
<th>Booth(s) No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Society of Nephrology</td>
<td>825</td>
</tr>
<tr>
<td>IPNA 2019 Congress</td>
<td>1.152</td>
</tr>
<tr>
<td>ISPD - International Society for Peritoneal Dialysis</td>
<td>1.015</td>
</tr>
<tr>
<td>Jafron Biomedical Co., Ltd</td>
<td>1.050</td>
</tr>
<tr>
<td>Japanese Society of Nephrology</td>
<td>1.000</td>
</tr>
<tr>
<td>Jiangxi Hongda Medical Equipment Group Ltd</td>
<td>165</td>
</tr>
<tr>
<td>Jiangxi Sanxin Medtec Co., Ltd</td>
<td>630</td>
</tr>
<tr>
<td>Joline GmbH &amp; Co. KG</td>
<td>655</td>
</tr>
<tr>
<td>Journal of Kidney Care (JKC)</td>
<td>800</td>
</tr>
<tr>
<td>Karger Publishers</td>
<td>615</td>
</tr>
<tr>
<td>KDIGO (Kidney Disease: Improving Global Outcomes)</td>
<td>1.285</td>
</tr>
<tr>
<td>Likamed</td>
<td>1.065</td>
</tr>
<tr>
<td>Lonshine Technologies Inc.</td>
<td>1.225A Innovation Hub</td>
</tr>
<tr>
<td>Maider Medical Industry Equipment Co., Ltd</td>
<td>340</td>
</tr>
<tr>
<td>Maltron International Ltd</td>
<td>270</td>
</tr>
<tr>
<td>MaXimus</td>
<td>1.070</td>
</tr>
<tr>
<td>Medcomp</td>
<td>015</td>
</tr>
<tr>
<td>MediBeacon</td>
<td>112</td>
</tr>
<tr>
<td>Medica S.p.A.</td>
<td>040</td>
</tr>
<tr>
<td>Medical Devices Corporation SDN BHD</td>
<td>280</td>
</tr>
<tr>
<td>Medikit Co., Ltd</td>
<td>1.280</td>
</tr>
<tr>
<td>Meditechlab - Suissemed Technologies</td>
<td>255</td>
</tr>
<tr>
<td>Medtronic</td>
<td>125</td>
</tr>
<tr>
<td>MedVision AG</td>
<td>1.055</td>
</tr>
<tr>
<td>MedXL Europe BV</td>
<td>035</td>
</tr>
<tr>
<td>Mundipharma</td>
<td>1.030</td>
</tr>
<tr>
<td>Nanning Passion Medical Equipment Co., Ltd</td>
<td>1.156</td>
</tr>
<tr>
<td>NephroCan</td>
<td>115</td>
</tr>
<tr>
<td>NephroFlow</td>
<td>985</td>
</tr>
<tr>
<td>Nephrokit Innovation</td>
<td>1.370</td>
</tr>
<tr>
<td>Nikkiso Europe GmbH</td>
<td>870</td>
</tr>
<tr>
<td>Ningbo Tianyi Medical Appliance Co., Ltd</td>
<td>865</td>
</tr>
<tr>
<td>Nipoka</td>
<td>1.330</td>
</tr>
<tr>
<td>Nipro Medical Europe</td>
<td>130</td>
</tr>
<tr>
<td>Novak M</td>
<td>1.450</td>
</tr>
<tr>
<td>NxStage Medical Inc</td>
<td>215</td>
</tr>
<tr>
<td>Omeros Corporation</td>
<td>1.150</td>
</tr>
<tr>
<td>Oxford University Press</td>
<td>610</td>
</tr>
<tr>
<td>PakuMed medical products Gmbh</td>
<td>305</td>
</tr>
<tr>
<td>Peripal AG</td>
<td>1.225B Innovation Hub</td>
</tr>
<tr>
<td>Physicians' Academy for Cardiovascular Education (PACE-CME)</td>
<td>1.130</td>
</tr>
<tr>
<td>Physidia</td>
<td>1.045</td>
</tr>
<tr>
<td>PKD International</td>
<td>620</td>
</tr>
<tr>
<td>Plinth 2000 Ltd</td>
<td>1.155</td>
</tr>
<tr>
<td>Quanta Dialysis Technologies</td>
<td>1.040</td>
</tr>
<tr>
<td>Reata Pharmaceuticals</td>
<td>1.290</td>
</tr>
<tr>
<td>Retrophin</td>
<td>095</td>
</tr>
<tr>
<td>Rontis AG</td>
<td>665</td>
</tr>
<tr>
<td>Sanofi Genzyme</td>
<td>150</td>
</tr>
<tr>
<td>Serumwerk Bernburg AG</td>
<td>880</td>
</tr>
<tr>
<td>Sin-ergy Srl</td>
<td>124</td>
</tr>
<tr>
<td>Suzhou Jun Kang Medical Technology Co., Ltd</td>
<td>1.365</td>
</tr>
<tr>
<td>TauroPharm GmbH</td>
<td>300</td>
</tr>
<tr>
<td>Toray Medical Co., Ltd</td>
<td>680</td>
</tr>
<tr>
<td>Transonic</td>
<td>1.020</td>
</tr>
<tr>
<td>Triomed AB</td>
<td>760</td>
</tr>
<tr>
<td>Vifor Fresenius Medical Care Renal Pharma</td>
<td>140</td>
</tr>
<tr>
<td>WEGO Healthcare (Shenzhen) Co., Ltd</td>
<td>875</td>
</tr>
<tr>
<td>Wisepress Medical Bookshop</td>
<td>600</td>
</tr>
</tbody>
</table>
3M Health Care

3M Separation and Purification Sciences Division, formerly known as Membrana, is one of the largest independent producers of membranes for medical and industrial filtration applications worldwide; an expert in membrane technology and development! The 3M Separation and Purification Sciences Division offers a wide range of capillary and flat sheet membranes, for hemodialysis, blood oxygenation as well as plasmapheresis.
Website: www.3m.com/membrana

5.9 s.r.l. - Tassinari Bilance

5.9 - TASSINARI BILANCE is an Italian leading company of weighing systems for medical application, allowing the medical staff to monitor the patient’s weight constantly during invasive medical treatments. What distinguishes 5.9 is the precision of the integrated weighing system with an accuracy about 50gr for 150 kg, and reaching 20gr division for 60kg for pediatric products. 5.9 has therefore developed a product range including bed scales and armchair scales able to weigh in any position, and therapy chairs; nowadays 5.9 s.r.l. continues to invest in research to offer modern and immediate products for the whole medical team.
Website: www.5dot9.it

A UNO TEC SRL

A UNO TEC designs and realizes customized automatic machines for the assembly of plastic medical disposables, specializing in Infusion and Dialysis therapies. Its wide variety of clients, spread across the world, has contributed to enrich the company’s technical knowledge and innovating capability, ensuring an efficient turnkey service. A UNO TEC is a young, dynamic and flexible company, manufacturing sturdy, reliable, easy-to-use and innovative automatic assembly machines. All realizations are created with a focus on high quality of materials, in order to ensure a rapid return-on-investment and long-lasting life.
Website: www.aunotec.it
Acime Frame ................................................................. Booth: 1.325
Established in 1990 and based in northern France, ACIME FRAME designs, manufactures and supplies mobile units for the transport and care of patients in hospitals and private clinics throughout the world. Among our wide range of innovative products, we manufacture Treatment Chairs for Dialysis and Hemodialysis units. We are the leader company in France for the supplying of dialysis/hemodialysis chairs. All our products have the CE mark and are produced following the ISO chart. Our main strengths are: - Reactivity - Creativity - Innovation - Quality and patient orientated products - Sturdiness and life span.
Website: www.acimeframe.com

Actualway Medical Devices ......................................................... Booth: 1.240
We are Actualway®, a Portuguese manufacturer of care treatment medical equipment such as Therapy, Sampling/Blood Donation, Gynaecological, Multifunctional Chairs, Couches and many accessories. We have been increasing our distribution all over the world thanks to big efforts in promoting our products. Our sales strategy is based on building a long term relationship with all our partners providing quality and service. The best way to take care is to get our partners’ and patients’ satisfaction meeting their needs. We produce reliable, strong and comfortable products because we do care. Come and join us so that we can expand business together!
Website: www.actualway.pt

Aferetica Srl ................................................................. Booth: 1.360
Aferetica is a Startup located in Mirandola Biomedical District (Italy) founded by managers with long-time experience in blood Purification, who wanted to leverage their competence in purification therapies and the know-how in biomedical technologies to apply apheresis techniques in new fields, such as organ management for transplantation. Aferetica mission is to drive/incentive the building of a network, able to create, validate and use apheresis therapies in clinical Practice, initiating their use in new clinical areas. Aferetica wants to meet current transplantation needs transforming organ preservation in organ recovering/regeneration, through the combination of Aphaeresis & perfusion techniques.
Website: www.aferetica.com
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency. Website: www.alexionpharma.eu

Allmed operates in over 40 countries around the world. Its leading dialyzer brands, POLYPURE® and PLATINUM® incorporate a proprietary Micro-Undulate Polysulfone membrane, with outstanding performances in both efficiency and biocompatibility aspects. In its four production plants Allmed manufacture, beside dialysers and relevant fibres, a complete range of dialysis products: Allmed is committed and capable to offer customised solutions to professionals and patients. The innovative ALLMED NIDUS® breakthrough technology is the only system dedicated to haemodialysis therapies for infant with body weight from 800g. to 8kg. Allmed is also OEM manufacturer for filters, tubing systems and accessories used in other medical fields. Website: www.allmedgroup.com

Headquartered in Cambridge, MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases with unmet need. ONPATTRO™ (patisiran), for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, is Alnylam’s first U.S. FDA-approved RNAi therapeutic. In addition, Alnylam has three investigational medicines in late-stage development. Website: www.alnylam.com
AMGEN (Europe) GmbH

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Website: www.amgen.com

AMICUS THERAPEUTICS

Amicus Therapeutics is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases.

Website: www.amicusrx.com/

ASAHI KASEI MEDICAL EUROPE GMBH

Asahi Kasei Medical is a world leader in research, development, and production of devices and systems for blood treatment and purification based on advanced membrane separation and adsorption technologies. It serves the global market with hemodialysis, intensive care, therapeutic apheresis and blood transfusion high-tech advanced products. Information about Asahi’s membranes, adsorbents and full range of products can be found on our website.

Website: www.asahi-kasei.co.jp/medical/en
Astellas Pharma Europe Ltd................................................................................................................Booth: 1.335
Astellas is a pharmaceutical company that is committed to turning innovative science into medical solutions that bring value and hope to patients worldwide. Keeping our focus on addressing unmet medical needs and conducting our business with openness, integrity and a collaborative approach enables us to improve the health of people around the world.
Website: www.astellas.com/eu/

AstraZeneca......................................................................................................................................Booth: 885
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
Website: www.astrazeneca.com

Aurinia Pharmaceuticals Inc. ........................................................................................................Booth: 070
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerulosclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topic formulation, for the treatment of dry eye syndrome (DES).
Website: www.auriniapharma.com/
Exhibitors

**B. Braun Avitum AG** ............................................................................................................... Booth: 460
A family-owned company founded in 1839 in Melsungen, Germany, B. Braun today is one of the world’s leading healthcare companies with more than 63,000 employees working in 64 countries. The product range includes dialysis machines and dialysis consumables for chronic dialysis and acute blood purification. In addition to its role as a manufacturer of dialysis equipment, B. Braun is also an important provider of dialysis treatment. B. Braun operates more than 370 renal care centers. Additional care services such as holiday dialysis and pre-dialysis programs are offered in most markets and B. Braun Avitum cooperates fully with local transplant organizations.
Website: www.bbraun-dialysis.com

**Bain Medical** .......................................................................................................................... Booth: 925
BAIN MEDICAL is a professional manufacturer of hemodialysis products. Our main products Dialyzer, Blood Tubing Line (BTL) and AV Fistula needle (AVF) have been exported to over 70 countries and cover more than 50 percent of domestic market, where all of them enjoy a good reputation of high quality with competitive price. Many top brands are doing OEM/OBL with us and our company has developed into the largest supplier of BTL in the world.
Website: www.bainmedical.com

**BAXTER** ................................................................................................................................. Booth: 360
Baxter International Inc. provides a broad portfolio of essential hospital and renal products, including home, acute and in-center dialysis: sterile IV solutions; infusion systems and devices; parenteral nutrition; surgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Website: www.baxter.com
BAYER ....................................................................................................................................Booth: 840
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. Website: www.bayer.com

Bionic Medizintechnik GmbH ............................................................................................Booth: 1.135
Bionic Medizintechnik GmbH is specialized in products for vascular access and therapy chairs in the dialysis field. The product range covers a variety of more than 100 types of dialysis fistula needles, dialysis catheters and numerous accessories for connection and disconnection. Bionic therapy chairs provide the utmost patient comfort and safety and exceed your expectations in functionality and design. Website: www.bionic-jms.com, www.therapychair.com, www.vascular-access.com

BIOTEQUE CORPORATION ...............................................................................................Booth: 1.400
Bioteque Corporation provides solutions in many critical applications such as dialysis, cardiovascular catheters, endourology, interventional radiology. With years of effort, we have satisfied medical accreditation and also obtained acknowledgement from leading international medical corporations. We are supplying quality products include: Pigtail Drainage Catheter, Double Pigtail Ureteral Stent, PCN kits for Nephrostomy, Hemodialysis Bloodline, AV Fistula Needles, IV Infusion Bags, Double Lumen Dialysis Catheter, CVC catheter, CAPD solution system. Our facility is ISO13485, CE-2460 accredited and passed FDA establishment audit. For more information, visit our website. Website: www.bioteq.com.tw
Bodystat Ltd.......................................................................................................................Booth: 1.143
Are you looking for an easy, fast and accurate method to calculate Dry Weight? The Multiscan 5000 is non-invasive and measures the Volume of Fluid Overload, as well as showing Body Composition, Hydration and BIVA Vector graph immediately on the colour touch screen. Since 1990, Bodystat has specialised in bio-impedance technology, spectroscopy and Cole Modelling. Raw data and Phase Angle are calculated at 50 frequencies up to 1000kHz to help assess Dry Weight and to help assess nutritional status pre and post dialysis. View: Calf Bioimpedance Ratio Improves Dry Weight Assessment and Blood Pressure Control in Hemodialysis Patients. (Yi-Lun Zhou et al) Am J Nephrol 2010;32:109-116. Website: www.bodystat.com

Boehringer Ingelheim and Eli Lilly Diabetes Alliance.........................................................Booth: 123
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in diabetes that centres on compounds representing several of the largest diabetes treatment classes. This alliance leverages the strengths of two of the world’s leading pharmaceutical companies. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Website: www.boehringer-ingelheim.com and www.lillydiabetes.com.

BORLA INDUSTRIE ............................................................................................................Booth: 1.255
Borla, established in 1965, design, manufacture and deal worldwide a range of over 1200 different components. Borla guarantee to their customers a full service and the manufacture follow up for each component in own plants, starting from the first project concept design, the prototype manufacture until the final mould. Website: www.borla.it
CLEARUM GmbH

CLEARUM manufactures customized membranes for low and high flux dialyzers as well as for special filters. We provide high performance, biocompatible, synthetic dialysis membranes based on PS and PES as an ideal basis for an optimal therapy. We guarantee a continuous quality control - from the raw material to the final product, taking processes and environment into consideration. Our well-equipped laboratory and the close collaboration with medical experts and clinics worldwide offer a high standard of our products and their properties.

Website: www.clearum.de

Clinical Nephrology

For more than 40 years, Clinical Nephrology, a Dustri-Verlag publication, has been one of the leading journals in its field. Under the editorship of H.H. Malluche (Lexington, KT, USA) - supported by 20 Section Editors - the editorial quality has improved significantly due to a remarkable increase of manuscript submissions. Also ask for our special fellowship program. Our online Journal, Clinical Nephrology-Case Studies, offers the possibility to publish open-access cases.

Website: www.clinnephrol.com

Culligan

Culligan International is one of the longest-established, best-known companies in the water treatment sector, founded in Chicago in 1936. Culligan is a worldwide organization whose mission is water quality improvement. We have an extensive licensee distribution system in over 100 countries. Doctors, nurses and patients, get more than just great-tasting water from Culligan systems. Culligan supplies and services every water need of hospitals - cooling water, boiler water, water for hydrotherapy pools, full solutions for restaurant and canteen, drinking water, treatment and recycling for laundry and all the clinical needs.

Website: www.culligan.it
Curemed Nordic AB Sweden

Curemed Nordic AB is a Swedish medical company inventing new dialysis products. The products are made thinking to be cost-effective and saving time for the healthcare people at the same time they give safety to the dialysis patients worldwide. At our exhibition we show replacement clamp for dialysis catheters, fistula stop pressurtool on the fistula after ending dialysis session-saving nursing time, LineStrap to keep bloodlines in place, ErgoClamp - ergonomic clamp that needs much less power to close/open compared to old existing clamps on bloodlines. All products are made in Sweden. We are looking for distributors / partners worldwide. You are welcome to visit us.
Website: www.curemednordic.se

CytoSorbents Europe GmbH

CytoSorbents is a critical care focused immunotherapy company using blood purification to modulate systemic inflammation - with the goal of preventing or treating multi-organ failure. Its purification technology, based on biocompatible, highly porous polymer beads, actively removes toxic substances from blood and other bodily fluids by pore capture and adsorption. Over 56,000 treatments have been performed in more than 800 clinical departments around the world.
Website: www.cytosorb.com

D.Med Healthcare

D.Med Healthcare (“D.Med”), with headquarters in Düsseldorf (Germany), is a fast growing global medical products and services provider. D.Med focuses on provision of medical services such as dialysis and cardiology, and distributes a wide range of products for renal care, diabetes, cardiology, and urology. The company was founded in 2009 by its current CEO and owner, Sven-Axel Krentorz, and has 900+ employees in 23 countries in Europe, Asia, America, and Africa. We care for more than 4,500 dialysis patients in more than 60 dialysis clinics and at the patient’s home.
Website: www.dmed-healthcare.com
Exhibitors

DaVita .....................................................................................................................................Booth: 005
DaVita is a global provider of kidney care services, operating in 11 countries and serving more than 220,000 patients at 2,800-plus dialysis centers around the world. DaVita strives to improve patients’ quality of life, in coordination with physicians, through clinical innovation and optimized clinical outcomes, and is purely focused on providing healthcare services. We aim to build the greatest healthcare community the world has ever seen by innovating and adding value to kidney care while being a role model for global care.
Website: www.davita.com/international

DIALIFE SA .............................................................................................................................Booth: 380
Based in Switzerland, Dialife is a global provider of high quality products, equipment and services for renal care. We offer a comprehensive range of devices and products for hemodialysis treatment, including dialysis machines, dialyzers, tubing sets, fistula needles, sodium bicarbonate cartridges, concentrates, disinfectants, endotoxin filters, on/off kits and more. We also provide turnkey solutions to set up hemodialysis centers, as well as transfer technology for the production of dialysis products.
Website: www.dialifegroup.com

Dr. Schär AG/SPA ...............................................................................................................Booth: 1.320
Dr. Schär has been developing foods for people with special nutritional needs for almost 40 years. The low-protein product line, FLAVIS, supports recommended medical nutrition therapy (MNT) for chronic kidney disease (CKD). At FLAVIS, we strive to facilitate dietary adherence in CKD patients in order to preserve kidney function and slow the progression towards renal replacement therapy (dialysis, kidney transplant). In addition to being low in protein, FLAVIS products are low in sodium, phosphorus, and potassium. They are also rich in fiber and provide adequate calories to reduce risk of protein-energy-wasting (PEW).
Website: www.drschaer.com
DWA GmbH & Co. KG

DWA is a global player for conception, planning and integration of water treatment, concentrate supply and media supply systems for dialysis centers. As manufacturer and supplier of all required systems for media supply DWA has established an excellent image. DWA products “made in Germany” are successful and operate reliably world-wide. In the sensitive world of dialysis DWA’s innovative technologies allow users and patients to look to the future with trust and confidence. Dialysis center operators profit from DWA’s many years of experience and technical know-how as a full-range supplier, plus the safe and trouble-free operation of all equipment.
Website: www.dwa-online.com

Education & Future Events

Keeping doctors, working in the fields of nephrology, dialysis and transplantation, continuously up to date is one of the key missions of ERA-EDTA. Visit the booth to collect information about the courses organised and/or supported by ERA-EDTA in several countries and to receive more information about other courses and events of great educational level.
Website: www.enp-era-edta.org/#/enp/cme

Effe Emme

We have been producing single use set for more than 35 years. We are focused on the Haemodialysis market, producing bloodlines and accessories. We have implemented our range adding oncology, infusion and transfusion sets. We follow doctors’ and nurses’ requests and produce customized sets. Our company structure, always evolving, allows us to promptly react to the increasing requirements of the market. Our customers have confidence in us as a reliable partner with a track record of long lasting cooperation. To guarantee flexibility we also have some articles always available in stock, for immediate delivery.
Website: www.effeemme.it
Emodial develops advanced solutions for the vascular access management in hemodialysis, oncology, intensive care and parenteral nutrition: a complete line of dressings releasing silver ions with antibacterial and anti-inflammatory action and the innovative waterproof pockets for catheter. Since its foundation, Emodial has been committed to develop the “therapeutical alliance”, a model based on the direct cooperation between the main actors of the vascular access scenario: doctors, nurses, patients, patients associations, caregivers. Starting from their experience, Emodial creates solutions to accomplish its mission: improve the patient's quality of life, raise healthcare standards, contain spending and time, reduce the healthcare risks.

Website: www.emodial.com

With more than 7,000 active members, the ERA-EDTA is one of the biggest nephrology associations worldwide leading European nephrology and one of the most important European Medical Associations. It organises annual congresses and a Scientific Education Interactive Day (SEID), it produces guidelines, it collects data and performs epidemiological studies through its Registry. It supports fellowships and research projects. Its publications are NDT and CKJ (this last journal is Open Access). The ERA-EDTA also has an online Educational platform: the European Nephrology Portal (ENP) which includes NDT-Educational@ENP. The 2020 Congress will be held June 6-9 in Milan (Italy). Visit the booth to receive more information!

Website: www.era-edta.org

The 57th ERA-EDTA Annual Congress will be held on June 6-9, 2020 at the MiCo, Milan (Italy). Visit the booth to learn more about the Congress venue and the city hotels.

Website: www.era-edta.org
ISPD and EuroPD will be jointly hosting the 2020 Congress in Glasgow, Scotland, from 2-5 May. This will be the largest gathering of PD experts in Europe next year and is expected to attract over 2,000 delegates from around the world. The programme will aim to strengthen participant’s knowledge of PD and Home Haemodialysis on a national, regional and international scale through a multidisciplinary programme. We hope you can join us and take this opportunity to share best practice and develop future collaborative partnerships for many years to come.

Website: www.ispd-europd2020.com

European Society for Paediatric Nephrology

The aim of the Society is to promote research knowledge of paediatric nephrology through teaching, scientific meetings and other methods, for the benefit of children with renal disease.

Website: www.espn-online.org

Fameco GME

Fameco GME is French company specialized in refurbished medical equipment such as Dialysis, Anesthesia, Ventilation and Endoscopy. With a team of 40 people including 18 technicians and engineers, we provide quality machines from the major brands. Our refurbishing process follows strict procedures and technical support continues after sales, coming with 6 months warranty on parts. We can also provide spare parts, consumables, technical training and will always go for the fittest solution to your need.

Website: www.fameco.eu

Farmasol Medical Devices Company Inc

Farmasol as a pioneer in Turkey, now becomes also well-known in global hemodialysis market. As a part of international production structure, we have the biggest and the most modern production site in Turkey. It supports medical care all over Turkey and her neighborhood with a wide range of hemodialysis products and services. Farmasol is one of the very few companies in the global market, who manufactures almost all dialysis consumables, dialyzers, bicarb bag and cartridges, AV bloodlines, fistula needles and hemodialysis solutions, compatible with most well known dialysis machines. Farmasol presently exports 80% of her products abroad in more than 50 countries.

Website: www.farmasol.com.tr
Exhibitors

Fist Assist Devices, LLC ................................................................. Booth: 1.225C Innovation Hub
Fist Assist Devices, LLC is a Silicon Valley, CA USA medical device startup. We have created a novel, external intermittent pneumatic compression device for arm vein identification and enhancement. Our device is the first renal failure wearable for the patient. We are committed to developing a global device to assist in arm vein enlargement and vein identification for all phases of renal failure (Stage 4, 5 and maturation). We are presently selling our device in India and will be submitting our trial results for FDA and CE MARK allowance.
Website: www.fistassistdevices.com

Fresenius Kabi Deutschland GmbH.................................................................Booth: 1.460
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Product portfolio: I.V. generic drugs, infusion therapies, clinical nutrition products and medical devices for administering these products. Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. The company also develops biosimilars with a focus on oncology and autoimmune diseases.
Website: www.fresenius-kabi.com

Fresenius Medical Care .................................................................Booth: 420
Fresenius Medical Care is the world’s leading provider of products and services for people with chronic kidney failure. We care for more than 333,000 patients in our global network of more than 3,900 dialysis clinics. At the same time, we operate 42 production sites on all continents, to provide dialysis products such as dialysis machines, dialyzers and related disposables. Along with its core business, the company provides related medical services in the field of Care Coordination. Creating a future worth living. For patients. Worldwide. Every day. This vision guides us in our efforts to give our patients around the world a better life by offering them high-quality products and outstanding health care.
Website: www.freseniusmedicalcare.com
GARDHEN BILANCE..............................................................................................................Booth: 740
Travelling in the future, from 35 years
The company was born in 1983. After 5 years it started to manufacture medical devices with or without measurement functions with its own brand. Today designs and develops many medical devices, most of them to satisfy the specific request of the customers. A great commitment of the R&D division is able to launch appreciated novelties. Marketing and communication are as well renovated with a New LOGO, a new website, a new catalogue and many other services. A confirmation of the competitive plan started a few years ago. We offer solutions for small and large needs, without saving energy.
Welcome to our family
Website: www.gardhenbilance.it

Geistlich Pharma AG ..........................................................................................................Booth: 1.140
The Swiss family owned company Geistlich Pharma develops and produces pharmaceutical and medicinal products since 1851 with a worldwide distribution and provides valuable assistance in solving medical problems. Products such as the antimicrobial catheter lock solution TauroSept® for the prevention and treatment of CRBSIs, originate from the company’s own research facilities in central Switzerland.
Website: www.geistlich-pharma.com

GREINER ................................................................................................................................Booth: 310
GREINER GmbH is a German family-owned company with a vast experience of almost 100 years. With its 3 branches – medbest, hairline and traffic – it is one of the leading manufacturers of seats and chairs for specific application areas, e.g. dialysis, chemotherapy, infusion/transfusion therapy, surgery chairs for day clinics. GREINER GmbH provides high quality and innovative products, which are all made in Germany. The main focus is on the equipment of hospitals, medical practices, hairdresser’s shops and vehicles. The basis for this success is excellent quality, competence, design, partnership and sustainability. Our satisfied customers all over the world are the best evidence of this.
Website: www.greiner-gmbh.de
GSK ......................................................................................................................................Booth: 1.235
GSK is a science-led global healthcare company with a mission to help people do more, feel better, live longer. We research, manufacture and make available a broad range of medicines, vaccines and consumer healthcare products.
Website: www.gsk.com

Guangdong Biolight Meditech Co., Ltd. ...............................................................................Booth: 580
Guangdong Biolight Meditech Co., Ltd, is a leading company in China for hemodialysis solution of renal failure disease. We have products including dialysis machine, RO water treatment system, dialyzer, blood line, fistula needle, dialysis powder/concentrate (A+B), Bi-Cartridge/Bi-Bag etc. Our dialysis machine D30 has got CE approval from TUV, we are the only one manufacturer in China who get CE certificate from Germany. We have dialyzer, high flux or low flux, 1.2 / 1.4 / 1.6 / 1.8 / 2.0 square meters, manufactured in 2 factories China & Germany respectively which ensures higher quality.
You are welcome to Biolight always.
Website: www.blt.com.cn

Hansa Biopharma ...............................................................................................................Booth: 1.220
Hansa Biopharma is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary, antibody-degrading enzyme in late-stage clinical development for kidney transplant patients, with the potential for further development in other solid organ transplantation and acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects, including NiceR, through which the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology.
Website: www.hansamedical.com
Healthwell Medical Tech. Co., Ltd. is a company specialized in blood purification industry, it was founded by a team with more than 12 years experience of investment, operation and management in the field. It is committed to building kidney disease management and hemodialysis internet ecological chain with “Internet platform, smart equipment, consumables, dialysis treatment, big data, value-added services”, including building SAAS system cloud platform, producing intelligent equipment and supporting equipment, introducing domestic and foreign big health strategic platform, establishing chain dialysis center, setting up kidney disease management center, etc.
Website: www.healthwellmedical.com

HERCO Wassertechnik GmbH develops and offers complete water treatment solutions for dialysis applications since 1980. Products are: Water softeners, filters, reverse osmosis, ring main, bed head media panels, central concentrate distribution- and mixing systems. Reverse osmosis units for haemodialysis purposes according to MDD, TÜV approved.
Website: www.herco-wt.de

Immundiagnostik AG, founded in 1986 by Dr. F. P. Armbruster (CEO), is specialised on the development, production, and world-wide distribution of innovative parameters and detection methods for laboratory diagnostics and medical research. Focused on the development of immunological tools, of HPLC and molecular biology methods, and of new applications for mass spectrometry (LC-MS/MS), IDK concentrates on the development and production of laboratory diagnostics( from screening to monitoring). IDK holds a strong portfolio in markers of cardio-reno-vascular system, skeletal system, oxidative stress/anti-aging, gastroenterology and nutrition. The company owns more than 35 patents worldwide.
Website: www.immundiagnostik.com
Exhibitors

Immuno-Biological Laboratories (IBL-Japan) .................................................................Booth: 114
IBL-Japan is a profound antibody and ELISA producer with unique and niche biomarkers in kidney disease research such as α-Klotho, Gd-IgA1, Angiotensinogen, soluble (Pro) renin receptor, AIM and so on. α-Klotho ELISA supplied by IBL-Japan is widely used in aging related research including kidney failure and Alzheimer’s Disease. IBL's Gd-IgA1 ELISA and antibody KM55 are also supplied as novel useful tools of IgA Nephropathy (IgAN) in basic and clinical research. Bio-Connect Diagnostics based in Netherland who is an expert for suppling diagnostic and research products is officially appointed as a distributor for IBL-Japan products in the European market.
Website: www.ibl-japan.co.jp/en/

INUMA PHARM ..............................................................................................................Booth: 1.420
Imuna Pharm is the biggest producer of Dialysis and Infusion solutions in Slovak republic with over 60 years of experience. Imuna has most modern manufacturing facility, built 3 years ago. Currently offers contract manufacturing services in production of single & multi-chamber bags from 100ml to 5000ml. IMUNA has its own branded products while manufacturing for other multinational companies as well. Imuna is holder of EU GMP and ISO standards. Few years ago Imuna has started with preparation for market launch in US territories. Imuna also produce Citrate solutions, various drugs as immunomodulators, food supplements, tablets and Cell implants.
Website: www.imuna.sk/en

InBody CO. LTD ............................................................................................................Booth: 075
InBody is a body composition analyzer manufacturing company based in Seoul, Korea and it has developed a solid foundation to create a reputation as the leaders of the industry not only for its precise technology, but also through its customer education and service system which stands parallel to the company’s core value “Education, Motivation, Application, and Innovation” InBody has been chosen by many noticeable references throughout various industries such as hospitals, sports clubs, global corporate’s, fitness centers and etc. InBody is dedicated to inspiring and leading people to live a healthier life, so that one day health will not only be measured by knowing your weight but by having an accurate insight in your body composition.
Website: www.inbody.com/global
Infomed SA .................................................................................................................................................. Booth: 1.060
Infomed, worldwide player on blood purification devices offers complete solutions for chronic and acute renal replacement (homecare and hospital environment) and for plasma therapies. Active since 1997, Infomed continuously innovates to create devices designed to reach your topmost needs. Dimi, our homecare dialysis device, is the partner for a new life at home. Dimi was thought to offer the freedom to provide the optimal treatment conditions fulfilling the patient requirements. Our products are adapted for adult, child and babies. Infomed is your trustful supporter for your extracorporeal project.
Website: www.infomed.biz

International Society of Nephrology ........................................................................................................ Booth: 825
The International Society of Nephrology (ISN) is advancing kidney care worldwide. Through our scientific and capacity-building activities in advocacy, education and research, we bridge gaps in global kidney care, engaging in a collaborative effort to improve kidney disease prevention, diagnosis and treatment. With over 10,000 professional members from over 150 countries, the ISN represents a wide international network and an efficient platform for timely scientific exchange, debate and communication between healthcare professionals involved in preventing and treating kidney disease. By collaborating with more than 100 national and regional societies, we reach out to an additional 30,000 health professionals globally.
Website: www.theisn.org

IPNA 2019 Congress .................................................................................................................................... Booth: 1.152
The International Pediatric Nephrology Association (IPNA) boasts 1500 pediatric nephrologists and medical professionals from 103 different countries. The Association is committed to disseminating knowledge concerning kidney disease in children in areas where care is most needed. The IPNA Congress is held every three years; the next IPNA Congress will be held on October 17-21, 2019 in Venice (Italy). The IPNA Congress is a very important occasion to meet internationally renowned specialists, present new research projects and also a networking moment that will enable Association’s members to make decisions as per the next steps to be taken for the future of Pediatric Nephrology.
Website: www.ipna2019.org
ISPD - International Society for Peritoneal Dialysis

The ISPD promotes the global uptake, practice and optimal outcomes of Peritoneal Dialysis through enhanced advocacy, research and education to help improve the health and well-being of people affected by acute kidney injury or living with end-stage kidney disease.

Website: www.ispd.org

Jafron Biomedical Co., Ltd.

Jafron is mainly engaged in “Disposable Hemoperfusion Cartridge” and other Chinese-created and world-leading products. Its market share ranks first in the hemoperfusion industry, covering more than 3,400 large and medium-sized hospitals in over 30 provinces in domestic market. Meanwhile, more than 30 countries are widely using Jafron’s hemoperfusion products in poisoning, critical disease, kidney disease, liver disease, autoimmune disease and other fields, treating hundreds of thousands of patients every year.

Website: www.jafron.com

JAPANESE SOCIETY OF NEPHROLOGY

The mission of the JSN is to aid in the practice and study of Nephrology. In order to achieve this the JSN conducts a range of activities. These include holding regular meetings as a forum for the diffusion of information, producing regular journals, coordinating clinical research, promoting cooperation with related societies in Japan and internationally, as well as providing recognition to those who have made significant contributions in the field of Nephrology.

Website: www.jsn.or.jp/en/
Jiangxi Hongda Medical Equipment Group Ltd. ................................................................. Booth: 165
Jiangxi Hongda Medical Equipment Group Ltd. is a Chinese leading manufacturer of disposable medical devices. Hemodialysis product like Hemodialysis blood line and A.V. Fistula needle is our main product marketing and promoting orientation in the next two years, the two products have been registered in our SFDA since 2015, now have been rapidly entered into the local market and largely exporting to Southeast Asian Countries with high level of quality standard and creditable service.
Website: www.jxhd.cn

JIANGXI SANXIN MEDTEC CO.,LTD .................................................................................... Booth: 630
Jiangxi SanXin Medtec Co.,ltd is a public company since 1997, which is specialist in Renal care solutions with 5 manufacturing bases in China with more than 1500 employees. The company has 71 patents and 62 registered products with CE, FDA(510K),CMD,WHO. There are four product lines including Hemodialysis solutions, Injection, Infusions and catheters.
Website: www.sanxin-med.com

Joline GmbH & Co. KG................................................................. Booth: 655
Joline is an internationally active medical device company located in the South of Germany with more than 15 years experience in minimally invasice therapies. Joline is an expert provider of catheter, balloon and stent technology for varoiur medical applications and maintains an important tradition of “Made in Germany” quality in all ist products and services. All Joline products are developed and produced exclusively in Germany. We integrate quality aspects in our daily work and strive to meet the high standards of our customers. The highest priority we place on the health and safety of our patients.
Website: www.joline.de
Journal of Kidney Care (JKC) ..................................................................................................................Booth: 800
Journal of Kidney Care (JKC) is the essential bi-monthly peer-reviewed publication for all members of the multidisciplinary renal team. It covers several clinical areas of renal medicine, such as dialysis, transplantation, diabetes, anaemia, pharmacy and nutrition. JKC’s content is aimed at doctors, nurses, healthcare assistants, dietitians, pharmacists, physiotherapists, paediatric specialists, clinical technologists, social workers, vascular access specialists, and transplant surgeons and coordinators specialising in kidney care. In the UK it is also the official journal for both the British Renal Society (BRS) and the Association of Nephrology Nurses UK (ANN UK).
Website: www.magonlinelibrary.com/journal/jokc

KARGER Publishers ..................................................................................................................Booth: 615
S. Karger Medical Publishers is a publishing house whose titles in the field of nephrology include several scientific journals, e.g. ‘Kidney Diseases’ and ‘Nephron’ as well as the renowned book series ‘Contributions to Nephrology’. New releases presented include the titles ‘Remote Patient Management in Peritoneal Dialysis’ and ‘Recent Advances in Pathogenesis and Treatment of Kidney Diseases’. Publications are accessible online at www.karger.com/nephrology, with full-text search of articles, pay-per-view options and many other services. Founded 129 years ago, this Swiss-based family-owned publishing house combines highly sophisticated production technology with customized services for its authors, editors and readers.
Website: www.karger.com

KDIGO (Kidney Disease: Improving Global Outcomes) ......................................................................Booth: 1.285
Kidney Disease: Improving Global Outcomes (KDIGO) is an independent foundation incorporated in Belgium accountable to the public and the patients it serves. Its mission is to improve the care and outcomes of kidney disease patients worldwide through the development and implementation of global clinical practice guidelines. KDIGO has published 10 clinical practice guidelines to date. New guidelines are under development and guideline update projects are currently underway as well. KDIGO also has a Global Network of more than 1200 prominent volunteers from around the world. They serve on guideline work groups, conference steering committees and its governing body, the Executive Committee.
Website: www.kdigo.org
Exhibitors

**LiKAMED**

LiKAMED is a globally leading manufacturer of therapy chairs. Our products combine quality, patient comfort, longevity and cost efficiency with design and more than 40 years of experience. In addition to a wide range of products, we also offer service and technical expertise to cover every needs of our customers all over the world.
Website: www.likamed.de

**Lonshine Technologies Inc.**

Lonshine Technologies Inc. is a high-tech manufacturer and service provider that specializes in R&D, manufacturing and distribution of smart mobile ultrasonic imaging systems. We developed the very first handheld smart ultrasound in China. Our company owns the complete intellectual properties of all our products, and it is ISO&CE certified by TUV in Germany. Our core R&D team boasts a proud group of overseas scholars. With offices in Suzhou, in Beijing and Chengdu, Lonshinetech is confident in making modern medical technology affordable with uncompromising quality.
Website: www.lonshinetech.com

**Maider Medical Industry Equipment Co., Ltd.**

Maider is a national leading hi-tech enterprise in the field of automation, engaged in developing and manufacturing of sterile medical products automation machines, to provide optimum automation solutions for global customers. Abundant experiences, high quality products and deeply understanding towards customers, Maider brings big success for more than 100 customers from all over the world.
Website: www.maiderchina.com

**MALTRON INTERNATIONAL LIMITED**

Dry weight assessments in patients with chronic kidney disease remains a major challenge especially for complicated patients. BioScan touch i8 is a non-invasive device which provides fast & accurate measurement helping prevent cardiovascular morbidity in dialysis patients. Early diagnosis plays an important role, take control, make a difference, be proactive & understand changes in body composition, particularly in patients receiving long term hemodialysis. Assessment of body composition & fluid volume is important & should be performed in all patients. BioScan touch i8 provides healthcare professionals with an objective measure of patients along with targets for interventions which could improve patient experience & outcome.
Website: www.maltronint.com
MaXimus

MaXimus is an intelligent data analytics platform intended for controlling diagnosis treatment and business processes in the medicine and healthcare. Data management system for high efficiency in the health care business; All guidelines and regulations embedded to guide medical staff to reach the goal with the best quality and low cost; Customization of any regulations possible; Telemedicine used to lower treatment cost and increase results; “Data knowledge” inside the system as a service to help medical staff in business processes; Full telemetry and data aggregation according to business requirements “two clicks“ to get proper information; “Data mining“ implementation Intellectual health records with stuff messaging to help fast feedback reaction;
Address: 3/1, Kulneva str., Moscow, 121170, Russian Federation. RuMed
Website: www.nefrosovet.ru

MEDCOMP

This year the innovators of Medcomp proudly introduce the Symetrex Long Term Hemodialysis Catheter, engineered and designed to preserve access. Symetrex combines RF tipping technology with a unique anti-wall suction design to produce low recirculation, high flow catheter that meets the demands of the clinician. As well as Symetrex we will also be exhibiting Medcomp’s flagship product Split Cath. The most innovative long-term dialysis catheter design in the last 15 years. Rounding off the dialysis line Medcomp also offers DuraLock-C, an antibacterial anticoagulant catheter locking solution. Duralock is provided in pre-filled syringes packed and sterilized in Tyvek pouches for a more efficient off dialysis protocol.
Website: www.medcompnet.com

MediBeacon

MediBeacon develops proprietary, non-invasive, real-time monitoring systems for kidney function, gastrointestinal permeability and other light-activated diagnostics. MediBeacon’s transdermal GFR monitor and fluorescent tracer agent are used to measure Glomerular Filtration Rate (GFR) in preclinical research. The device allows to measure and track GFR over time, without requiring the animal to be restrained. The system obviates the need for blood sampling, urine collection, and laboratory assays and thus enables superior trial design. Use of the technology enhances preclinical kidney therapeutic assessment, nephrotoxicity evaluation and fundamental understanding of kidney function in animals.
Website: www.medibeacon.com
MEDICA

MEDICA SPA ........................................................................................................................................... Booth: 040
Medica Group is operating since 1985 in the biomedical district of Mirandola (Italy). Development of innovative products for blood purification has always been company’s core business, manufactured in two facilities, one in Italy and one in Tunisia, with a highly automated production systems. Hollow fiber spinning for hemofiltration, plasmapheresis and water ultrafiltration represents the core technology of the company. In recent years, the drive to find new products and markets has led the Group to launch the Medica Water Division, for the development and commercialization of microbial water filtration devices and to develop products for bio-regenerative medicine.
Website: www.medica.it

MEDICAL DEVICES CORPORATION........................................................................................................ Booth: 280
Medical Devices Corporation is a company specialising in renal replacement therapy, established by a group of entrepreneurs comprising nephrologists, dialysis nurse and researchers who believe in balancing sustainable business growth with corporate social responsibility. Our Company offer patients the flexibility, comfort and convenience of home-based dialysis. We offer a range safe and affordable products and innovations that is revolutionising the renal care industry around the world. We have developed an ultra-portable PD Cycler that less than 3kg and support real-time remote patient monitoring.
Website: www.medical-devices-corp.com

Medikit Co., Ltd. ........................................................................................................................................ Booth: 1.280
Medikit is one of the world’s leading manufacturers in certain categories of vascular access medical devices, especially fluorine resin HD catheter for use by hospitals and emergency services. Our is a global medical technology company whose goal is to fundamentally improve the quality of health through our medical devices. We take our social responsibility seriously and have a positive vision for the future: to become an organization that, by helping minimize unnecessary suffering and death from disease, will be recognized and respected as one of the world’s most reliable and best performing companies.
Website: www.medikit.co.jp/english/index.html
MEDITECHLAB - SUISSEMED TECHNOLOGIES.................................................................Booth: 255
Suisse Med Technologies is a market leader in providing synthetic hollow fiber spinning lines and
dialyser assembly lines. Our technology is designed to deliver optimal cost of goods while ensuring
worldwide quality standards. Our fibre technologies cover PSU, PSE and PVDF for both Blood and
water purification. Recent advances allow us to produce Virus free water for dialysis or industries. We
support our customers achieve their financial goals by offering a wide range of additional services such
as go-to-market strategies, regulatory compliance, ISO-10993 compliant devices and qualified raw
materials. Our subsidiary, Meditechlab, helps its customers to meet international norms: ISO 9001,ISO
13485 and 93/42/EEC (CE-mark).
Website: www.suissemt.com

Medtronic ...............................................................................................................................Booth: 125
Making healthcare better is our priority and we believe technology can play an even greater role in
improving people’s lives. In addition to alleviating pain, restoring health, extending lives, we work in
partnership with others to create seamless, more efficient care. Learn how we’re taking healthcare
Further, Together at Bellco.net
Website: www.bellco.net/default.aspx?lang=en

MedVision AG .....................................................................................................................Booth: 1.055
As an internationally operating system supplier for medical data processing, MedVision stands for
quality and innovation. For over 25 years, we have been developing efficient and economical standard
application software for the medical sector. With the NEPHRO information system and the accredited
Benchmarking Analyser QuasyNeT and SiQuiD, MedVision is market leader for nephrological information
systems in Germany. OEM versions of our information system are sold worldwide by our cooperation
partners. And globally, we are technology leader for IT in dialysis facilities.
Website: www.medvision.eu
MedXL Europe BV ..........................................................Booth: 035
MedXL designs and manufactures medical devices and prefilled syringes for the North American, South American, European and North African medical and pharmaceutical industries. MedXL produce the well know lock solution in a prefilled citrate syringe CITRAFLOW and saline flush syringes PraxiJect and in a combi pack as PRAXIFLOW. Our 25,000 square ft facility in Canada, is equipped with Class 10,000 clean rooms. Within these areas, we perform manufacturing in isolator cells which allow us to reach Class 100 ratings for certain products. Our workstations for prefilled syringe filling have particle and bioburden counts that are 4 times more stringent than those required by industry standards.
Web site: www.medxl-europe.com
Website: www.medxl-europe.com

Mundipharma..............................................................Booth: 1.030
The Mundipharma network of independent associated companies was founded by doctors over 60 years ago to meet the unmet needs of patients. The network now operates in over 120 countries worldwide. The network aims to develop and accelerate patient access to innovative medicines across our specialist driven primary care (respiratory, diabetes), secondary care (pain and oncology) and biosimilars platforms.
Website: www.mundipharma.com

Nanning Passion Medical Equipment Co., Ltd ..................................................Booth: 1.156
NanNing Passion Medical Equipment Co., Ltd is specialized in researching, developing manufacturing and distributing of medical ICU equipment and hemodialysis products. We have strong technical strength, comprising an experienced team with expertise and high technologies from Europe. Having introduced advanced manufacturing and inspecting facilities. We are able to perform dynamic monitoring covering full process of materials purchase, production and finished products. Presently Passion medical specializes in manufacturing and distributing dialysis chair, blood donor chair and multi function ICU BED. ISO9001, ISO13485, CE and FDA certifications, product patent passed.
Website: www.passionmedical.net
NephroCan .................................................................Booth: 115
NephroCan Inc. is a top Canadian company in the hemodialysis field, committed to improving the quality of life for patients with End Stage Renal Disease (ESRD) by offering innovative and trusted hemodialysis consumables and machinery. With our accumulated knowledge and over 25 years of expertise, NephroCan is consistently striving to offer the highest quality hemodialysis products. Our promise is to improve therapy methods year after year.
Website: www.nephrocan.com

NephroFlow .................................................................Booth: 985
NephroFlow is a process driven software platform that actively supports nurses and nephrologists in every step of the care trajectory. It provides them with valuable work instruments to facilitate a fluent transfer between treatment planning, preparation, administration and follow-up. By eliminating administrative overhead, facilitating better communication and using realtime data, NephroFlow’s mobile and desktop work instruments can help save up to 45 minutes per day per nurse and can help improve patient safety, quality of care, work efficiency and work satisfaction.
NephroFlow helps you move post the post-it in a critical care environment.
Website: www.nephroflow.com

Nephrokit Innovation .................................................................Booth: 1370
Nephrokit Innovation is an inventive French company based in the suburbs of Paris, founded by Dr. Mokhtar Chawki, a skilled nephrologist. Inventive devices Papyrus, Iris and Mozaik are devoted to reduce fistula bleeding before, during and after dialysis. The company has also developed Samurai pouch for central catheters and exit sites peritoneal dialysis catheters. All the devices are Class 1, designed and manufactured in France, and they are sterile and CE labelled. We are mainly based in France but have suppliers in Scandinavia, Italy, The Netherlands, Belgium, Switzerland, Morocco and the Middle East. Nephrokit is on the way to build a joint venture for USA and to register the devices to FDA. All the devices are patented by Nephrokit and exclusive property of the company.
Website: www.nephrokit.fr
NIKKISO

Nikkiso, a pioneer in Dialysis and Acute Blood Purification, strives to advance complex medical technologies that optimise patient care in End-stage Renal and Critical Care areas. Through our commitment to improving clinical efficiency and patient experience, Nikkiso has built a global reputation for unparalleled quality and innovation as evidenced in the launches of DBB-EXA, the first fully automated dialysis system and of Aquarius+, which enables the care-giver to deliver a complete range of CRRT modalities, whether utilising heparin or citrate as the anticoagulant.

Visit the Nikkiso booth (Nr. 870) and discover our latest innovations in medical technology.

Website: www.nikkisomedical.com

NINGBO TIANYI MEDICAL APPLIANCE CO., LTD

Ningbo Tianyi Medical Appliance Co., Ltd

Tianyimed is an famous medical supplies enterprise, equipped with advanced facilities, that integrates R&D, sourcing, manufacturing, marketing & sales and after-service since 1988. The company specializes in the production of disposable medical polymer appliances. The major products consist of seven categories: Dialysis consumables, feeding devices and catheters, puncture injection equipment, physical therapy and rehabilitation equipment, medical polymer materials and high quality products, medical hygienic medical and surgical dressing materials, ward nursing equipment and apparatus.

Website: www.tianyimedical.cn

NIPOKA

NIPOKA helps researchers to determine the exact foot process morphology in biopsies and kidney sections of mice and rat. With our revolutionary procedure PEMP, it is finally possible to reliably identify foot process effacement without any bias. NIPOKA is a planned spin-off from the University Greifswald.

Website: www.nipoka.com
Nipro Medical Europe ...........................................................................................................Booth: 130
Nipro Medical Europe is part of Nipro Corporation Japan, a leading global healthcare company established in 1954. With over 27,000 employees worldwide, Nipro serves the Medical Device, Pharmaceutical, and Pharmaceutical Packaging industries. Nipro is a global market leader with over 5 decades providing renal solutions for dialysis and dialysis-related treatment. We specialize in developing dialysis machines, water treatment systems, and a comprehensive portfolio of disposable medical equipment. In order to address the needs of patients, healthcare professionals, and procurement managers alike, Nipro is driven by innovation and patient safety to offer the highest quality products that optimize time, effort, and costs.
Website: www.nipro-europegroupcompanies.com

Novak M ..............................................................................................................................Booth: 1.450
Novak M together with Novak M Swiss and Novak M Deutschland is a worldwide oriented company with a clear vision. Since 1979, we have been developing and manufacturing medical equipment to help professionals bring treatment to higher level. An important step towards foreign recognition was the Red Dot Award in 2009.
Website: www.novak-m.si

NxStage Medical Inc .............................................................................................................Booth: 215
NxStage provides the life changing benefits of home hemodialysis to a wider range of patients than ever before, with a simple, flexible and portable home hemodialysis therapy solution specifically designed for the patient. NxStage is more than a company; we are leading the renal revolution. Our innovative products are helping to shape and transform renal care.
Website: www.nxstage.com
Omeros Corporation ................................................................. Booth: 1.150
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing therapeutics for large-market and orphan indications targeting inflammation and complement-mediated diseases. Leading Omeros’ pipeline is narsoplimab (OMS721), a fully human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the complement system’s lectin pathway. Phase 2 and 3 clinical programs are ongoing in hematopoietic stem cell-associated thrombotic microangiopathy (HSCT-TMA), IgA nephropathy, and atypical hemolytic-uremic syndrome. For HSCT-TMA and IgA nephropathy, the FDA has granted breakthrough therapy designation.
Website: www.omeros.com

Oxford University Press .......................................................... Booth: 610
Oxford University Press is a leading publisher in nephrology journals, books and online products. Our worldwide publishing furthers the University's objectives of excellence in scholarship, research, and education. Visit us at stand 610 to discover the latest content and news from Nephrology Dialysis Transplantation (ndt) and Clinical Kidney Journal (ckj), the official journals of the ERA-EDTA. You can also browse our extensive collection of books, available to buy with an exclusive 20% conference discount and 35% discount for ERA-EDTA members.
Website: www.oup.com

PakuMed medical products gmbh , Germany .......................... Booth: 305
PakuMed medical products gmbh is founded in 1990 in Germany specialized in the development, manufacture and worldwide distribution of special medical products for oncology, nephrology, surgery, interventional radiology. Highly qualified medical competence, flexibility and close cooperation with our customers as well as best service are our strong points. Innovative products complete our product range. (e.g. titanium port systems for apheresis and dialysis treatment) Every system from PakuMed stands for three aspects: they are tailored for the indications and requirements: they are simple and safe in operation and during treatment, and offer a high degree of wearing comfort. Made in Germany.
Website: www.pakumed.de
Peripal AG ......................................................... Booth: 1.225B Innovation Hub
Peripal is a Swiss med-tech start-up company based in Zurich. Our PeriSafe® device is a Swiss innovation and is designed to help PD patients to perform their daily dialysis treatment. Unlike current systems, connections are performed inside of a protected device, and the patient does not need to touch transfer set nor dialysis lines while they’re open. In addition, the cumbersome breaking of the dialysis bag frangible and the clamping of the dialysis lines are replaced by simply pushing a button. With making the PD treatment simpler, more standardized and processed in a protected environment, Peripal's vision is to enable more patients to perform the treatment at home. Website: www.peripal.com

Physicians' Academy for Cardiovascular Education (PACE-CME) .................. Booth: 1.130
The Physicians' Academy for Cardiovascular Education (PACE-CME) foundation is an organization that is established to meet the need for high-quality medical education. The rationale for establishing PACE-CME comes from the recognition that physician education plays an increasingly important role in our efforts to reduce the global burden of cardiovascular disease, diabetes and kidney disease. The PACE foundation is an initiative of renowned experts in different areas of cardiovascular disease. Since its inception, PACE-CME has initiated a large number of high quality educational initiatives worldwide. Website: www.pace-cme.org

Physidia ......................................................... Booth: 1.045
Physidia is a French company created in 2010, with an expertise in the development, manufacturing and distribution of innovative technology for daily home dialysis. Physidia is present today in 16 countries, operating directly in France and The United Kingdom and through distributor partners in the rest of Europe. Physidia's innovations are based on several technological breaking points, offering a robust, portable and connected device, whilst ensuring a performing treatment in total autonomy. Created by an expert team, Physidia S3 monitor has been specifically developed to respond to the needs of simplicity and safety of ESRD patients in home hemodialysis. Website: www.physidia.com
Exhibitors

PKD International

Global alliance of patient organisations dedicated to improving the lives of children, adults and families affected by polycystic kidney disease. We are a non-governmental association, formed in 2007.
Website: www.pkdinternational.org

Plinth Medical

Plinth Medical is a leading UK manufacturer of specialist standard and bariatric examination and treatment solutions for the medical industry. Our extensive range includes products specifically designed for busy dialysis units, ideal for handling high risk patients for procedures such as dialysis, peritoneal dialysis, plasmapheresis diagnosis, oncology and chemotherapy. With over 40 years of continuous experience in the medical furniture world, our team have the knowledge, dedication and a range of products second to none. All our products are CE marked, come with a 5 year warranty and we hold ISO9001 accreditation. We are currently on the lookout for new distributors and partners.
Website: www.plinthmedical.com

Quanta Dialysis Technologies

Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use both in the clinic and the home. Quanta’s lead product SC+ is designed to empower dialysis patients by giving them greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. Quanta is based in Alcester, UK, and was founded in 2008 as a spin out from IMI plc. For more information, please visit www.quantadt.com.
Website: www.quantadt.com

Reata Pharmaceuticals

Reata’s mission is to develop novel therapeutics for patients with serious and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Our lead product candidates, bardoxolone methyl and omaveloxolone, are Nrf2 activators. Bardoxolone methyl is currently in a pivotal Phase 2/3 (CARDINAL) study for the treatment of chronic kidney disease caused by Alport syndrome and a pivotal Phase 3 (FALCON) study for treatment of ADPKD.
Website: www.reatapharma.com
Retrophin

Retrophin is a biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options.
Website: www.retrophin.com

Rontis AG

Rontis is a Switzerland-based company with a history in R&D & manufacturing of medical devices, pharmaceuticals, nutrition and dermaceutical products and provides of dialysis services. We produce disposables for Nephrology, Liquid Administration and products for Interventional Cardiology & Radiology and kyphoplasty. We also provide OEM services and custom-made solutions. Pharmaceuticals: Rontis has a vertically integrated manufacturing system that is supported by our the R&D division. Infant Nutrition / Consumer Healthcare: we have developed a range of infant / baby nutrition formulas, as well as specialized dermaticals for babies and children.
Website: www.rontis.com

Sanofi Genzyme

Sanofi Genzyme’s sense of responsibility is grounded in our commitment to patients. We were founded to address the needs of patients with rare diseases who previously had no available treatment options, and we remain committed to advancing the understanding of these diseases and developing new therapies for unmet medical needs. We establish patient assistance and humanitarian programs help build sustainable healthcare systems, partner with advocacy groups on disease awareness and patient support, and provide a broad range of services, all on behalf of our number one priority: patients.
Website: www.sanofigenzyme.com

Serumwerk Bernburg AG

Serumwerk Bernburg AG is a medium-sized pharmaceutical company with more than 60 years’ tradition in the development and production of medicinal products, medical devices and active pharmaceutical ingredients. We have in recent years focused increasingly on the development of innovative products based on natural biopolymers and an iron preparation to prevent anaemia, which are internationally at the forefront and are marketed worldwide in cooperation with selected partners. Our core business is based on production at our German site, whereby we guarantee high quality standards and secure regional jobs. Our sales partners in more than 60 countries have shown trust in our “Made in Germany” products.
Website: www.serumwerk.com
**Exhibitors**

**SIN-ERGY SRL** .......................................................................................................................... Booth: 124
The Italian Society of Nephrology represent Italian nephrologists and has about 3000 members. It promotes training activities managing an annual National Congress, organizing an intensive training week a year focused on special topics and encourages young researchers’ scientific training through scholarships and financing research projects. The Society is also committed to the kidney disease prevention, early diagnosis and organ donation culture awareness. It manages several registers: Dialysis and Transplantation, Italian Register of Renal Biopsies, National Register of Therapeutic Apheresis, Register Peritoneal Dialysis, Register of the Polycystic Kidney.
Website: www.sinitaly.org

**Suzhou Jun Kang Medical Technology Co., Ltd.** ............................................................. Booth: 1.365
Suzhou Jun Kang Medical Technology Co., Ltd. is a high-tech joint venture of modern manufacturing enterprise specializes in extracorporeal circulation and blood purification products. Currently the main products are Jun Kang Medical high flux and hollow fiber dialyzers. We also can produce and supply with the core material of dialyzer-PES membrane. We have setup the Class 100,000 for the spinning and injection molding workshops, Class 10,000 assembly workshop; obtained CE and ISO13485 certificate for hemodialyzer. With excellent quality, the products of dialyzer and membrane have been exporting to American, Europe, Southeast Asia, Middle East, African countries, and so on around the world.
Website: www.junkangmedical.com/html/en/

**TauroPharm GmbH** ................................................................................................................ Booth: 300
TauroPharm GmbH is a life science company specialized in antimicrobial medical devices. One of the company’s core interests is to offer a safe and effective technology for locking central venous access devices (catheters and ports). TauroLock™, a non-antibiotic lock solution, which is capable of dramatically reducing catheter related blood stream infections (CRBSI) is free of side-effects. The active compound is taurolidine which is not an antibiotic, but a derivative of an amino acid. TauroLock™ is highly effective in eradicating bacteria and fungi and has been successfully tested on more than five hundred organisms, including multi resistant forms such as MRSA and VRE. It is to be used in dialysis, oncology, intensive care and parenteral nutrition. To improve catheter patency TauroLock™ products contain 4% citrate and in addition heparin or urokinase.
Website: www.taurolock.de
Toray Medical Co., Ltd .................................................................Booth: 680
Toray Medical Co., Ltd. is a member company of Toray Group, specializing in healthcare field business. Toray is a leading manufacturer of synthetic fibers and dedicated to the development of dialysis products under its corporate slogan, “Innovation by Chemistry”. Toray supports high quality and advanced medical care with bio-compatible polymethylmethacrylate dialyzer “FILTRYZER”, high flux polysulfone dialyzer “TORAYSULFONE”, “TORAYLIGHT” and dialysis machine.
Website: www.toray-medical.com/en/

TRANSONIC .......................................................................................Booth: 1.020
Transonic is the global leader in blood flow measurement technology. Transonic’s gold standard Hemodialysis Monitor has revolutionized hemodialysis by assessment of dialysis adequacy with delivered blood flow and recirculation measurements, vascular access patency through access flow measurements, and cardiac function through measurement of cardiac output and derived parameters.
Website: www.transonic.com

Triomed AB .........................................................................................Booth: 760
Keeping patients on peritoneal dialysis (PD) is beneficial both for patients and health care providers. Patients transition from PD to hemodialysis for a number of reasons. Some of the most important are peritonitis, inadequate dialysis and/or ultrafiltration and the logistic burden of PD. Triomed’s vision is to develop systems that ensure that PD remains the preferred dialysis alternative both for patients and health care providers. Supported by world leading medical experts and engineers, Triomed is developing revolutionary therapy systems, Carry Life Renal and Carry Life UF, that are effective, simple, safe, ergonomic and economic.
Website: www.triomed.se
Vifor Fresenius Medical Care Renal Pharma ................................................................. Booth: 140
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma.
Website: www.vfmcrp.com; www.viforpharma.com

WEGO Blood Purification Business Group ................................................................. Booth: 875
WEGO Group was established in 1988, now it has 10 business groups with 90+ subsidiaries, business segments from medical polymer products, orthopedic products, blood purification products & clinics, biotechnology products, medicine products, cardiovascular consumables to real estate, financing, etc. WEGO Blood Purification Business Group was founded in 2004, it is devoted to blood purification field. We manage 7 subsidiaries and cooperate with 2 international medical enterprises - Terumo and Nikkiso. With hemodialysis, peritoneal dialysis and dialysis clinics as our strategic orientation, we offer the complete blood purification related products and service to serve global kidney disease patients whole heartedly.

Wisepress Medical Bookshop .................................................................................... Booth: 600
Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.
Website: www.wisepress.com
## CEPD Programme at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>G1</th>
<th>G2A</th>
<th>G2B</th>
<th>F1</th>
<th>A1</th>
<th>A2</th>
<th>A3</th>
<th>A4</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 - 08.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.45 - 12.25</td>
<td>CEPD 1 - Primary &amp; Secondary GN, vasculitis and autoimmune diseases</td>
<td>CEPD 2 - CKD</td>
<td>CEPD 3 - Hypertension, diabetes, CV diseases in CKD</td>
<td>CEPD 4 - Bone Mineral disorders in CKD</td>
<td>CEPD 5 - Genetic diseases and rare diseases</td>
<td>CEPD 6 - Basic &amp; translational Nephrology</td>
<td>CEPD 7 - Nephropathology course</td>
<td></td>
</tr>
<tr>
<td>12.25 - 13.00</td>
<td>Lunch break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00 - 16.40</td>
<td>CEPD 8 - Haemodialysis and vascular access</td>
<td>CEPD 9 - Renal transplantation</td>
<td>CEPD 10 - AKI</td>
<td>CEPD 11 - Peritoneal dialysis</td>
<td>CEPD 12 - Electrolytes and urolithiasis</td>
<td>CEPD 13 - ERA-EDTA Registry</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00 - 18.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00 - 20.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00 - 19.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Congress programme - see next table

### Legend

- **Fluids and electrolytes, tubular transport, physiology**
- **Hereditary disorders, development, pregnancy, paediatric nephrology**
- **Glomerular diseases and general clinical nephrology**
- **Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging**
- **End Stage Renal Disease and dialysis**
- **Home therapies, peritoneal dialysis**
- **Transplantation and immunology**
- **Hypertension, diabetes, vascular diseases**
- **Acute Kidney Injury and Intensive care nephrology**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-08.30</td>
<td>Congress Opening</td>
</tr>
<tr>
<td>08.45-12.25</td>
<td></td>
</tr>
<tr>
<td>12.25-13.00</td>
<td>Lunch break</td>
</tr>
<tr>
<td>13.00-16.40</td>
<td></td>
</tr>
<tr>
<td>16.00-20.00</td>
<td>Exhibition</td>
</tr>
<tr>
<td>18.00-19.30</td>
<td>Welcome Reception</td>
</tr>
<tr>
<td>17.00-18.00</td>
<td>Welcome Ceremony + Lecture Rafael Yuste “Diseases of emergence”</td>
</tr>
<tr>
<td>15.15-16.45</td>
<td>Special Session Latest DKD clinical trials: changing the course of the disease</td>
</tr>
</tbody>
</table>

CEPD programme - see previous table

LEGENDA

- Fluids and electrolytes, tubular transport, physiology
- Hereditary disorders, development, pregnancy, paediatric nephrology
- Glomerular diseases and general clinical nephrology
- Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging
- End Stage Renal Disease and dialysis
- Home therapies, peritoneal dialysis
- Transplantation and immunology
- Hypertension, diabetes, vascular diseases
- Acute Kidney Injury and intensive care nephrology
LEGENDA

Fluids and electrolytes, tubular transport, physiology

Hereditary disorders, development, pregnancy, paediatric nephrology

Glomerular diseases and general clinical nephrology

Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging

End Stage Renal Disease and dialysis

Home therapies, peritoneal dialysis

Transplantation and immunology

Hypertension, diabetes, vascular diseases

Acute Kidney Injury and intensive care nephrology

Programme at a Glance - Friday, June 14th, 2019

G1 G2A G2B F1 A1 A2 A3 A4 Presentation Theatre

08.00 - 09.30
S 01 - ERA-EDTA Registry
S 02 - Phosphate and FGF23
S 03 - Paediatric Nephrology
S 04 - The many facets of hypoxia in CKD
FC 01 - Molecular insight in renal pathology
FC 02 - What should CKD patients eat?
FC 03 - Vascular access
FC 04 - Bone disease in dialysis

09.30 - 10.45 Posters, coffee break and exhibition visit

PACE-CME Boehringer Ingelheim/Lilly
Baxter Healthcare Fresenius Medical Care
NxStage Medical AstraZeneca

10.45 - 11.30
PL 1 - Sanjay Jain "Interface of molecular mechanisms, pathology and genetics of developmental kidney diseases"

11.30 - 11.45 Break

11.45 - 13.15
S 05 - Late Breaking Clinical Trials
S 06 - The many faces of monoclonal gammopathy of undetermined significance
S 07 - Improving outcomes in DKD
S 08 - Redefining the ontology of kidney diseases using genomic analysis
S 09 - Brain and nervous system in CKD
FC 05 - Delivery of dialysis: a holistic approach
FC 06 - The next generation of transplant therapeutical approaches
FC 07 - Managing hypertension
FC 08 - Protein energy wasting and inflammation
FC 09 - Novel molecular mechanisms of diabetic nephropathy
FC 10 - Clinical CKD
FC 11 - Improving outcome in dialysis patients

13.15 - 14.45
Fresenius Medical Care
Baxter Healthcare
Charité-Vifor Fresenius Medical Care Renal Pharma
Novo Nordisk Amgen Europe MundiPharma
Sanofi Genzyme
Retrophin

15.00 - 16.30
S 10 - ASN Highlights
S 11 - ANCA-associated vasculitis
S 12 - Blood pressure targets
S 13 - Precision medicine for the sensitized transplant recipient
FC 08 - Protein energy wasting and inflammation
FC 09 - Novel molecular mechanisms of diabetic nephropathy
FC 10 - Clinical CKD
FC 11 - Improving outcome in dialysis patients
FC 12 - Genetics in kidney disease: unravelling complex interactions
FC 13 - Clinical nephrology: predicting outcome
FC 14 - AKI: still difficult to define
FC 15 - Novel discoveries in CKD pathophysiology
## Programme at a Glance - Friday, June 14th, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenters</th>
<th>Sponsors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 - 09.30</td>
<td>S 01 - ERA-EDTA Registry, S 02 - Phosphate and FGF23, S 03 - Paediatric Nephrology, S 04 - The many facets of hypoxia in CKD, FC 01 - Molecular insight in renal pathology, FC 02 - What should CKD patients eat?</td>
<td><strong>Presentation Theatre</strong></td>
<td></td>
</tr>
<tr>
<td>09.30 - 10.45</td>
<td>Posters, coffee break and exhibition visit</td>
<td><strong>PACE-CME Boehringer Ingelheim/Lilly, Baxter Healthcare, Fresenius Medical Care</strong></td>
<td><strong>NxStage Medical, AstraZeneca</strong></td>
</tr>
<tr>
<td>10.45 - 11.30</td>
<td>PL 1 - Sanjay Jain, &quot;Interface of molecular mechanisms, pathology and genetics of developmental kidney diseases&quot;</td>
<td><strong>Fresenius Medical Care, Baxter Healthcare, Charité-Vilor Fresenius Medical Care Renal Pharma, Novo Nordisk, Amgen Europe, Mundipharma, Sanofi Genzyme</strong></td>
<td><strong>Retrophin 13.15-14.00</strong></td>
</tr>
<tr>
<td>11.30 - 11.45</td>
<td>Break</td>
<td><strong>Fresenius Medical Care, Baxter Healthcare, Charité-Vilor Fresenius Medical Care Renal Pharma, Novo Nordisk, Amgen Europe, Mundipharma, Sanofi Genzyme</strong></td>
<td><strong>Retrophin 13.15-14.00</strong></td>
</tr>
<tr>
<td>11.45 - 13.15</td>
<td>S 05 - Late Breaking Clinical Trials</td>
<td><strong>S 06 - The many facets of monoclonal gammonopahy of undetermined significance, S 07 - Improving outcomes in DDK, S 08 - Redefining the ontology of kidney diseases using genomic analysis, S 09 - Brain and nervous system in CKD, FC 05 - Delivery of dialysis: a holistic approach, FC 06 - The next generation of transplant therapeutical approaches, FC 07 - Managing hypertension</strong></td>
<td><strong>Fresenius Medical Care, Baxter Healthcare, Charité-Vilor Fresenius Medical Care Renal Pharma, Novo Nordisk, Amgen Europe, Mundipharma, Sanofi Genzyme</strong></td>
</tr>
<tr>
<td>13.15 - 14.45</td>
<td>S 10 - ASN Highlights, S 11 - ANCA-associated vasculitis, S 12 - Blood pressure targets for the sensitized transplant recipient, S 13 - Precision medicine for the sensitized transplant recipient, FC 08 - Protein energy wasting and inflammation, FC 09 - Novel molecular mechanisms of diabetic nephropathy, FC 10 - Clinical CKD, FC 11 - Improving outcome in dialysis patients</td>
<td><strong>Baxter Healthcare, Charité-Vilor Fresenius Medical Care Renal Pharma, Novo Nordisk, Amgen Europe, Mundipharma, Sanofi Genzyme</strong></td>
<td><strong>Retrophin 13.15-14.00</strong></td>
</tr>
<tr>
<td>16.30 - 17.00</td>
<td>Posters, coffee break and exhibition visit</td>
<td><strong>Baxter Healthcare, Charité-Vilor Fresenius Medical Care Renal Pharma, Novo Nordisk, Amgen Europe, Mundipharma, Sanofi Genzyme</strong></td>
<td><strong>Retrophin 13.15-14.00</strong></td>
</tr>
<tr>
<td>17.00 - 18.30</td>
<td>S 18 - Fluids and electrolytes, tubular transport, physiology, Hereditary disorders, development, pregnancy, paediatric nephrology, Glomerular diseases and general clinical nephrology, Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging, End Stage Renal Disease and dialysis, Home therapies, peritoneal dialysis, Transplantation and immunology, Hypertension, diabetes, vascular diseases, Acute Kidney Injury and intensive care nephrology</td>
<td><strong>Baxter Healthcare, Charité-Vilor Fresenius Medical Care Renal Pharma, Novo Nordisk, Amgen Europe, Mundipharma, Sanofi Genzyme</strong></td>
<td><strong>Retrophin 13.15-14.00</strong></td>
</tr>
</tbody>
</table>

**Legend**
- Fluids and electrolytes, tubular transport, physiology
- Hereditary disorders, development, pregnancy, paediatric nephrology
- Glomerular diseases and general clinical nephrology
- Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging
- End Stage Renal Disease and dialysis
- Home therapies, peritoneal dialysis
- Transplantation and immunology
- Hypertension, diabetes, vascular diseases
- Acute Kidney Injury and intensive care nephrology

*www.era-edta2019.org*
LEGENDA
Fluids and electrolytes, tubular transport, physiology
Hereditary disorders, development, pregnancy, paediatric nephrology
Glomerular diseases and general clinical nephrology
Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging
End Stage Renal Disease and dialysis
Home therapies, peritoneal dialysis
Transplantation and immunology
Hypertension, diabetes, vascular diseases
Acute Kidney Injury and intensive care nephrology

Programme at a Glance - Saturday, June 15th, 2019

08.00 - 09.30
S 18 - Renal Replacement Therapy in the Intensive Care Unit
S 19 - Molecular mechanisms of kidney atrophy and fibrosis
S 20 - Haemodialysis. From incremental approaches to frequent treatments
S 21 - Regenerative medicine
S 22 - New insights in molecular mechanism of cardiovascular diseases in CKD
FC 16 - Cystic diseases: new genes and modifiers
FC 17 - Rehabilitation and physical exercise in CKD
FC 18 - Fighting DKD
FC 19 - Defining outcome in transplantation
FC 20 - Improving cardiovascular complications in CKD

09.30 - 10.45 Posters, coffee break and exhibition visit

ERA-EDTA General Assembly
PACE-CME-Vifor Fresenius Medical Care Renal Pharma
PACE-CME-Novo Nordisk
AstraZeneca Takeda Astellas Asahi Kasei Medical Europe

10.45 - 11.30
PL 2 - Katlin Susztak
"Single-cell transcriptomics in kidney disease"

11.30 - 11.45 Break

11.45 - 13.15
S 23 - Optimizing peritoneal dialysis prescription
S 24 - Complement mediated kidney injury
S 25 - Controversy: does haemodiafiltration improve patient outcomes and survival?
S 26 - CKD-MBD patterns and therapeutic approaches: update 2019
S 27 - The gut-kidney-cardiovascular axis
FC 18 - Fighting DKD
FC 19 - Defining outcome in transplantation
FC 20 - Improving cardiovascular complications in CKD

13.15 - 14.45
Vifor Fresenius Medical Care Renal Pharma
Alexion Pharmaceuticals
B.Braun Avitum PACE-CME-Resverlogix
Fresenius Kabi
Bayer AG
Amicus Therapeutics
Zydus Trans-Immune (A Division of Cadila Healthcare)

15.00 - 16.30
S 28 - Improving the organ donor pool
S 29 - Cardiovascular disease in CKD: risk factors and remedies
S 30 - The hidden risks of haemodialysis
S 31 - The role of diet in the prevention of CKD progression: food for thought
S 32 - The paradox of estimated GFR in the era of precision medicine
FC 21 - Immunological kidney diseases
FC 22 - CKD-MBD
FC 23 - ESAs and iron: anaemia and beyond
FC 24 - How to prevent AKI
FC 25 - Kidney diseases from childhood to adult
FC 26 - Experimental hypertension
FC 27 - Novel approaches to AKI: exosomes and RNA interference
FC 28 - Revisiting PD: a systems biology approach

16.30 - 17.00 Posters, coffee break and exhibition visit

17.00 - 18.30
S 32 - Home haemodialysis: on the move
S 33 - Overcoming age with frailty evaluation in the kidney transplant recipient
S 34 - Delivering good quality dialysis - what should we measure?
S 35 - The paradox of estimated GFR in the era of precision medicine
BUD2019 - tavole sino FP 0519.indd   4
03/06/19   17.03
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 - 09.30</td>
<td>S 18 - Renal Replacement Therapy in the Intensive Care Unit</td>
</tr>
<tr>
<td></td>
<td>S 19 - Molecular mechanisms of kidney atrophy and fibrosis</td>
</tr>
<tr>
<td></td>
<td>S 20 - Haemodialysis. From incremental approaches to frequent treatments</td>
</tr>
<tr>
<td></td>
<td>S 21 - Regenerative medicine</td>
</tr>
<tr>
<td></td>
<td>S 22 - New insights in molecular mechanism of cardiovascular diseases in CKD</td>
</tr>
<tr>
<td></td>
<td>FC 16 - Cystic diseases: new genes and modifiers</td>
</tr>
<tr>
<td></td>
<td>FC 17 - Rehabilitation and physical exercise in CKD</td>
</tr>
<tr>
<td>09.30 - 10.45</td>
<td>09.30 - 10.45 Posters, coffee break and exhibition visit</td>
</tr>
<tr>
<td></td>
<td>PL 2 - Katiin Susztak “Single-cell transcriptomics in kidney disease”</td>
</tr>
<tr>
<td>10.45 - 11.30</td>
<td>S 23 - Optimizing peritoneal dialysis prescription</td>
</tr>
<tr>
<td></td>
<td>S 24 - Complement mediated kidney injury</td>
</tr>
<tr>
<td></td>
<td>S 25 - Controversy: does haemodilatation improve patient outcomes and survival?</td>
</tr>
<tr>
<td></td>
<td>S 26 - CKD-MBD patterns and therapeutic approaches; update 2019</td>
</tr>
<tr>
<td></td>
<td>S 27 - The gut-kidney-cardiovascular axis</td>
</tr>
<tr>
<td></td>
<td>FC 18 - Fighting DKD</td>
</tr>
<tr>
<td></td>
<td>FC 19 - Defining outcome in transplantation</td>
</tr>
<tr>
<td></td>
<td>FC 20 - Improving cardiovascular complications in CKD</td>
</tr>
<tr>
<td>11.30 - 11.45</td>
<td>11.30 - 11.45 Break</td>
</tr>
<tr>
<td>11.45 - 13.15</td>
<td>S 28 - Improving the organ donor pool</td>
</tr>
<tr>
<td></td>
<td>S 29 - Cardiaco vascular disease in CKD: risk factors and remedies</td>
</tr>
<tr>
<td></td>
<td>S 30 - The hidden risks of haemodialysis</td>
</tr>
<tr>
<td></td>
<td>S 31 - The role of diet in the prevention of CKD progression: food for thought</td>
</tr>
<tr>
<td></td>
<td>FC 21 - Immunological kidney diseases</td>
</tr>
<tr>
<td></td>
<td>FC 22 - CKD-MBD</td>
</tr>
<tr>
<td></td>
<td>FC 23 - ESAs and iron: anaemia and beyond</td>
</tr>
<tr>
<td></td>
<td>FC 24 - How to prevent AKI</td>
</tr>
<tr>
<td>13.15 - 14.45</td>
<td>13.15 - 14.45 Vifor Fresenius Medical Care Renal Pharma</td>
</tr>
<tr>
<td></td>
<td>Alexion Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>B.Braun Avitum</td>
</tr>
<tr>
<td></td>
<td>PACE-CME-Passverlogix</td>
</tr>
<tr>
<td></td>
<td>Fresenius Kabi</td>
</tr>
<tr>
<td></td>
<td>Bayer AG</td>
</tr>
<tr>
<td></td>
<td>Amicus Therapeutics</td>
</tr>
<tr>
<td></td>
<td>Zydus Trans-Immune (A Division of Cadila Healthcare)</td>
</tr>
<tr>
<td>15.00 - 16.30</td>
<td>S 32 - Home haemodialysis: on the move</td>
</tr>
<tr>
<td></td>
<td>S 33 - Overcoming age with frailty evaluation in the kidney transplant recipient</td>
</tr>
<tr>
<td></td>
<td>S 34 - Delivering good quality dialysis - what should we measure?</td>
</tr>
<tr>
<td></td>
<td>S 35 - The paradox of estimated GF in the era of precision medicine</td>
</tr>
<tr>
<td></td>
<td>FC 25 - Kidney diseases from childhood to adult</td>
</tr>
<tr>
<td></td>
<td>FC 26 - Experimental hypertension</td>
</tr>
<tr>
<td></td>
<td>FC 27 - Novel approaches to AKI: exosomes and RNA interference</td>
</tr>
<tr>
<td></td>
<td>FC 28 - Revising PD: a systems biology approach</td>
</tr>
<tr>
<td>16.30 - 17.00</td>
<td>16.30 - 17.00 Posters, coffee break and exhibition visit</td>
</tr>
<tr>
<td></td>
<td>S 36 - The role of diet in the prevention of CKD progression: food for thought</td>
</tr>
<tr>
<td></td>
<td>S 37 - The paradox of estimated GF in the era of precision medicine</td>
</tr>
<tr>
<td></td>
<td>FC 25 - Kidney diseases from childhood to adult</td>
</tr>
<tr>
<td></td>
<td>FC 26 - Experimental hypertension</td>
</tr>
<tr>
<td></td>
<td>FC 27 - Novel approaches to AKI: exosomes and RNA interference</td>
</tr>
<tr>
<td></td>
<td>FC 28 - Revising PD: a systems biology approach</td>
</tr>
</tbody>
</table>
PROGRAMME AT A GLANCE - SUNDAY, JUNE 16TH, 2019

08.30 - 10.00
S 36 - AKI: Current problems in clinical practice
S 37 - Frail elderly: Management best at home
S 38 - Novel therapies in hereditary kidney diseases
S 39 - Digging the aetiology of hypertension
FC 29 - Fluids and electrolytes
FC 30 - From cell physiology to new therapeutical targets
FC 31 - Haemodialysis improving solute removal
FC 32 - Finetuning immunosuppression in kidney transplantation

10.00 - 10.15 Break

10.15 - 11.00
PL 3 - Csaba P. Kovesdy "The pre-dialysis to renal replacement therapy transition"

11.00 - 12.30
Nephrology Pearls
# Programme at a Glance - Sunday, June 16th, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 - 10.00</td>
<td>S 36 - AKI: current problems in clinical practice</td>
</tr>
<tr>
<td></td>
<td>S 37 - Frail elderly: management and best at home</td>
</tr>
<tr>
<td></td>
<td>S 38 - Novel therapies in hereditary kidney diseases</td>
</tr>
<tr>
<td></td>
<td>S 39 - Digging the aetiology of hypertension</td>
</tr>
<tr>
<td></td>
<td>FC 29 - Fluids and electrolytes</td>
</tr>
<tr>
<td></td>
<td>FC 30 - From cell physiology to new therapeutical targets</td>
</tr>
<tr>
<td></td>
<td>FC 31 - Haemodialysis improving solute removal</td>
</tr>
<tr>
<td></td>
<td>FC 32 - Finetuning immunosuppression in kidney transplantation</td>
</tr>
<tr>
<td>10.00 - 10.15</td>
<td>Break</td>
</tr>
<tr>
<td>10.15 - 11.00</td>
<td>PL 3 - Csaba P. Kovesdy “The pre-dialysis to renal replacement therapy transition”</td>
</tr>
<tr>
<td>11.00 - 12.30</td>
<td>Nephrology Pearls</td>
</tr>
</tbody>
</table>

---

**LEGENDA**

<table>
<thead>
<tr>
<th>Fluids and electrolytes, tubular transport, physiology</th>
<th>Hereditary disorders, development, pregnancy, paediatric nephrology</th>
<th>Glomerular diseases and general clinical nephrology</th>
<th>Chronic Kidney Disease: pathophysiology, epidemiology, prevention, progression, aging</th>
<th>End Stage Renal Disease and dialysis</th>
<th>Home therapies, peritoneal dialysis</th>
<th>Transplantation and immunology</th>
<th>Hypertension, diabetes, vascular diseases</th>
<th>Acute Kidney Injury and Intensive care nephrology</th>
</tr>
</thead>
</table>

---

www.era-edta2019.org
ERA-EDTA announce the first Scientific and Educational Interaction Day

SEID

to be held on October 26, 2019

A day of succinct sessions focussing on clinical issues related to systemic diseases which affect the kidney; from prevention and diagnosis to therapy. It will also include a vascular access practical session.

On October 25, there will be an exclusive satellite: “New Drugs in Kidney Disease Symposium”

www.era-edta.org
Held jointly with
www.era-edta2019.org

56th ERA-EDTA Congress
Budapest, Hungary
June 13th-16th 2019

www.era-edta2019.org